

DANBIO publikationsliste

PhD- og doktorafhandlinger

Doktorafhandling:

Effectiveness of tumor necrosis factor inhibitors in patients with psoriatic arthritis and axial spondyloarthritis – treatment response, drug retention and predictors thereof. Bente Glintborg, MD, PhD. Copenhagen Center for Arthritis Research (COPECARE), Center for Rheumatology and Spine Diseases, Centre of Head and Orthopaedics, Rigshospitalet, Glostrup, University of Copenhagen, Denmark. Antaget til forsvar oktober 2018, forsvaret november 2018.

Modern treatment strategies in rheumatoid arthritis. Impact on, and predictor of, disease activity and disease course. Merete Lund Hetland, MD, PHD. Department of Rheumatology Hvidovre and Glostrup Hospitals, University of Copenhagen, Denmark. Antaget til forsvar december 2010, forsvaret februar 2011.

Ph.d-afhandlinger:

Smoking cessation among people with rheumatoid arthritis. Ida Kristiane Roelsgaard, Copenhagen Center for Arthritis Research, Center for Rheumatology and Spine Diseases, Rigshospitalet, Glostrup. University of Copenhagen, Faculty of Health and Medical Sciences. Forsvaret januar 2020.

Infection risk and treatment effectiveness in patients with rheumatoid arthritis initiating therapy with biologic disease modifying antirheumatic drugs. Epidemiological studies based on data from DANBIO and national registries. Kathrine Lederballe Grøn, Copenhagen Center for Arthritis Research, Center for Rheumatology and Spine Diseases, Rigshospitalet, Glostrup. University of Copenhagen, Faculty of Health and Medical Sciences. Forsvaret August 2019.

Rheumatoid arthritis, Ankylosing Spondylitis and hospitalization with Pneumonia. Mette Holland-Fischer, MD, Reumatologisk afdeling, Aalborg Universitetshospital. Forsvaret oktober 2018.

Disease modifying therapies in psoriatic arthritis – prognostic factors and treatment outcomes. Pil Højgaard, MD, Center for Rheumatology and Spine Diseases, Rigshospitalet, Glostrup; The Parker Institute, Bispebjerg og Frederiksberg Hospital. Forsvaret juni 2018

Aiming at remission in rheumatoid arthritis – the role of biomarkers. Cecilie Cornelia Heegaard Brahe, MD, Copenhagen Center for Arthritis Research, Center for Rheumatology and Spine Diseases, Rigshospitalet, Glostrup. Forventes forsvaret juni 2018.

The role of tendon and cartilage involvement in pain, loss of function and disease progression in rheumatoid arthritis – a study based on questionnaires, clinical assessment and imaging. Daniel Erik Malm, MD, Copenhagen Center for Arthritis Research, Center for Rheumatology and Spine Diseases, Rigshospitalet, Glostrup. Antaget til forsvar 2017, forsvaret januar 2018.

Magnetic resonance imaging as measure of disease control and true remission in rheumatoid arthritis. Signe Møller-Bisgaard, MD, Department of Rheumatology Slagelse Hospital & Copenhagen Center for Arthritis Research, Center for Rheumatology and Spine Diseases, Rigshospitalet, Glostrup. Antaget til forsvar november 2015, forsvaret januar 2016.

Structural joint damage and hand bone loss in patients with rheumatoid arthritis. Lykke Ørnbjerg, MD, Copenhagen Center for Arthritis Research, Center for Rheumatology and Spine Diseases, Rigshospitalet, Glostrup. Antaget til forsvar december 2015, forsvaret februar 2016.

Rheumatoid Arthritis and Work – Risk and Risk Factors for Long Term Sickness Absence, Unemployment, and Disability Pension. Sofie Mandrup Hansen, MSc, National Research Centre for the Working Environment. Antaget til forsvar januar 2016, forsvaret marts 2016.

Potential biomarkers of treatment response and adverse drug reactions to TNF- alfa inhibitor therapy in patients with rheumatoid arthritis. Sophine B. Krintel, MD, Copenhagen Center for Arthritis Research, Center for Rheumatology and Spine Diseases. Antaget til forsvar september 2012, forsvaret februar 2013.

Self-efficacy in outpatients with rheumatoid arthritis. Jette Primdahl, nurse. Faculty of Health Sciences, University of Southern Denmark. Antaget til forsvar april 2011, forsvaret juni 2011.

Health-related quality of life in patients with rheumatoid arthritis. A comparative validation of selected measurement instruments. Louise Linde, MD. The DANBIO registry. Department of Rheumatology, Hvidovre Hospital. Antaget til forsvar september 2009, forsvaret november 2009.

Peer-reviewed artikler:

- 1) Elde KD, Madsen OR. FRAX 10-yr Fracture Risk in Rheumatoid Arthritis—Assessments With and Without Bone Mineral Density May Lead to Very Different Results in the Individual Patient. *J Clin Densitom* 2019; 22: 31–38.
- 2) Glintborg B, Loft AG, Omerovic E, Hendricks O, Linauskas A, Espesen J, Danebod K, Jensen DV, Nordin H, Dalgaard EB, Chrysidis S, Kristensen S, Raun JL, Lindegaard H, Manilo N, Jakobsen SH, Jensen Hansen IM, Pedersen DD, Sørensen IJ, Andersen LS, Grydehøj J, Mehnert F, Krogh NS, and Hetland ML. Response to 'To switch or not to switch': the missing piece in the puzzle of biosimilar literature?' by Scherlinger et al. *Ann Rheum Dis* 2019.
- 3) Curtis JR, Brahe CH, Østergaard M, Hetland LM, Hambardzumyan K, Saevarsdottir S, Wang X, Flake II DD, Sasso EH, and Huizinga TW. Predicting risk for radiographic damage in rheumatoid arthritis: comparative analysis of the multi-biomarker disease activity score and conventional measures of disease activity in multiple studies. *Curr Med Res Opin* 2019; 1–11.
- 4) Grøn KL, Arkema E V, Glintborg B, Mehnert F, Østergaard M, Dreyer L, Nørgaard M, Krogh NS, Askling J, Hetland ML, and ARTIS Study Group. Risk of serious infections in patients with rheumatoid arthritis treated in routine care with abatacept, rituximab and tocilizumab in Denmark and Sweden. *Ann Rheum Dis* 2019; 78: 320–327.
- 5) Brahe C, Østergaard M, Johansen J, Defranoux N, Wang X, Bolce R, Sasso EH, Ørnbjerg LM, Hørslev-Petersen K, Stengaard-Pedersen K, Junker P, Ellingsen T, Ahlquist P, Lindegaard H, Linauskas A, Schlemmer A, Dam MY, Hansen I, Lottenburger T, Ammitzbøll C, Jørgensen A, Krintel SB, Raun J, and Hetland ML. Predictive value of a multi-biomarker disease activity score for clinical remission and radiographic progression in patients with early rheumatoid arthritis: a post-hoc study of the OPERA trial. *Scand J Rheumatol* 2019; 48: 9–16.
- 6) Hetland M, Østergaard M, Stengaard-Pedersen K, Junker P, Ejbjerg B, Jacobsen S, Ellingsen T, Lindegaard H, Pødenphant J, Vestergaard A, Jurik AG, Krogh NS, Hørslev-Petersen K, and The CIMESTRA Study Group*. Anti-cyclic citrullinated peptide antibodies, 28-joint Disease Activity Score, and magnetic resonance imaging bone oedema at baseline predict 11 years' functional and radiographic outcome in early rheumatoid arthritis. *Scand J Rheumatol* 2019; 48: 1–8.
- 7) Brahe CH, Krabbe S, Østergaard M, Ørnbjerg L, Glinatsi D, Røgind H, Glinatsi D, Røgind H, Jensen HS, Hansen A, Nørregaard J, Jacobsen S, Terslev L, Huynh TK, Jensen DV, Manilo N, Asmussen K, Frandsen PB, Boesen M, Rastiemadabadi Z, Carlsen LM, Møller JM, Krogh NS, and Hetland ML. Dose tapering and discontinuation of biological therapy in rheumatoid arthritis patients in routine care – 2-year outcomes and predictors. *Rheumatology* 2019; 58: 110–119.
- 8) Chatzidionysiou K, Lukina G, Gabay C, Hetland M, Hauge E, Pavelka K, Nordström D, Canhão H, Tomsic M, Rotar Z, Lie E, Kvien TK, van Vollenhoven RF, and Saevarsdottir S. Smoking and response to rituximab in rheumatoid arthritis: results from an international European collaboration. *Scand J Rheumatol* 2019; 48: 17–23.
- 9) Canet LM, Sánchez-Maldonado JM, Cáliz R, Ramos AR-, Lupiañez CB, Canhão H, Martínez-Bueno M, Escudero A, Segura-Catena J, Sorensen SB, Hetland ML, Soto-Pino MJ, Ferrer MA, García A, Glintborg B, Filipescu I, Pérez-Pampin E, González-Utrilla A, López Nevot MA, Conesa-Zamora P, den Broeder A, De Vita S, Jacobsen SEH, Collantes-Estevez E, Quartuccio L, Canzian F, Fonseca JE, Coenen MJH, Andersen V, and Sainz J. Polymorphisms at phase I-metabolizing enzyme and hormone receptor loci influence the

response to anti-TNF therapy in rheumatoid arthritis patients. *Pharmacogenomics J* 2019; 19: 83–96.

- 10) Glintborg B, Loft AG, Omerovic E, Hendricks O, Linauskas A, Espesen J, Danebod K, Jensen DV, Nordin H, Dalgaard EB, Chrysidis S, Kristensen S, Raun JL, Lindegaard H, Manilo N, Jakobsen SH, Hansen IMJ, Pedersen DD, Sørensen IJ, Andersen LS, Grydehøj J, Mehnert F, Krogh NS, and Hetland ML. To switch or not to switch: results of a nationwide guideline of mandatory switching from originator to biosimilar etanercept. One-year treatment outcomes in 2061 patients with inflammatory arthritis from the DANBIO registry. *Ann Rheum Dis* 2019; 78: 192–200.
- 11) Møller-Bisgaard S, Hørslev-Petersen K, Ejbjerg B, Hetland ML, Ørnbjerg LM, Glinatsi D, Møller J, Boesen M, Christensen R, Stengaard-Pedersen K, Madsen OR, Jensen B, Villadsen JA, Hauge EM, Bennett P, Hendricks O, Asmussen K, Kowalski M, Lindegaard H, Nielsen SM, Bliddal H, Krogh NS, Ellingsen T, Nielsen AH, Balding L, Jurik AG, Thomsen HS, and Østergaard M. Effect of Magnetic Resonance Imaging vs Conventional Treat-to-Target Strategies on Disease Activity Remission and Radiographic Progression in Rheumatoid Arthritis. *JAMA* 2019; 321: 461.
- 12) DANBIO, Dansk Reumatologisk Database, præsenterer sin fjortende årsrapport. *Ugeskriftet.dk* den 21. Oktober 2019
- 13) Secher, AE, B. Glintborg, H. Gudbergsen, NS Krogh, IJ Sørensen, DV Jensen, R. Christensen, M. Skougaard, PL Pedersen, and ML Hetland. Comparing patient-reported outcomes entered at home versus at hospital, and testing touch screens for initial recruitment to scientific trials in arthritis patients. *Scand J Rheumatol* 2018; 1–7.
- 14) Emamifar A, Jensen Hansen IM. The influence of thyroid diseases, diabetes mellitus, primary hyperparathyroidism, vitamin B12 deficiency and other comorbid autoimmune diseases on treatment outcome in patients with rheumatoid arthritis. *Medicine (Baltimore)* 2018; 97: e10865.
- 15) Højgaard P, Ballegaard C, Cordtz R, Zobbe K, Clausen M, Glintborg B, Kristensen L, and Dreyer L. Gender differences in biologic treatment outcomes—a study of 1750 patients with psoriatic arthritis using Danish Health Care Registers. *Rheumatology* 2018; 57: 1651–1660.
- 16) Glintborg B, Loft AG, Omerovic E, Hendricks O, Linauskas A, Espesen J, Danebod K, Jensen DV, Nordin H, Dalgaard EB, Chrysidis S, Kristensen S, Raun JL, Lindegaard H, Manilo N, Jakobsen SH, Jensen Hansen IM, Pedersen DD, Sørensen IJ, Andersen LS, Grydehøj J, Mehnert F, Krogh NS, and Hetland ML. Response to: ‘Mandatory, cost-driven switching from originator etanercept to its biosimilar SB4: Possible fallout on non-medical switching’ by Cantini and Benucci. *Ann. Rheum. Dis.* 2018; annrheumdis-2018-214788.
- 17) Rom AL, Wu C Sen, Olsen J, Jawaheer D, Hetland ML and Mørch LS. Parental Rheumatoid Arthritis and Autism Spectrum Disorders in Offspring: A Danish Nationwide Cohort Study. *J Am Acad Child Adolesc Psychiatry* 2018; 57: 28–32.e1.
- 18) Radner H, Chatzidionysiou K, Nikiphorou E, Gossec L, Hyrich KL, Zabalán C, van Eijk-Hustings Y, Williamson PR, Balanescu A, Burmester GR, Carmona L, Dougados M, Finckh A, Haugeberg G, Hetland ML, Oliver S, Porter D, Raza K, Ryan P, Santos MJ, van der Helm-van Mil A, van Riel P, von Krause G, Zavada J, Dixon WG, and Askling J. 2017 EULAR recommendations for a core data set to support observational research and clinical care in rheumatoid arthritis. *Ann Rheum Dis* 2018; 77: 476–479.
- 19) Chatzidionysiou K, Hetland ML, Frisell T, Di Giuseppe D, Hellgren K, Glintborg B, Nordström D, Aaltonen K, Törmänen MR, Kristianslund EK, Kvien TK, Provan SA, Guðbjörnsson B, Dreyer L, Kristensen LE,

- Jørgensen TS, Jacobsson L, and Askling J. Opportunities and challenges for real-world studies on chronic inflammatory joint diseases through data enrichment and collaboration between national registers: the Nordic example. *RMD Open* 2018; 4: e000655.
- 20) Nexo MA, Carlsen K, Pedersen J, Hetland ML, Watt T, Hansen SM, and Bjorner JB. Long-term sickness absence of 32 chronic conditions: a Danish register-based longitudinal study with up to 17 years of follow-up. *BMJ Open* 2018; 8: e020874.
 - 21) Glintborg B, Sørensen J, Hetland ML. Does a mandatory non-medical switch from originator to biosimilar infliximab lead to increased use of outpatient healthcare resources? A register-based study in patients with inflammatory arthritis. *RMD Open* 2018; 4: e000710.
 - 22) Herly M, Stengaard-Pedersen K, Vestergaard P, Østergaard M, Junker P, Hetland ML, Hørslev-Petersen K, and Ellingsen T. The D-vitamin metabolite 1,25(OH)₂D in serum is associated with disease activity and Anti-Citrullinated Protein Antibodies in active and treatment naïve, early Rheumatoid Arthritis Patients. *Scand J Immunol* 2018; 88: e12704.
 - 23) Glintborg B, Lindström U, Aaltonen K, Kristianslund E, Gudbjornsson B, Chatzidionysiou K, Askling J, Nordström D, Hetland ML, Di Giuseppe D, Dreyer L, Kristensen LE, Jørgensen TS, Eklund K, Grondal G, Ernestam S, Joensuu J, Törmänen MRK, Skydsgaard H, Hagfors J, Kvien TK, Lie E, Fagerli K, Geirsson AJ, Jonsson H, Provan SA, Krogh NS, and Jacobsson LTH. Biological treatment in ankylosing spondylitis in the Nordic countries during 2010–2016: a collaboration between five biological registries. *Scand J Rheumatol* 2018; 47: 465–474.
 - 24) Krabbe S, Glintborg B, Østergaard M, Hetland ML. Extremely poor patient-reported outcomes are associated with lack of clinical response and decreased retention rate of tumour necrosis factor inhibitor treatment in patients with axial spondyloarthritis. *Scand. J. Rheumatol.* 2018; 1–5.
 - 25) Sode J, Bank S, Vogel U, Andersen PS, Sørensen SB, Bojesen AB, Andersen MR, Brandslund I, Dessau RB, Hoffmann HJ, Glintborg B, Hetland ML, Loch H, Heegaard NH, and Andersen V. Genetically determined high activities of the TNF-alpha, IL23/IL17, and NFkB pathways were associated with increased risk of ankylosing spondylitis. *BMC Med Genet* 2018; 19: 165.
 - 26) Michelsen B, Sexton J, Smolen JS, Aletaha D, Krogh NS, van der Heijde D, Kvien TK, and Hetland ML. Can disease activity in patients with psoriatic arthritis be adequately assessed by a modified Disease Activity index for PSoriatic Arthritis (DAPSA) based on 28 joints? *Ann Rheum Dis* 2018; 77: 1736–1741.
 - 27) Curtis JR, Flake DD, Weinblatt ME, Shadick NA, Østergaard M, Hetland ML, Brahe CH, Hwang YG, Furst DE, Strand V, Etzel CJ, Pappas DA, Wang X, Hwang CC, Sasso EH, Gutin A, Hitraya E, and Lanchbury JS. Adjustment of the multi-biomarker disease activity score to account for age, sex and adiposity in patients with rheumatoid arthritis. *Rheumatology* 2018.
 - 28) Ørnbjerg LM. Structural joint damage and hand bone loss in patients with rheumatoid arthritis. *Dan Med J.* 2018 Mar;65(3). pii: B5452. PubMed PMID: 29510810.
 - 29) Kringelbach TM, Glintborg B, Hogdall EV, Johansen JS, Hetland ML; Biomarker Protocol Study Group. Identification of new biomarkers to promote personalized treatment of patients with inflammatory rheumatic disease: protocol for an open cohort study. *BMJ Open* 2018;8(2):e019325.
 - 30) Hammer NM, Midtgaard J, Hetland ML, Krogh NS, Esbensen BA. Physical activity behaviour in men with inflammatory joint disease: a cross-sectional register-based study. *Rheumatology* 2018. doi: 10.1093/rheumatology/kex498. [Epub ahead of print].

- 31) Loft ND, Skov L, Rasmussen MK, Gniadecki R, Dam TN, Brandslund I, Hoffmann HJ, Andersen MR, Dessau RB, Bergmann AC, Andersen NM, Abildtoft MK, Andersen PS, Hetland ML, Glintborg B, Bank S, Vogel U, Andersen V. Genetic polymorphisms associated with psoriasis and development of psoriatic arthritis in patients with psoriasis. *PLoS One* 2018;13(2):e0192010.
- 32) Brahe CH, Dehlendorff C, Østergaard M, Johansen JS, Ørnbjerg LM, Hørslev-Petersen K, Stengaard-Pedersen K, Junker P, Ellingsen T, Lindegaard H, Hansen I, Lottenburger T, Jacobsen S, Jurik AG, Hetland ML. Circulating serum interleukin-6, serum chitinase-3-like protein-1, and plasma vascular endothelial growth factor are not predictive for remission and radiographic progression in patients with early rheumatoid arthritis: post-hoc explorative and validation studies based on the CIMESTRA and OPERA trials. *Scand J Rheumatol* 2018:1-11. doi: 10.1080/03009742.2017.1376107. [Epub ahead of print].
- 33) Glintborg B, Kringelbach T, Bolstad N, Warren DJ, Eng G, Sørensen IJ, Loft AG, Hendricks O, Hansen I, Linauskas A, Nordin H, Kristensen S, Lindegaard H, Jensen DV, Goll GL, Høgdall E, Gehin J, Enevold C, Nielsen CH, Krogh NS, Johansen JS, Hetland ML. Drug concentrations and anti-drug antibodies during treatment with biosimilar infliximab (CT-P13) in routine care. *Scand J Rheumatol* 2018:1-4. doi: 10.1080/03009742.2017.1376110. [Epub ahead of print].
- 34) Madsen OR. Stability of fatigue, pain, patient global assessment and the Bath Ankylosing Spondylitis Functional Index (BASFI) in spondyloarthropathy patients with stable disease according to the Bath Ankylosing Spondylitis Disease Activity Index (BASDAI). *Rheumatol Int* 2018;38(3):425-432.
- 35) Dreyer L, Cordtz RL, Hansen IMJ, Kristensen LE, Hetland ML, Mellemkjaer L. Risk of second malignant neoplasm and mortality in patients with rheumatoid arthritis treated with biological DMARDs: a Danish population-based cohort study. *Ann Rheum Dis* 2018;77(4):510-514.
- 36) Sode J, Krintel SB, Carlsen AL, Hetland ML, Johansen JS, Hørslev-Petersen K, Stengaard-Pedersen K, Ellingsen T, Burton M, Junker P, Østergaard M, Heegaard NHH. Plasma MicroRNA Profiles in Patients with Early Rheumatoid Arthritis Responding to Adalimumab plus Methotrexate vs Methotrexate Alone: A Placebo-controlled Clinical Trial. *J Rheumatol*. 2018;45(1):53-61.
- 37) Cordtz RL, Zobbe K, Højgaard P, Kristensen LE, Overgaard S, Odgaard A, Lindegaard H, Dreyer L. Predictors of revision, prosthetic joint infection and mortality following total hip or total knee arthroplasty in patients with rheumatoid arthritis: a nationwide cohort study using Danish healthcare registers. *Ann Rheum Dis* 2018;77(2):281-288.
- 38) Kuettel D, Primdahl J, Christensen R, Ørnbjerg LM, Hørslev-Petersen K. Impact of patient-reported flares on radiographic progression and functional impairment in patients with rheumatoid arthritis: a cohort study based on the AMBRA trial. *Scand J Rheumatol* 2018;47(2):87-94.
- 39) Ballegaard C, Højgaard P, Dreyer L, Cordtz R, Jørgensen TS, Skougaard M, Tarp S, Kristensen LE. Impact of Comorbidities on Tumor Necrosis Factor Inhibitor Therapy in Psoriatic Arthritis: A Population-Based Cohort Study. *Arthritis Care Res* 2018;70(4):592-599.
- 40) Sode J, Vogel U, Bank S, Andersen PS, Hetland ML, Loch H, Heegaard NHH, Andersen V. Confirmation of an IRAK3 polymorphism as a genetic marker predicting response to anti-TNF treatment in rheumatoid arthritis. *Pharmacogenomics J* 2018;18(1):81-86.
- 41) Duhn PH, Sode J, Hagen CM, Christiansen M, Loch H. Mitochondrial haplogroups in patients with rheumatoid arthritis: No association with disease and disease manifestations. *PLoS One* 2017;12(12):e0188492.

- 42) Ibfelt EH, Sørensen J, Jensen DV, Dreyer L, Schiøttz-Christensen B, Thygesen PH, Colic A, Raun JL, Manilo N, Rødgaard A, Poulsen UE, Rasmussen C, Hansen T, Unger B, Pelck R, Kincses A, Nordin H, Lorenzen T, Theibich A, Jensen Hansen IM, Espesen J, Grydehøj J, Holland-Fischer M, Loft AG, Hetland ML. Validity and completeness of rheumatoid arthritis diagnoses in the nationwide DANBIO clinical register and the Danish National Patient Registry. *Clin Epidemiol* 2017;9:627-632.
- 43) Roelsgaard IK, Thomsen T, Østergaard M, Christensen R, Hetland ML, Jacobsen S, Andersen L, Tønnesen H, Rollefstad S, Semb AG, Esbensen BA. The effect of an intensive smoking cessation intervention on disease activity in patients with rheumatoid arthritis: study protocol for a randomised controlled trial. *Trials* 2017;18(1):570.
- 44) Emamifar A, Hangaard J, Jensen Hansen IM. Thyroid disorders in patients with newly diagnosed rheumatoid arthritis is associated with poor initial treatment response evaluated by disease activity score in 28 joints-C-reactive protein (DAS28-CRP): An observational cohort study. *Medicine* 2017;96(43):e8357.
- 45) Emamifar A, Levin K, Jensen Hansen IM. Patients with newly diagnosed rheumatoid arthritis are at increased risk of diabetes mellitus: an observational cohort study. *Acta Reumatol Port* 2017;42(4):310-317.
- 46) Mercer LK, Regierer AC, Mariette X, Dixon WG, Baecklund E, Hellgren K, Dreyer L, Hetland ML, Cordtz R, Hyrich K, Strangfeld A, Zink A, Canhao H, Hernandez MV, Tubach F, Gottenberg JE, Morel J, Zavada J, Iannone F, Askling J, Listing J. Spectrum of lymphomas across different drug treatment groups in rheumatoid arthritis: a European registries collaborative project. *Ann Rheum Dis* 2017;76(12):2025-2030.
- 47) Rasch LA, Boers M, Hill CL, Voshaar M, Hoogland W, de Wit M, Flurey C, Davis B, Hetland ML, Brahe CH, Gossec L, Wells GA, Tugwell P, Kuriya B, Goel N, Singh JA, Duarte C, Da Silva J, van Schaardenburg D, Proudman S, van Tuyl LHD; Working Group on the Patients' Perspective on Remission in Rheumatoid Arthritis. Validating Rheumatoid Arthritis Remission Using the Patients' Perspective: Results from a Special Interest Group at OMERACT 2016. *J Rheumatol* 2017;44(12):1889-1893.
- 48) Rifbjerg-Madsen S, Christensen AW, Christensen R, Hetland ML, Bliddal H, Kristensen LE, Danneskiold-Samsøe B, Amris K. Pain and pain mechanisms in patients with inflammatory arthritis: A Danish nationwide cross-sectional DANBIO registry survey. *PLoS One* 2017;12(7):e0180014.
- 49) Thomsen T, Aadahl M, Beyer N, Hetland ML, Løppenthin K, Midtgaard J, Christensen R, Østergaard M, Jennum PJ, Esbensen BA. The efficacy of motivational counselling and SMS reminders on daily sitting time in patients with rheumatoid arthritis: a randomised controlled trial. *Ann Rheum Dis* 2017;76(9):1603-1606.
- 50) Goin DE, Smed MK, Pachter L, Purdom E, Nelson JL, Kjærgaard H, Olsen J, Hetland ML, Zoffmann V, Ottesen B, Jawaheer D. Pregnancy-induced gene expression changes in vivo among women with rheumatoid arthritis: a pilot study. *Arthritis Res Ther* 2017;19(1):104.
- 51) Rifbjerg-Madsen S, Wæhrens EE, Danneskiold-Samsøe B, Amris K. Psychometric properties of the painDETECT questionnaire in rheumatoid arthritis, psoriatic arthritis and spondyloarthritis: Rasch analysis and test-retest reliability. *Health Qual Life Outcomes* 2017;15(1):110.
- 52) Glintborg B, Sørensen IJ, Loft AG, Lindegaard H, Linauskas A, Hendricks O, Hansen IMJ, Jensen DV, Manilo N, Espesen J, Klarlund M, Grydehøj J, Dieperink SS, Kristensen S, Olsen JS, Nordin H, Chrysidis S, Dalsgaard Pedersen D, Sørensen MV, Andersen LS, Grøn KL, Krogh NS, Pedersen L, Hetland ML; all departments of rheumatology in Denmark. A nationwide non-medical switch from originator infliximab

to biosimilar CT-P13 in 802 patients with inflammatory arthritis: 1-year clinical outcomes from the DANBIO registry. *Ann Rheum Dis* 2017;76(8):1426-1431.

- 53) Hansen SM, Hetland ML, Pedersen J, Østergaard M, Rubak TS, Bjorner JB. Work ability in rheumatoid arthritis patients: a register study on the prospective risk of exclusion and probability of returning to work. *Rheumatology* 2017;56(7):1135-1143.
- 54) Kristensen AM, Stengaard-Pedersen K, Hetland ML, Hørslev-Petersen K, Junker P, Østergaard M, Höllsberg P, Deleuran B, Hvid M. Expression of soluble CD83 in plasma from early-stage rheumatoid arthritis patients is not modified by anti-TNF- α therapy. *Cytokine* 2017;96:1-7.
- 55) Løgstrup BB, Masic D, Laurbjerg TB, Blegvad J, Herly M, Kristensen LD, Urbonaviciene G, Hedemann-Nielsen A, Ellingsen T. Left ventricular function at two-year follow-up in treatment-naive rheumatoid arthritis patients is associated with anti-cyclic citrullinated peptide antibody status: a cohort study. *Scand J Rheumatol* 2017;46(6):432-440.
- 56) Chatzidionysiou K, Lie E, Lukina G, Hetland ML, Hauge EM, Pavelka K, Gabay C, Scherer A, Nordström D, Canhao H, Santos MJ, Tomsic M, Rotar Z, Hernández MV, Gomez-Reino J, Ancuta I, Kvien TK, van Vollenhoven R. Rituximab Retreatment in Rheumatoid Arthritis in a Real-life Cohort: Data from the CERERRA Collaboration. *J Rheumatol* 2017;44(2):162-169.
- 57) Iannone F, Courvoisier DS, Gottenberg JE, Hernandez MV, Lie E, Canhãõ H, Pavelka K, Hetland ML, Turesson C, Mariette X, Choquette D, Finckh A. Body mass does not impact the clinical response to intravenous abatacept in patients with rheumatoid arthritis. Analysis from the "pan-European registry collaboration for abatacept (PANABA). *Clin Rheumatol* 2017;36(4):773-779.
- 58) Ørnberg LM, Østergaard M, Jensen T, Hørslev-Petersen K, Stengaard-Pedersen K, Junker P, Ellingsen T, Ahlquist P, Lindegaard H, Linauskas A, Schlemmer A, Dam MY, Hansen I, Lottenburger T, Ammitzbøll CG, Jørgensen A, Krintel SB, Raun J, Hetland ML; OPERA Study Group, Slot O, Nielsen LK, Skjødt H, Majgaard O, Lorenzen T, Horn HC, Kowalski M, Johansen IL, Pedersen PM, Manilo N, Bliddal H. Hand bone loss in early rheumatoid arthritis during a methotrexate-based treat-to-target strategy with or without adalimumab-a substudy of the optimized treatment algorithm in early RA (OPERA) trial. *Clin Rheumatol*. 2017;36(4):781-789.
- 59) Glinthorg B, Sørensen IJ, Østergaard M, Dreyer L, Mohamoud AA, Krogh NS, Hendricks O, Andersen LS, Raun JL, Kowalski MR, Danielsen L, Pelck R, Nordin H, Pedersen JK, Kraus DG, Christensen SR, Hansen IM, Esbesen J, Schlemmer A, Loft AG, Al Chaer N, Salomonsen L, Hetland ML. Ankylosing Spondylitis versus Nonradiographic Axial Spondyloarthritis: Comparison of Tumor Necrosis Factor Inhibitor Effectiveness and Effect of HLA-B27 Status. An Observational Cohort Study from the Nationwide DANBIO Registry. *J Rheumatol*. 2017 Jan;44(1):59-69.
- 60) Nissen CB, Hørslev-Petersen K, Primdahl J. Cardiovascular risk profiles in a hospital-based population of patients with psoriatic arthritis and ankylosing spondylitis: a cross-sectional study. *Rheumatol Int* 2017;37(1):113-120.
- 61) Jensen Hansen IM, Asmussen Andreasen R, van Bui Hansen MN, Emamifar A. The Reliability of Disease Activity Score in 28 Joints-C-Reactive Protein Might Be Overestimated in a Subgroup of Rheumatoid Arthritis Patients, When the Score Is Solely Based on Subjective Parameters: A Cross-sectional, Exploratory Study. *J Clin Rheumatol* 2017;23(2):102-106.
- 62) Møller-Bisgaard S, Ejbjerg BJ, Eshed I, Hørslev-Petersen K, Hetland ML, Jurik AG, Thomsen H, Torfing T, Stengaard-Pedersen K, Junker P, Krogh NS, Lottenburger T, Ellingsen T, Andersen LS, Skjødt H, Svendsen AJ, Tarp U, Hansen IT, Pødenphant J, Pedersen JK, Lindegaard H, Hanson LG, Vestergaard A, Glinatsi D,

- Østergaard M. Effect of a treat-to-target strategy based on methotrexate and intra-articular betamethasone with or without additional cyclosporin on MRI-assessed synovitis, osteitis, tenosynovitis, bone erosion, and joint space narrowing in early rheumatoid arthritis: results from a 2-year randomized double-blind placebo-controlled trial (CIMESTRA). *Scand J Rheumatol* 2017;46(5):335-345.
- 63) Mercer LK, Askling J, Raaschou P, Dixon WG, Dreyer L, Hetland ML, Strangfeld A, Zink A, Mariette X, Finckh A, Canhao H, Iannone F, Zavada J, Morel J, Gottenberg JE, Hyrich KL, Listing J. Risk of invasive melanoma in patients with rheumatoid arthritis treated with biologics: results from a collaborative project of 11 European biologic registers. *Ann Rheum Dis* 2017;76(2):386-391.
- 64) Hellgren K, Dreyer L, Arkema EV, Glintborg B, Jacobsson LT, Kristensen LE, Feltelius N, Hetland ML, Askling J; ARTIS Study Group, For the DANBIO Study Group. Cancer risk in patients with spondyloarthritis treated with TNF inhibitors: a collaborative study from the ARTIS and DANBIO registers. *Ann Rheum Dis* 2017;76(1):105-111.
- 65) Glinatsi D, Heiberg MS, Rudin A, Nordström D, Haavardsholm EA, Gudbjornsson B, Østergaard M, Uhlig T, Grondal G, Hørslev-Petersen K, van Vollenhoven R, Hetland ML. Head-to-head comparison of aggressive conventional therapy and three biological treatments and comparison of two de-escalation strategies in patients who respond to treatment: study protocol for a multicenter, randomized, open-label, blinded-assessor, phase 4 study. *Trials*. 2017;18(1):161.
- 66) Hetland ML, Krogh NS, Hørslev-Petersen K, Schiøttz-Christensen B, Sørensen IJ, Dorte Vendelbo J. Using an electronic platform interactively to improve treatment outcome in patients with rheumatoid arthritis: new developments from the DANBIO registry. *Clin Exp Rheumatol* 2016; 34 Suppl 101(5): 75-78.
- 67) Ibfelt EH, Jensen DV, Hetland ML. The Danish nationwide clinical register for patients with rheumatoid arthritis: DANBIO. *Clin Epidemiol* 2016;8:737-742.
- 68) Ørnbjerg LM, Østergaard M, Jensen T, Hyldstrup L, Bach-Mortensen P, Bøyesen P, Thormann A, Tarp U, Bøhme WP, Lindegaard H, Poulsen UE, Schlemmer A, Graudal N, Rødgaard A, Espesen J, Kollerup GB, Glintborg B, Madsen OR, Jensen DV, Hetland ML. Establishment of age- and sex-adjusted reference data for hand bone mass and investigation of hand bone loss in patients with rheumatoid arthritis treated in clinical practice: an observational study from the DANBIO registry and the Copenhagen Osteoarthritis Study. *Arthritis Res Ther* 2016;18:53.
- 69) Thomsen T, Aadahl M, Beyer N, Hetland ML, Løppenthin K, Midtgaard J, Christensen R, Esbensen BA. Motivational counselling and SMS-reminders for reduction of daily sitting time in patients with rheumatoid arthritis: a descriptive randomised controlled feasibility study. *BMC Musculoskelet Disord* 2016;17(1):434.
- 70) Courvoisier DS, Alpizar-Rodriguez D, Gottenberg JE, Hernandez MV, Iannone F, Lie E, Santos MJ, Pavelka K, Turesson C, Mariette X, Choquette D, Hetland ML, Finckh A. Rheumatoid Arthritis Patients after Initiation of a New Biologic Agent: Trajectories of Disease Activity in a Large Multinational Cohort Study. *EBioMedicine* 2016;11:302-306.
- 71) Nielsen MA, Andersen T, Etzerodt A, Kragstrup TW, Rasmussen TK, Stengaard-Pedersen K, Hetland ML, Hørslev-Petersen K, Junker P, Østergaard M, Hvid M, Moestrup SK, Deleuran B. A disintegrin and metalloprotease-17 and galectin-9 are important regulators of local 4-1BB activity and disease outcome in rheumatoid arthritis. *Rheumatology* 2016;55(10):1871-9.

- 72) Chatzidionysiou K, Lie E, Nasonov E, Lukina G, Hetland ML, Tarp U, Ancuta I, Pavelka K, Nordström DC, Gabay C, Canhão H, Tomsic M, van Riel PL, Gomez-Reino J, Kvien TK, van Vollenhoven RF. Erratum to: Effectiveness of two different doses of rituximab for the treatment of rheumatoid arthritis in an international cohort: data from the CERERRA collaboration. *Arthritis Res Ther* 2016;18(1):144.
- 73) Kragstrup TW, Greisen SR, Nielsen MA, Rhodes C, Stengaard-Pedersen K, Hetland ML, Hørslev-Petersen K, Junker P, Østergaard M, Hvid M, Vorup-Jensen T, Robinson WH, Sokolove J, Deleuran B. The interleukin-20 receptor axis in early rheumatoid arthritis: novel links between disease-associated autoantibodies and radiographic progression. *Arthritis Res Ther* 2016;18:61.
- 74) Cordtz R, Mellekjær L, Glintborg B, Hetland ML, Madsen OR, Jensen Hansen IM, Dreyer L. Risk of virus-associated cancer in female arthritis patients treated with biological DMARDs – a cohort study. *Rheumatology* 2016;55(6):1017-22.
- 75) Chatzidionysiou K, Lie E, Nasonov E, Lukina G, Hetland ML, Tarp U, Ancuta I, Pavelka K, Nordström DC, Gabay C, Canhão H, Tomsic M, van Riel PL, Gomez-Reino J, Kvien TK, van Vollenhoven RF; Rheumatic Diseases Portuguese Register. Effectiveness of two different doses of rituximab for the treatment of rheumatoid arthritis in an international cohort: data from the CERERRA collaboration. *Arthritis Res Ther* 2016;18:50. Erratum in: *Arthritis Res Ther* 2016;18(1):144.
- 76) Glintborg B, Højgaard P, Lund Hetland M, Steen Krogh N, Kollerup G, Jensen J, Chrysidis S, Jensen Hansen IM, Holland-Fischer M, Højland Hansen T, Nilsson C, Espesen J, Nordin H, Rasmussen Loft AG, Pelck R, Lorenzen T, Flejsborg Oeftiger S, Unger B, Jaeger F, Mosborg Petersen P, Rasmussen C, Dreyer L. Impact of tobacco smoking on response to tumour necrosis factor-alpha inhibitor treatment in patients with ankylosing spondylitis: results from the Danish nationwide DANBIO registry. *Rheumatology* 2016;55(4):659-68.
- 77) Hansen SM, Hetland ML, Pedersen J, Østergaard M, Rubak TS, Bjorner JB. Effect of rheumatoid arthritis on longterm sickness absence in 1994-2011: A Danish cohort study. *J Rheumatol* 2016;43(4):707-15.
- 78) Kragstrup TW, Jalilian B, Keller KK, Zhang X, Laustsen JK, Stengaard-Pedersen K, Hetland ML, Hørslev-Petersen K, Junker P, Østergaard M, Hauge EM, Hvid M, Vorup-Jensen T, Deleuran B. Changes in Soluble CD18 in Murine Autoimmune Arthritis and Rheumatoid Arthritis Reflect Disease Establishment and Treatment Response. *PLoS One* 2016;11(2):e0148486.
- 79) Gottenberg JE, Courvoisier DS, Hernandez MV, Iannone F, Lie E, Canhão H, Pavelka K, Hetland ML, Turesson C, Mariette X, Finckh A. Brief Report: Association of Rheumatoid Factor and Anti-Citrullinated Protein Antibody Positivity With Better Effectiveness of Abatacept: Results From the Pan-European Registry Analysis. *Arthritis Rheumatol* 2016;68(6):1346-52.
- 80) Gudmann NS, Munk HL, Christensen AF, Ejstrup L, Sørensen GL, Loft AG, Karsdal MA, Bay-Jensen AC, He Y, Siebuhr AS, Junker P. Chondrocyte activity is increased in psoriatic arthritis and axial spondyloarthritis. *Arthritis Res Ther* 2016;18(1):141.
- 81) Munk HL, Gudmann NS, Christensen AF, Ejstrup L, Sørensen GL, Loft AG, Bay-Jensen AC, Siebuhr AS, Junker P. Cartilage collagen type II seromarker patterns in axial spondyloarthritis and psoriatic arthritis: associations with disease activity, smoking and HLA-B27. *Rheumatol Int* 2016;36(4):541-9.
- 82) Højgaard P, Glintborg B, Kristensen LE, Gudbjornsson B, Love TJ, Dreyer L. The influence of obesity on response to tumour necrosis factor- α inhibitors in psoriatic arthritis: results from the DANBIO and ICEBIO registries. *Rheumatology* 2016;55(12):2191-9.

- 83) Hørslev-Petersen K, Hetland ML, Ørnbjerg LM, Junker P, Pødenphant J, Ellingsen T, Ahlquist P, Lindegaard H, Linauskas A, Schlemmer A, Dam MY, Hansen I, Lottenburger T, Ammitzbøll CG, Jørgensen A, Krintel SB, Raun J, Johansen JS, Østergaard M, Stengaard-Pedersen K; OPERA Study-Group. Clinical and radiographic outcome of a treat-to-target strategy using methotrexate and intra-articular glucocorticoids with or without adalimumab induction: a 2-year investigator-initiated, double-blinded, randomised, controlled trial (OPERA). *Ann Rheum Dis* 2016; 75(9):1645-53.
- 84) Gabay C, Riek M, Hetland ML, Hauge EM, Pavelka K, Tomšič M, Canhao H, Chatzidionysiou K, Lukina G, Nordström DC, Lie E, Ancuta I, Hernández MV, van Riel PL, van Vollenhoven R, Kvien TK. Effectiveness of tocilizumab with and without synthetic disease-modifying antirheumatic drugs in rheumatoid arthritis: results from a European collaborative study. *Ann Rheum Dis* 2016;75(7):1336-42.
- 85) Krintel SB, Dehlendorff C, Hetland ML, Hørslev-Petersen K, Andersen KK, Junker P, Pødenphant J, Ellingsen T, Ahlquist P, Lindegaard HM, Linauskas A, Schlemmer A, Dam MY, Hansen I, Horn HC, Jørgensen A, Raun J, Ammitzbøll CG, Østergaard M, Stengaard-Pedersen K, Johansen JS. Prediction of treatment response to adalimumab: a double-blind placebo-controlled study of circulating microRNA in patients with early rheumatoid arthritis. *Pharmacogenomics J* 2016;16(2):141-6.
- 86) Finckh A, Neto D, Iannone F, Loza E, Lie E, van Riel P, Hetland ML, Pavelka K, Gottenberg JE, Canhão H, Mariette X, Turesson C. The impact of patient heterogeneity and socioeconomic factors on abatacept retention in rheumatoid arthritis across nine European countries. *RMD Open* 2015;1(1):e000040.
- 87) Thomsen T, Beyer N, Aadahl M, Hetland ML, Løppenthin K, Midtgaard J, Esbensen BA. Sedentary behaviour in patients with rheumatoid arthritis: A qualitative study. *Int J Qual Stud Health Well-being* 2015;10:28578.
- 88) Sode J, Vogel U, Bank S, Andersen PS, Hetland ML, Loch H, Heegaard NH, Andersen V. Genetic Variations in Pattern Recognition Receptor Loci Are Associated with Anti-TNF Response in Patients with Rheumatoid Arthritis. *PLoS One* 2015;10(10):e0139781.
- 89) Walker UA, Jaeger VK, Chatzidionysiou K, Hetland ML, Hauge EM, Pavelka K, Nordström DC, Canhão H, Tomšič M, van Vollenhoven R, Gabay C. Rituximab done: what's next in rheumatoid arthritis? A European observational longitudinal study assessing the effectiveness of biologics after rituximab treatment in rheumatoid arthritis. *Rheumatology* 2016;55(2):230-6.
- 90) Lindström Egholm C, Krogh NS, Pincus T, Dreyer L, Ellingsen T, Glintborg B, Kowalski MR, Lorenzen T, Madsen OR, Nordin H, Rasmussen C, Hetland ML. Discordance of Global Assessments by Patient and Physician Is Higher in Female than in Male Patients Regardless of the Physician's Sex: Data on Patients with Rheumatoid Arthritis, Axial Spondyloarthritis, and Psoriatic Arthritis from the DANBIO Registry. *J Rheumatol* 2015;42(10):1781-5.
- 91) Jørgensen TS, Kristensen LE, Christensen R, Bliddal H, Lorenzen T, Hansen MS, Østergaard M, Jensen J, Zanjani L, Laursen T, Butt S, Dam MY, Lindegaard HM, Espesen J, Hendricks O, Kumar P, Kincses A, Larsen LH, Andersen M, Næser EK, Jensen DV, Grydehøj J, Unger B, Dufour N, Sørensen V, Vildhøj S, Hansen IM, Raun J, Krogh NS, Hetland ML. Effectiveness and drug adherence of biologic monotherapy in routine care of patients with rheumatoid arthritis: a cohort study of patients registered in the Danish biologics registry. *Rheumatology* 2015;54(12):2156-65.
- 92) Andersen T, Hvid M, Johansen C, Stengaard-Pedersen K, Hetland ML, Hørslev-Petersen K, Junker P, Østergaard M, Deleuran B. Interleukin-23 in early disease development in rheumatoid arthritis. *Scand J Rheumatol* 2015;44(6):438-42.

- 93) Greisen SR, Møller HJ, Stengaard-Pedersen K, Hetland ML, Hørslev-Petersen K, Junker P, Østergaard M, Hvid M, Deleuran B. Macrophage activity assessed by soluble CD163 in early rheumatoid arthritis: association with disease activity but different response patterns to synthetic and biologic DMARDs. *Clin Exp Rheumatol* 2015;33(4):498-502.
- 94) Møller-Bisgaard S, Hørslev-Petersen K, Ejbjerg BJ, Boesen M, Hetland ML, Christensen R, Møller J, Krogh NS, Stengaard-Pedersen K, Østergaard M. Impact of a magnetic resonance imaging-guided treat-to-target strategy on disease activity and progression in patients with rheumatoid arthritis (the IMAGINE-RA trial): study protocol for a randomized controlled trial. *Trials* 2015;16:178.
- 95) Esbensen BA, Thomsen T, Hetland ML, Beyer N, Midtgaard J, Løppenthin K, Jennum P, Østergaard M, Sørensen J, Christensen R, Aadahl M. The efficacy of motivational counseling and SMS-reminders on daily sitting time in patients with rheumatoid arthritis: protocol for a randomized controlled trial. *Trials* 2015;16:23.
- 96) Kearsley-Fleet L, Závada J, Hetland ML, Nordström DC, Aaltonen KJ, Listing J, Zink A, Gati T, Rojkovich B, Iannone F, Gremese E, van Riel PL, van de Laar MA, Lie E, Kvien TK, Canhã H, Fonseca JE, Rotar Ž, Loza E, Carmona L, Askling J, Johansson K, Finckh A, Dixon WG, Hyrich KL; EULAR Study Group for Registers and Observational Drug Studies. The EULAR Study Group for Registers and Observational Drug Studies: comparability of the patient case mix in the European biologic disease modifying anti-rheumatic drug registers. *Rheumatology* 2015;54(6):1074-9.
- 97) Eng GP, Bendtzen K, Bliddal H, Stoltenberg M, Szkudlarek M, Fana V, Lindegaard HM, Omerovic E, Højgaard P, Jensen EK, Bouchelouche PN. Antibodies to infliximab and adalimumab in patients with rheumatoid arthritis in clinical remission: a cross-sectional study. *Arthritis* 2015;2015:784825.
- 98) Cordtz R, Mellekjær L, Glintborg B, Hetland ML, Dreyer L. Malignant progression of precancerous lesions of the uterine cervix following biological DMARD therapy in patients with arthritis. *Ann Rheum Dis* 2015;74(7):1479-80.
- 99) Axelsen MB, Eshed I, Hørslev-Petersen K, Stengaard-Pedersen K, Hetland ML, Møller J, Junker P, Pødenphant J, Schlemmer A, Ellingsen T, Ahlquist P, Lindegaard H, Linauskas A, Dam MY, Hansen I, Horn HC, Ammitzbøll CG, Jørgensen A, Krintel SB, Raun J, Krogh NS, Johansen JS, Østergaard M; OPERA study group. A treat-to-target strategy with methotrexate and intra-articular triamcinolone with or without adalimumab effectively reduces MRI synovitis, osteitis and tenosynovitis and halts structural damage progression in early rheumatoid arthritis: results from the OPERA randomised controlled trial. *Ann Rheum Dis* 2015;74(5):867-75.
- 100) Højgaard P, Glintborg B, Hetland ML, Hansen TH, Lage-Hansen PR, Petersen MH, Holland-Fischer M, Nilsson C, Loft AG, Andersen BN, Adelsten T, Jensen J, Omerovic E, Christensen R, Tarp U, Ostgård R, Dreyer L. Association between tobacco smoking and response to tumour necrosis factor α inhibitor treatment in psoriatic arthritis: results from the DANBIO registry. *Ann Rheum Dis* 2015;74(12):2130-6.
- 101) Rom AL, Wu CS, Olsen J, Kjaergaard H, Jawaheer D, Hetland ML, Vestergaard M, Mørch LS. Fetal growth and preterm birth in children exposed to maternal or paternal rheumatoid arthritis: a nationwide cohort study. *Arthritis Rheumatol* 2014;66(12):3265-73.
- 102) Hetland ML, Jensen DV, Krogh NS. Monitoring patients with rheumatoid arthritis in routine care: experiences from a treat-to-target strategy using the DANBIO registry. *Clin Exp Rheumatol* 2014;32(5 Suppl 85):S-141-6.

- 103) Ammitzbøll CG, Steffensen R, Bøgsted M, Hørslev-Petersen K, Hetland ML, Junker P, Johansen JS, Pødenphant J, Østergaard M, Ellingsen T, Stengaard-Pedersen K. CRP genotype and haplotype associations with serum C-reactive protein level and DAS28 in untreated early rheumatoid arthritis patients. *Arthritis Res Ther* 2014;16(5):475.
- 104) Grøn KL, Ornbjerg LM, Hetland ML, Aslam F, Khan NA, Jacobs JW, Henrohn D, Rasker JJ, Kauppi MJ, Lang HC, Mota LM, Aggarwal A, Yamanaka H, Badsha H, Gossec L, Cutolo M, Ferraccioli G, Gremese E, Bong Lee E, Inanc N, Direskeneli H, Taylor P, Huisman M, Alten R, Pohl C, Oyoo O, Stropuviene S, Drosos AA, Kerzberg E, Ancuta C, Mofti A, Bergman M, Detert J, Selim ZI, Abda EA, Rexhepi B, Sokka T. The association of fatigue, comorbidity burden, disease activity, disability and gross domestic product in patients with rheumatoid arthritis. Results from 34 countries participating in the Quest-RA program. *Clin Exp Rheumatol* 2014;32(6):869-77.
- 105) Hetland ML, Jensen DV, Krogh NS. Monitoring patients with rheumatoid arthritis in routine care: experiences from a treat-to-target strategy using the DANBIO registry. *Clin Exp Rheumatol* 2014;32(5 Suppl 85):141-6.
- 106) Ornbjerg LM, Østergaard M, Bøyesen P, Krogh NS, Thormann A, Tarp U, Poulsen UE, Espesen J, Schlemmer A, Graudal N, Kollerup G, Jensen DV, Madsen OR, Glintborg B, Christensen T, Lindegaard H, Bøhme W, Hansen A, Andersen AR, Hetland ML. Which factors influence radiographic progression during treatment with tumor necrosis factor inhibitors in clinical practice? Results from 930 patients with rheumatoid arthritis in the nationwide Danish DANBIO registry. *J Rheumatol* 2014;41(12):2352-60.
- 107) Løgstrup BB, Deibjerg LK, Hedemann-Andersen A, Ellingsen T. Left ventricular function in treatment-naive early rheumatoid arthritis. *Am J Cardiovasc Dis* 2014;4(2):79-86.
- 108) Sode J, Vogel U, Bank S, Andersen PS, Thomsen MK, Hetland ML, Loch H, Heegaard NH, Andersen V. Anti-TNF treatment response in rheumatoid arthritis patients is associated with genetic variation in the NLRP3-inflammasome. *PLoS One* 2014;9(6):e100361.
- 109) Glintborg B, Gudbjornsson B, Krogh NS, Omerovic E, Manilo N, Holland-Fischer M, Lindegaard HM, Loft AG, Nordin H, Johnsen L, Oeftiger SF, Hansen A, Rasmussen C, Grondal G, Geirsson AJ, Hetland ML. Impact of different infliximab dose regimens on treatment response and drug survival in 462 patients with psoriatic arthritis: results from the nationwide registries DANBIO and ICEBIO. *Rheumatology* 2014;53(11):2100-9.
- 110) Primdahl J, Sørensen J, Horn HC, Petersen R, Hørslev-Petersen K. Shared care or nursing consultations as an alternative to rheumatologist follow-up for rheumatoid arthritis outpatients with low disease activity – patient outcomes from a 2-year, randomised controlled trial. *Ann Rheum Dis* 2014;73:357-64.
- 111) Putrik P, Ramiro S, Kvien TK, Sokka T, Pavlova M, Uhlig T, Boonen A; Working Group 'Equity in access to treatment of rheumatoid arthritis in Europe'. Inequities in access to treatment of rheumatoid arthritis in Europe. *Ann Rheum Dis* 2014;73(1):198-206.
- 112) Primdahl J, Clausen J, Hørslev-Petersen K. Results from systematic screening for cardiovascular risk in outpatients with rheumatoid arthritis in accordance with the EULAR recommendations. *Ann Rheum Dis* 2013;72:1771-6.
- 113) Linde L, Sørensen J, Østergaard M, Hetland ML. Gain in quality-adjusted life-years in patients with rheumatoid arthritis during 1 year of biological therapy: a prospective study in clinical practice. *J Rheumatol* 2013;40(9):1479-86. Erratum in: *J Rheumatol* 2013;40(9):1634. Merete, Lund Hetland [corrected to Hetland, Merete Lund].

- 114) Glintborg B, Østergaard M, Krogh NS, Andersen MD, Tarp U, Loft AG, Lindegaard HM, Holland-Fischer M, Nordin H, Jensen DV, Olsen CH, Hetland ML. Clinical response, drug survival, and predictors thereof among 548 patients with psoriatic arthritis who switched tumor necrosis factor α inhibitor therapy: Results from the Danish Nationwide DANBIO registry. *Arthritis Rheum* 2013;65(5):1213-23.
- 115) Krintel SB, Grunert VP, Hetland ML, Johansen JS, Rothfuss M, Palermo G, Essieux L, Klause U. The frequency of anti-infliximab antibodies in patients with rheumatoid arthritis treated in routine care and the associations with adverse drug reactions and treatment failure. *Rheumatology* 2013;52(7):1245-53.
- 116) Madsen OR. Agreement between the DAS28-CRP assessed with 3 and 4 variables in patients with rheumatoid arthritis treated with biological agents in the daily clinic. *J Rheumatol* 2013;40(4):379-85.
- 117) Glintborg B, Ostergaard M, Krogh NS, Andersen MD, Tarp U, Loft AG, Lindegaard HM, Holland-Fischer M, Nordin H, Jensen DV, Olsen CH, Hetland ML. Clinical response, drug survival and predictors thereof among 548 switchers of tumor necrosis factor- α -inhibitor therapy in psoriatic arthritis. Results from the Danish nationwide DANBIO registry. *Ann Rheum Dis* 2013;65(5):1213-23.
- 118) Krintel SB, Grunert VP, Hetland ML, Johansen JS, Rothfuss M, Palermo G, Essieux L, Klause U. The frequency of anti-infliximab antibodies in patients with rheumatoid arthritis treated in routine care and the associations with adverse drug reactions and treatment failure. *Rheumatology* 2013; 52(7):1245-53.
- 119) Dreyer L, Mellekjær L, Andersen AR, Bennett P, Poulsen UE, Juulsgaard Ellingsen T, Hansen TH, Jensen DV, Linde L, Lindegaard HM, Loft AG, Nordin H, Omerovic E, Rasmussen C, Schlemmer A, Tarp U, Hetland ML. Incidences of overall and site specific cancers in TNF- α -inhibitor treated patients with rheumatoid arthritis and other arthritides - a follow-up study from the DANBIO Registry. *Ann Rheum Dis* 2013;72(1):79-82.
- 120) Primdahl J, Wagner L, Holst R, Hørslev-Petersen K and the AMBRA Study group. The impact on self-efficacy of different types of follow-up care and disease status in patients with rheumatoid arthritis—A randomized trial. *Patient Educ Couns* 2012;88:121-8.
- 121) Sørensen J, Linde L, Østergaard M, Hetland ML. Quality adjusted life expectancies in patients with rheumatoid arthritis – comparison of index scores from EQ-5D, 15D and SF-6D. *Value in Health* 2012;15:334-9.
- 122) Ørnbjerg LM, Østergaard M, Bøyesen P, Krogh NS, Thormann A, Tarp U, Poulsen UE, Espesen J, Ringsdal VS, Graudal N, Kollerup G, Jensen DV, Madsen OR, Glintborg B, Christensen T, Lindegaard H, Dencker D, Hansen A, Andersen AR, Hetland ML. Impact of tumour necrosis factor inhibitor treatment on radiographic progression in rheumatoid arthritis patients in clinical practice: results from the nationwide Danish DANBIO registry. *Ann Rheum Dis* 2012;72(1):57-63.
- 123) Hetland ML, Jensen DV, Tarp U. DANBIO: Danish Rheumatology Database. *Ugeskr f Laeger* 2012;174(42):2520. Danish. No abstract available.
- 124) Glintborg B, Ostergaard M, Krogh NS, Tarp U, Manilo N, Loft AG, Hansen A, Schlemmer A, Fana V, Lindegaard HM, Nordin H, Rasmussen C, Ejstrup L, Jensen DV, Petersen PM, Hetland ML. Clinical response, drug survival and predictors thereof in 432 ankylosing spondylitis patients after switching tumour necrosis factor- α -inhibitor therapy: results from the Danish nationwide DANBIO registry. *Ann Rheum Dis* 2012;72(7):1149-55.
- 125) Krintel SB, Essieux L, Wool A, Johansen JS, Schreiber E, Zekharya T, Akiva P, Ostergaard M, Hetland ML. CD6 and syntaxin binding protein 6 variants and response to tumor necrosis factor alpha inhibitors in

Danish patients with rheumatoid arthritis. PLoS One 2012;7(6):e38539.

- 126) Krintel SB, Palermo G, Johansen JS, Germer S, Essioux L, Benayed R, Badi L, Ostergaard M, Hetland ML. Investigation of single nucleotide polymorphisms and biological pathways associated with response to TNF- α -inhibitors in patients with rheumatoid arthritis. *Pharmacogenet Genomics* 2012;22(8):577-89.
- 127) Jawaheer D, Olsen J, Hetland ML. Sex differences in response to anti-tumor necrosis factor therapy in early and established rheumatoid arthritis - results from the DANBIO registry. *J Rheumatol.* 2012;39(1):46-53.
- 128) Hetland ML, Jacobsen S, Manniche C, Tarp U. Behandlingsstrategi, hjertekarsygdom og databaser. *Ugeskr f Læger* 2011;173:715.
- 129) Hetland ML. Modern treatment strategies in rheumatoid arthritis. *Dan Med Bull* 2011;58:B4320.
- 130) Chatzidionysiou K, Lie E, Nasonov E, Lukina G, Hetland M, Tarp U, van Riel P, Nordström DC, Gomez-Reino J, Pavelka K, Tomsic M, Kvien T, van Vollenhoven RF, Gabay C. Effectiveness of disease-modifying antirheumatic drug co-therapy with methotrexate and leflunomide in rituximab-treated rheumatoid arthritis patients: results of a 1-year follow up study from the CERERRA collaboration. *Ann Rheum Dis* 2012;71(3):374-7.
- 131) Leffers HC, Østergaard M, Glintborg B, Krogh NS, Hansen A, Hansen MS, Tarp U, Lorentzen T, Foged H, Jacobsen MS, Hetland ML. Efficacy of abatacept and tocilizumab in rheumatoid arthritis patients treated in clinical practice. A cohort study from the national Danish DANBIO registry. *Ann Rheum Dis* 2011;70:1216-1222.
- 132) Chatzidionysiou K, Nasonov E, Lukina G, Hetland ML, Tarp U, Gabay C, van Riel PLCM, Nordström DC, Gomez-Reino J, Pavelka K, Tomsic M, Lie E, Kvien TK and van Vollenhoven RF. Highest clinical effectiveness of rituximab in anti-CCP and RF-positive RA patients and in those who failed at most one prior TNF antagonist – Pooled data from ten European registries. *Ann Rheum Dis* 2011;70:1575-80.
- 133) Madsen OR. Is DAS28-CRP with three and four variables interchangeable in individual patients selected for biological treatment in daily clinical practice? *Clin Rheumatol.* 2011;30(12):1577-82.
- 134) Hetland ML. DANBIO - powerful research databases and electronic patient record. *Rheumatology* 2011;50(1):69-77.
- 135) Primdahl J, Wagner L, Hørslev-Petersen K. Being an outpatient with rheumatoid arthritis – a focus group study on patients' self-efficacy and experiences from participation in a short course and one of three different outpatient settings. *Scand J Caring Sci* 2011;25(2):394-403.
- 136) Pedersen SJ, Sørensen IJ, Hermann KG, Madsen OR, Tvede N, Hansen MS, Thamsborg G, Andersen LS, Majgaard O, Loft AG, Erlendsson J, Asmussen K, Johansen JS, Jurik AG, Møller J, Hasselquist M, Mikkelsen D, Skjødt T, Hansen A, Østergaard M. Responsiveness of the ankylosing spondylitis disease activity score (ASDAS) and clinical and magnetic resonance imaging measures of disease activity in a 1 year prospective study of patients with spondyloarthritis treated with TNF- α -inhibitors. *Ann Rheum Dis* 2010;69(6):1065-71.
- 137) Hetland ML. Danish data document therapeutic effect differences of tumor necrosis factor inhibitors in patient with rheumatoid arthritis. *Ugeskrift for Læger.* 2010;172(26):2003; author reply 2003-4.
- 138) Pedersen SJ, Hetland ML, Sørensen IJ, Østergaard M, Nielsen HJ, Johansen SJ. Circulating levels of interleukin-6, vascular endothelial growth factor, YKL-40, matrix metalloproteinase-3, and total

aggregran in spondyloarthritis patients during 3 years of treatment with TNF- α -inhibitors. Clin Rheumatol 2010;29(11):1301-9.

- 139) Dixon WG, Carmona L, Finckh A, Hetland ML, Kvien TK, Landewe R, Listing J, Nicola PJ, Tarp U, Zink A, Askling J. EULAR points to consider when establishing, analysing and reporting safety data of biologics registers in rheumatology. Ann Rheum Dis 2010;69(9):1596-602.
- 140) Plant D, Flynn E, Mbarek H, Dieudé P, Cornelis F, Arlestig L, Dahlqvist SP, Goulielmos G, Boumpas DT, Sidiropoulos P, Johansen JS, Ørnbjerg LM, Hetland ML, Klareskog L, Filer A, Buckley CD, Raza K, Witte T, Schmidt RE, Worthington J. Investigation of potential non-HLA rheumatoid arthritis susceptibility loci in a European cohort increases the evidence for nine markers. Ann Rheum Dis 2010;69(8):1548-53.
- 141) Glintborg B, Ostergaard M, Dreyer L, Krogh NS, Tarp U, Hansen MS, Ribbjerg-Madsen S, Lorenzen T, Hetland ML. Treatment response, drug survival and predictors thereof in 764 patients with psoriatic arthritis treated with anti-tumor necrosis factor- α -therapy: Results from the Danish nationwide DANBIO registry. Arthritis Rheum 2011;63:382-90.
- 142) Glintborg B, Ostergaard M, Krogh NS, Dreyer L, Kristensen HL, Hetland ML. Predictors of treatment response and drug continuation in 842 patients with ankylosing spondylitis treated with anti-tumour necrosis factor: Results from 8 years' surveillance in the Danish nationwide DANBIO registry. Ann Rheum Dis. 2010;69(11):2002-8.
- 143) Linde L, Sørensen J, Østergaard M, Hørslev-Petersen K, Hetland ML. Does clinical remission lead to normalization of EQ-5D in patients with rheumatoid arthritis and is selection of remission criteria important? J Rheumatol 2010;37(2):285-90.
- 144) Hetland ML, Christensen IJ, Tarp U, Dreyer L, Hansen A, Hansen IT, Kollerup G, Linde L, Lindegaard HM, Poulsen UE, Schlemmer A, Jensen DV, Jensen S, Hostenkamp G, Østergaard M. Direct comparison of treatment responses, remission rates, and drug adherence in patients with rheumatoid arthritis treated with adalimumab, etanercept, or infliximab: Results from eight years of surveillance of clinical practice in the nationwide Danish DANBIO registry. Arthritis Rheum 2010;62(1):22-32.
- 145) Schefté DB, ML Hetland. An open source, self-explanatory touch screen in routine care. Validity of filling in the Bath measures on Ankylosing Spondylitis Disease Activity Index, Function Index, the Health Assessment Questionnaire and Visual Analogue Scales in comparison with paper versions. Rheumatology 2010;49(1):99-104.
- 146) Hetland ML, Christensen IJ, Tarp U, Dreyer L, Hansen A, Hansen IT, Kollerup G, Linde L, Lindegaard HM, Poulsen UE, Schlemmer A, Jensen DV, Jensen S, Hostenkamp G, Østergaard M: Comparison between adalimumab, etanercept, and infliximab in rheumatoid arthritis: Reply to comment by Francis and Block (letter). Arthritis Rheum 2010;62:2826-8.
- 147) Primdahl, J, Wagner L, Hørslev-Petersen K. Self-efficacy in Rheumatoid Arthritis: Translation and Test of Validity, Reliability and Sensitivity of the Danish version of the Rheumatoid Arthritis SE Questionnaire (RASE). Musculoskeletal Care 2010;8(3):123-35.
- 148) Dreyer L, Mellekjær L, Hetland ML Risiko for kræft blandt danske gigtpatienter i behandling med tumor-nekrosisalfa-hæmmere – et deskriptivt studie fra den landsdækkende database DANBIO. Ugeskr Laeger 2009;171(7):506-11.
- 149) Linde L, Sørensen J, Østergaard M, Hørslev-Petersen K, Rasmussen C, Jensen DV, Hetland ML. What factors influence the health status of patients with rheumatoid arthritis measured by the SF-12v2

health survey and the health assessment questionnaire? J Rheumatol 2009;36(10):2183-9.

- 150) Døhn UM, Boonen A, Hetland ML, Hansen MS, Knudsen LS, Hansen A et al. Erosive progression is minimal, but erosion healing rare, in rheumatoid arthritis patients treated with adalimumab. A 1 year investigator-initiated follow-up study using high-resolution computed tomography as the primary outcome measure. Ann Rheum Dis 2009;68(10):1585-90.
- 151) Hetland ML, Lindegaard HM, Hansen A, Pødenphant J, Unkerskov J, Ringsdal VS, Østergaard M, Tarp U. Do changes in prescription practice in patients with rheumatoid arthritis treated with biological agents affect treatment response and adherence to therapy? Results from the nationwide Danish DANBIO Registry. Ann Rheum Dis 2008;67(7):1023-6.
- 152) Hjardem E, Østergaard M, Pødenphant J, Tarp U, Andersen LS, Bing J, Peen E, Lindegaard HM, Ringsdal VS, Rødgaard A, Skøt J, Hansen A, Mogensen HH, Unkerskov J, Hetland ML. Do rheumatoid arthritis patients benefit from switching to a second biological drug in clinical practice? Ann Rheum Dis 2007;66(9):1184-9.
- 153) Østergaard M, Unkerskov J, Linde L, Krogh NS, Friis M, Ravn T, Ringsdal VS, Petri A, Andersen LS, Tarp U, Hansen A, Hjardem E, Hetland ML. Low remission rates but long drug survival in rheumatoid arthritis patients treated with infliximab or etanercept – results from the nationwide Danish „DANBIO“ database. Scand J Rheum 2007;36(2):151-4.
- 154) Hetland ML, Unkerskov J, Ravn T, Friis M, Tarp U, Andersen LS, Petri A, Khan H, Stenver DI, Hansen A, Østergaard M. Routine database registration of biological therapy increases the report of adverse events twenty-fold in clinical practise. First results from the Danish Database (DANBIO). Scand J Rheumatol 2005;34:40-4.
- 155) Hjardem E, Hetland ML, Østergaard M, Krogh NS, Kvien TK. Prescription practice of biological drugs in rheumatoid arthritis during the first three years of post-marketing use in Denmark and Norway: Criteriae are becoming less stringent. Ann Rheum Dis 2005; 64: 1220-3.12. Hetland ML. DANBIO – a nationwide registry of biological therapies in Denmark. Clin Exp Rheumatol 2005;23(5 Suppl 39):S205-7.
- 156) Hetland ML. DANBIO - a nationwide registry of biological therapies in Denmark. Clin Exp Rheumatol 2005;23(5 Suppl 39):S205-7.

Foredrag præsenteret ved internationale kongresser:

- 1) How well does whole body magnetic resonance imaging agree with whole body ultrasound in the assessment of joint inflammation in rheumatoid arthritis patients. Præsenteret ved ACR 2019 i Atlanta. Ng SN.
- 2) Similar one-year treatment retention of originator and biosimilar etanercept. Results of a nordic collaboration including 1015 patients with spondyloarthritis. Præsenteret ved ACR 2019 i Atlanta. Glintborg B.
- 3) Risk of medical complications following total hip or knee arthroplasty in patient with rheumatoid arthritis: A nationwide register-based cohort study. Præsenteret ved ACR 2019 i Atlanta. Cordtz R.
- 4) Risk of neurological adverse events during tumour necrosis factor inhibitor treatment for arthritis: A population-based cohort study from DANBIO and ARTIS. Præsenteret ved ACR 2019 i Atlanta. Kopp TI.
- 5) Risk of hospitalized infection in patients with chronic inflammatory arthritis treated with biological drugs – A matched cohort study. Præsenteret ved ACR 2019 i Atlanta. Krabbe S.

- 6) Incidence of overall and site-specific cancers in TNF inhibitor treated patients with psoriatic arthritis: A population-based cohort study from 4 Nordic countries. Præsentaeret ved EULAR 2019 i Madrid. Ballegaard C.
- 7) 6 and 12-month Drug Retention Rates and Treatment Outcomes in 941 Patients with Axial Spondyloarthritis Treated with Secukinumab in Routine Clinical Practice in 12 European Countries in the EuroSpA Research Collaboration Network. Præsenteret ved ACR 2019 i Atlanta. Michelsen B (foredraget holdt af Østergaard M)
- 8) Does Discordance Between Baseline Patient's and Evaluator's Global Assessment of Disease Activity Impact Retention and Remission Rates of a First TNF Inhibitor in Patients with Axial Spondyloarthritis? Data from the EuroSpA Research Collaboration Network. Præsenteret ved ACR 2019 i Atlanta. Michelsen B (foredraget holdt at Hetland, ML).
- 9) High Baseline Patient's Compared with Evaluator's Global Assessment Is Associated with Lower Retention and Remission Rates of First TNF Inhibitor in Psoriatic Arthritis Patients - Data from the EuroSpA Research Collaboration Network. Præsenteret ved ACR 2019 i Atlanta. Michelsen B (foredraget holdt at Hetland, ML).
- 10) Risk of Neurological Adverse Events during Tumour Necrosis Factor Inhibitor Treatment for Arthritis: A Population-Based Cohort Study from Danbio and the Danish National Patient Registry. Præsenteret ved ACR 2018 i Chicago. Dreyer L.
- 11) Dose Tapering and Discontinuation of Biological Therapy in Rheumatoid Arthritis Patients in Routine Care – 2-Year Outcomes and Predictors. Præsenteret ved ACR 2018 i Chicago. Brahe CH.
- 12) Drug Retention and Response Rates of TNFi Treatment in 21,470 Patients with Axial Spondyloarthritis Treated in Clinical Practice– Pooled Data from the EuroSpA Research Network Collaboration. Præsenteret ved ACR 2018 i Chicago. Brahe CH.
- 13) An MRI Guided Treat-to-Target Strategy in Rheumatoid Arthritis Patients in Clinical Remission Improved MRI Inflammation but Not Damage Progression - Results from the Imagine-RA Randomized Controlled Trial. Præsenteret ved ACR 2018 i Chicago. Møller-Bisgaard S.
- 14) Clinical registries in the Nordic Countries – real world data. Invited presentation. 37th Scand Congr Rheumatol Helsinki. Finland, Sept 5th-8th, 2018. Glintborg B.
- 15) Risk of serious infections in rheumatoid arthritis patients treated with abatacept, rituximab and tocilizumab in Denmark and Sweden. Præsenteret ved EULAR 2018 i Amsterdam. Grøn KL.
- 16) Patients' views on routine collection of patient-reported outcomes in rheumatology care – a danbio focus group study. Præsenteret ved EULAR 2018 i Amsterdam. Primdahl J.
- 17) Baseline comorbidities and overweight predict functional status and health-related quality of life 9 years later – a longitudinal cohort study of 428 patients with rheumatoid arthritis receiving standard care. Præsenteret ved EULAR 2018 i Amsterdam. Linde L.

- 18) Risk of Second Malignant Neoplasm and Mortality in Rheumatoid Arthritis Patients Treated with Biological Dmards: A Danish Population-Based Cohort Study. Præsenteret ved ACR 2017 i San Diego. Dreyer L.
- 19) In psoriatic arthritis fatigue is driven by inflammation, disease duration, and chronic pain: an observational DANBIO registry study. Præsenteret ved EULAR 2017 i Madrid. Jørgensen TS.
- 20) Patient and physician global assessments are poorly connected in individual patients with psoriatic arthritis and only poorly explained by other clinical markers of disease activity. Præsenteret ved EULAR 2017 i Madrid. Madsen OR.
- 21) Physician postgraduate experience has a predictive role for physician efficiency index regarding patients eith rheumatoid arthritis: a cohort, exploratory study. Præsenteret ved EULAR 2017 i Madrid. Emamifar A.
- 22) The impact of comorbidities on effect and discontinuation of tumour necrosis factor inhibitor therapy in psoriatic arthritis: A population-based cohort study. Præsenteret ved EULAR 2017 i Madrid. Ballegaard C.
- 23) 10+ Years' Follow-up of a Danish 2-Year Treat-to-Target RCT in Patients with Early Rheumatoid Arthritis: Baseline Predictors of Functional and Radiographic Outcomes. Præsenteret ved ACR 2016 i Washington DC. Hetland ML.
- 24) Physical Activity Behavior in Men with Inflammatory Arthritis: A Cross-Sectional Register Based Study of Physical Activity Correlates, Motivators, Barriers and Preferences. Præsenteret ved ACR 2016 i Washington DC. Esbensen BA.
- 25) Dose Reduction or Discontinuation of Biological Therapy in Patients with Rheumatoid Arthritis in Remission – 1-Year Results of a Guideline-Directed Longitudinal Cohort Study. Præsenteret ved ACR 2016 i Washington DC. Brahe CH.
- 26) Non-Medical Switch from Originator to Biosimilar Infliximab in Patients with Inflammatory Arthritis – Impact on s-Infliximab and Antidrug-Antibodies. Results from the Danish Rheumatologic Biobank and the Danbio Registry. Præsenteret ved ACR 2016 i Washington DC. Hetland ML.
- 27) A Nationwide Non-Medical Switch from Originator to Biosimilar Infliximab in Patients with Inflammatory Arthritis. Eleven Months' Clinical Outcomes from the Danbio Registry. Præsenteret ved ACR 2016 i Washington DC. Hetland ML.
- 28) Magnetic Resonance Imaging (MRI) Joint Space Narrowing Is an Independent Predictor of Radiographic and MRI Damage Progression in Patients with Early Rheumatoid Arthritis. Præsenteret ved ACR 2016 i Washington DC. Møller-Bisgaard S.
- 29) Collaboration between Research and Patient Organisations: Improving Patient Care through The Danish Rheumatologic Biobank. Præsenteret ved EULAR 2016 i London. Glintborg B.
- 30) Three months' clinical outcomes from a nationwide non-medical switch from originator to biosimilar infliximab in patients with inflammatory arthritis. Results from the DANBIO registry. Præsenteret ved EULAR 2016 i London. Glintborg B.
- 31) Non-medical switch from originator to biosimilar infliximab among patients with inflammatory rheumatic disease – impact on S-infliximab and antidrug-antibodies. Results from the national Danish Rheumatologic Biobank and the Danbio Registry. Præsenteret ved EULAR 2016 i London. Glintborg B.

- 32) The efficacy of motivational counselling and SMS-reminders on daily sitting time in patients with rheumatoid arthritis: A randomised controlled trial. Præsenteret ved EULAR 2016 i London. Esbensen BA.
- 33) Investigating the Ameliorating Effect of Pregnancy on Rheumatoid Arthritis Using Whole Transcriptome Analysis. Præsenteret ved ACR 2015 i San Fransisco. Mittal A.
- 34) Circulating Micro-RNA Profiles in Responders to Adalimumab Plus Methotrexate Versus Methotrexate Alone: A Placebo-Controlled Clinical Trial. Præsenteret ved ACR 2015 i San Fransisco. Sode J.
- 35) Polymorphisms in the FCN1 gene coding for m-ficoling are associated with disease activity, radiographic damage and are the strongest predictors of DAS28 remission in 180 DMARD naive early rheumatoid arthritis patients. Præsenteret ved EULAR 2015 i Rom. Ammitzbohl CG.
- 36) ADAM17 and galectin-9 are critical regulators of local 4-1BB activity and disease outcome in rheumatoid arthritis. Præsenteret ved EULAR 2015 i Rom. Nielsen MA.
- 37) The impact of patient characteristics and past treatment history on the evolution of functional disability in RA patients treated with abatacept. A PAN-European analysis of RA registries. Præsenteret ved EULAR 2015 i Rom. Finckh A.
- 38) Monitoring patients with rheumatoid arthritis in routine care – "Experiences from a Treat-to-Target strategy using the DANBIO registry". Præsenteret ved ACR 2014 i Boston. Hetland ML.
- 39) ACR/EULAR remission in RA patients in clinical practice – Does substitution of patient global with pain score change remission rates? Data from the Danish DANBIO registry. Præsenteret ved ACR 2014 i Boston. Hetland ML.
- 40) Malignant progression of precancerous lesions of the uterine cervix following DMARD therapy in female arthritis patients. Præsenteret ved ACR 2014 i Boston. Cordtz R.
- 41) Cancer incidence in TNF inhibitor treated patients with axial spondyloarthritis and psoriatic arthritis – a study from the ARTIS and DANBIO registers. Præsenteret ved ACR 2014 i Boston. Askling J.
- 42) Monitoring patients with rheumatoid arthritis in routine care – "Experiences from a Treat-to-Target strategy using the DANBIO registry". Præsenteret ved ACR 2014 i Boston. Hetland ML.
- 43) First results of a European registries collaborative project to compare the spectrum of lymphomas between different exposure groups in rheumatoid arthritis. Præsenteret ved ACR 2014 i Boston. Mercer L.
- 44) No increased risk of developing a first invasive melanoma in rheumatoid arthritis patients treated with biologics: Results of a collaborative project of 11 European biologics registers. Præsenteret ved ACR 2014 i Boston. Mercer L.
- 45) Genome-wide association analysis of pain reduction in rheumatoid arthritis patients treated with TNF inhibitors. Præsenteret ved ACR 2014 i Boston. Coenen MJH.
- 46) How to implement systematic cardio-vascular risk assessment in outpatients with inflammatory arthritis in nursing consultations in accordance with the EULAR recommendations – a Danish example. Præsenteret ved EULAR 2014 i Paris. Primdahl J.
- 47) Impact of different infliximab dose regimens on treatment response and drug survival in 462 patients with PSA. Results from the nationwide registries DANBIO and ICEBIO. Præsenteret ved EULAR 2014 i Paris. Glintborg B.

- 48) MicroRNA expression profiles associated with response to adalimumab and methotrexate versus methotrexate: A placebo-controlled clinical trial. Præsenteret ved ACR 2013 i San Diego. Krintel SB.
- 49) Very high remission rates are achieved by methotrexate and intraarticular glucocorticoids independent of induction therapy with adalimumab: Year 2 clinical results of an investigator-initiated randomised, controlled clinical trial of early, rheumatoid arthritis. Præsenteret ved ACR 2013 i San Diego. Hørslev-Petersen K.
- 50) Increased soluble PD-1: A link between generation of immunological memory and risk of disease flare in early RA. Præsenteret ved ACR 2013 i San Diego. Greisen S.
- 51) Differences in abatacept use in rheumatoid arthritis patients across Europe: A Pan-European database analysis of abatacept in European RA registries. Præsenteret ved ACR 2013 i San Diego. Neto D.
- 52) Modern treatment of rheumatoid arthritis. Præsenteret ved EULAR 2013 i Madrid. Hetland ML.
- 53) Duration of symptoms before diagnosis in patients with rheumatoid arthritis, psoriatic arthritis and ankylosing spondylitis. Præsenteret ved EULAR 2013 i Madrid. Sørensen J.
- 54) Prevalence of comorbidities in rheumatoid arthritis. Does gross domestic product matter? Results from 34 countries in the QUEST-RA program. Præsenteret ved EULAR 2013 i Madrid. Grøn KL.
- 55) Clinical response, drug survival and predictors thereof among 548 switchers of tumor necrosis factor alpha inhibitor therapy in psoriatic arthritis. Results from the Danish nationwide DANBIO registry. Præsenteret ved ACR 2012 i Washington DC. Glintborg B.
- 56) Biologics in rheumatoid arthritis. Præsenteret ved SCR 2012 i København. Hetland ML.
- 57) Shared care and nursing consultations: a useful alternative to rheumatologist initiated follow-up. Results from a two-year randomized controlled trial. Præsenteret ved SCR 2012 i København. Primdahl J, Horn HC, Hørslev-Petersen K.
- 58) Measuring outcomes in a busy practice. Præsenteret ved EULAR 2012 i Berlin. Hetland ML.
- 59) Clinical and radiological outcome in outpatients with rheumatoid arthritis followed by medical, nursing or shared care - a two year randomised controlled study. Præsenteret ved EULAR 2012 i Berlin. Primdahl J.
- 60) Efficacy of different doses of rituximab for the treatment of RA: Data from the Cererra collaboration. Præsenteret ved EULAR 2012 i Berlin. Chatzidionysiou K.
- 61) Clinical response, drug survival and predictors thereof in 432 patients with ankylosing spondylitis switching anti tumor necrosis factor- α -therapy: Results from the Danish nationwide DANBIO registry. Præsenteret ved EULAR 2012 i Berlin. Glintborg B.
- 62) M-ficolin, an activator of the complement system, predicts DAS28 remission in early DMARD naïve rheumatoid arthritis. Præsenteret ved EULAR 2012 i Berlin. Ammitzbøll CG.
- 63) Towards imaging remission: Determining a MRI inflammatory activity acceptable state in rheumatoid arthritis. Præsenteret ved EULAR 2012 i Berlin. Haavardsholm EA.

- 64) Efficacy of different doses of rituximab for the treatment of rheumatoid arthritis: Data from the CERERRA collaboration. Præsenteret ved ACR 2011 i Chigaco. Chatzidionysiou K.
- 65) Seropositivity and response to RTX: Data from the CERERRA collaboration. Præsenteret ved ACR 2011 i Chigaco. Chatzidionysiou K.
- 66) The organization of follow-up for outpatients with rheumatoid arthritis affects satisfaction and confidence but not disease activity, disability, pain or fatigue. Præsenteret ved EULAR 2011 i London. Primdahl, J.
- 67) Self-efficacy and follow-up with nursing, medical or shared care for outpatients with rheumatoid arthritis. Præsenteret ved ACR 2010 i Atlanta. Primdahl J, Wagner L, Hørslev-Petersen K.
- 68) Discontinuation of TNF-inhibitor treatment in clinical practice has a negative impact on radiographic progression 2 years after initiation of therapy. Results from the nationwide Danish DANBIO registry. Præsenteret ved ACR 2010 i Atlanta. Ørnbjerg LM.
- 69) Biologics registers: Benefits beyond their current scope. Progression of research studies to electronic patient records. Præsenteret ved EULAR 2010 i Rom. Hetland ML.
- 70) Controversies in anti-TNF therapy in RA. Efficacy of anti-TNFs in RA: Identical or different? Præsenteret ved EULAR 2010 i Rom. Hetland ML.
- 71) The Ankylosing Spondylitis Disease Activity Score (ASDAS) better reflects the inflammatory disease processes than BASDAI - a comparison with biomarkers of inflammation, cartilage and bone turnover in patients with axial spondyloarthritis treated with TNF- α -inhibitors. Præsenteret ved EULAR 2010 i Rom. Pedersen SJ.
- 72) Predictors of treatment response and drug continuation in 764 patients with psoriatic arthritis treated with anti-tumor necrosis factor therapy: Results from the Danish nationwide DANBIO registry. Præsenteret ved EULAR 2010 i Rom. Glintborg B.
- 73) Effectiveness of different DMARD co-therapies in rituximab-treated rheumatoid arthritis (RA) patients – results of a one-year follow up study from the CERRERA Collaboration. Præsenteret ved EULAR 2010 i Rom. Gabay C.
- 74) Predictors of treatment response and drug continuation in 764 patients with psoriatic arthritis treated with anti-tumor necrosis factor therapy: results from the Danish nationwide DANBIO registry. Præsenteret ved EULAR 2010 i Rom. Glintborg B.
- 75) Bone edema on magnetic resonance imaging predicts erosive progression on computed tomography at 12 months in RA patients in adalimumab and methotrexate combination therapy. Præsenteret ved EULAR 2010 i Rom. Døhn UM.
- 76) Impact of TNF-inhibitor treatment on radiographic joint destruction in rheumatoid arthritis patients treated in clinical practise. Præsenteret ved EULAR 2010 i Rom. Ørnbjerg L.
- 77) Scandinavian arthritis registries, Denmark. Præsenteret ved SCR 2010 i Bergen. Hetland ML.
- 78) Internet and patient data. Practical approaches to web-based data collection. Præsenteret ved EULAR 2009 i København. Hetland ML.

- 79) Male gender, low baseline disease activity and good treatment response are predictors of treatment continuation in 770 patients with ankylosing spondylitis treated with anti-tumour necrosis factor therapy. Præsenteret ved EULAR 2009 i København. Glintborg B.
- 80) The Danish version of the rheumatoid arthritis self-efficacy questionnaire (RASE). Præsenteret ved EULAR 2009 i København. Primdahl J, Wagner L, Hørslev-Petersen K.
- 81) Responsiveness of the ankylosing spondylitis disease activity index (ASDAS), and clinical and magnetic resonance imaging measures of disease activity in a 1 year prospective study of patients with spondyloarthritis treated with TNFa inhibitors. Præsenteret ved EULAR 2009 i København. Pedersen SJ.
- 82) TNF-inhibitors reduce radiographic joint destruction by 65% in rheumatoid arthritis patients treated in clinical practice. Results from the nationwide Danish DANBIO registry. Præsenteret ved EULAR 2009 i København. Østergaard M.
- 83) Erosion Repair Occurs, But Is Rare, In Adalimumab Treated Rheumatoid Arthritis Patients – A 1-Year Magnetic Resonance Imaging Study. Præsenterete ved ACR 2008 i San Fransisco. Døhn UM.
- 84) Predictors of ACR 70 response after one year of anti-TNF treatment in clinical practice. Results from the nationwide DANBIO registry. Præsenterete ved ACR 2008 i San Fransisco. Hetland ML
- 85) Efficacy of biologics in clinical practice – what do the registries show us? Præsenteret ved SCR 2008 i Levi, Finland. Hetland ML.
- 86) Clinical approaches to early inflammatory arthritis: Early diagnosis and detection of poor prognosis. Præsenteret ved EULAR 2008 i Paris. Hetland ML.
- 87) Rheumatoid arthritis (RA) patients treated with rituximab showed no mean erosive progression, but a small tendency towards regression, on magnetic resonance imaging (MRI) and conventional radiography 1 year after treatment. Præsenteret ved EULAR 2008 i Paris. Døhn UM.
- 88) Erosive progression is minimal, but erosion healing rare, in rheumatoid arthritis patients (RA) treated with adalimumab. A 1-year longitudinal investigator-initiated study using high-resolution computed tomography as the primary outcome measure. Præsenteret ved EULAR 2008 i Paris. Døhn UM.

Posters præsenteret og abstracts trykt ved internationale kongresser

- 1) M, Nordström D, Rotar Z, Gudbjornsson B, Dalkılıç E, Codreanu C, Loft AG, Lindström U, Moeller B, Sexton J, Pavelka K, Barcelos A, Sánchez-Piedra C, Eklund K, Tomsic M, Love TJ, Sari İ, Ionescu R, van de Sande M, van der Horst-Bruinsma I, Jones GT, Iannone F, Michelsen B, Hyldstrup L, Krogh NS, Østergaard M, and Hetland ML Does drug effectiveness of 2nd and 3rd TNF inhibitors in patients with psoriatic arthritis depend on the reason for withdrawal from the previous treatment? - Results from the EuroSpA Research Collaboration. Ann Rheum Dis 2019;78(suppl 2):1401–2.
- 2) Brahe CH, Ørnbjerg L, Jacobsson LTH, Nissen M, Kristianslund E, Mann H, Santos MJ, Pombo-Suarez M, Nordström D, Rotar Z, Gudbjornsson B, Onen F, Codreanu C, Lindström U, Moeller B, Sexton J, Pavelka K, Barcelos A, Sánchez-Piedra C, Eklund K, Tomsic M, Love TJ, Can G, Ionescu R, Loft AG, van de Sande M, van der Horst-Bruinsma I, Macfarlane G, Iannone F, Hyldstrup L, Krogh NS, Østergaard M, and Hetland ML. Drug retention and remission rates in 14,261 biologic-naïve patients with psoriatic arthritis starting TNF inhibitor treatment in routine care - Results from 12 registries in the EuroSpA research collaboration. Ann Rheum Dis 2019;78(suppl 2):1842–43.

- 3) Brahe CH, Ørnberg L, Jacobsson L, Nissen M, Kristianslund E, Mann H, Santos M, Pombo-Suarez M, Nordström D, Rotar Z, Gudbjornsson B, Onen F, Codreanu C, Loft A, Lindström U, Moeller B, Sexton J, Pavelka K, Barcelos A, Sánchez-Piedra C, Eklund K, and Lund Hetland M. Does Drug Effectiveness of 2nd and 3rd TNF Inhibitors in Patients with Psoriatic Arthritis Depend on the Reason for Withdrawal from the Previous Treatment? – Results from the EuroSpA Research Collaboration - ACR Meeting Abstracts. *Arthritis Rheumatol.* 2019; 71 (Suppl 10).
- 4) Chatzidionysiou K, Hetland ML, Frisell T, Giuseppe DD, Hellgren K, Glintborg B, Nordström D, Aaltonen K, Trokovic N, Kristianslund E, Kvien TK, Provan SA, Gudbjornsson B, Gröndal G, Dreyer L, Kristensen LE, Jørgensen TS, Jacobsson LTH, and Askling J. Effectiveness of TNS inhibitors Vs. non-TNF inhibitors (Abatacept, Tocilizumab and Rituximab) after failure of non-TNFi biologic DMARD in rheumatoid arthritis - Collaboration between five nations registers. *Ann Rheum Dis* 2019;78(suppl 2):703–4.
- 5) Cordtz R, Hawley S, Prieto-Alhambra D, Kristensen LE, Overgaard S, Odgaard A, and Dreyer L. Incidence of joint replacement surgery among biologics and non-biologics treated patients with rheumatoid arthritis: A propensity score matched cohort study from Denmark. *Ann Rheum Dis* 2019;78(suppl 2):297.1-297.
- 6) Curtis JR, Weinblatt ME, Shadick N, Brahe CH, Østergaard M, Hetland ML, Saevarsdottir S, Horton M, Mabey B, Flake D, Sasso EH, and Huizinga T. Validation of the adjusted multi-biomarker disease activity score for predicting risk of radiographic progression for patient with rheumatoid arthritis. *Ann Rheum Dis* 2019;78(suppl 2):300–301.
- 7) Glintborg B, Krogh NS, Mehnert F, and Hetland ML. Comorbidities in >5000 patients with rheumatoid arthritis initiating treatment with Methotrexate in routine care: Prevalence and impact on treatment outcomes. An observational cohort study from DANBIO. *Ann Rheum Dis* 2019;78(suppl 2):339.2-340.
- 8) Glintborg B, Georgiadis S, Nørgaard M, Mehnert F, Lederballe Grøn K, Krogh NS, and Hetland ML. Hepatobiliary Events in >5000 Patients with Inflammatory Arthritis Treated with Biosimilar or Originator Etanercept in Routine Care, Results from the Danish Nationwide DANBIO Registry - ACR Meeting Abstracts. *Arthritis Rheumatol.* 2019; 71 (Suppl 10).
- 9) Glintborg B, Ibsen R, Qvist BR, Hetland ML and Kjellberg J. Does a Mandatory Non-Medical Switch from Originator to Biosimilar Etanercept Lead to Increase in Healthcare Use and Costs? A Danish Register-Based Study of 1620 Patients with Inflammatory Arthritis - ACR Meeting Abstracts. *Arthritis Rheumatol.* 2019; 71 (Suppl 10).
- 10) Grøn K, Glintborg B, Mehnert F, Østergaard M, Dreyer L, Nørgaard M, Krogh NS, and Hetland ML. Overall infection risk in patients with rheumatoid arthritis receiving Abatacept, Rituximab and Tocilizumab. An observational cohort study. *Ann Rheum Dis* 2019;78(suppl 2):630.1-630.
- 11) Grøn K, Glintborg B, Nørgaard M, Mehnert F, Østergaard M, Dreyer L, Krogh NS, Bjørner JB, and Hetland ML. Direct comparison of Certolizumab pegol, Abatacept and Biosimilar Infliximab in patients with rheumatoid arthritis treated in routine care. Observational data from the Danish DANBIO registry analyzed like a randomized clinical trial. *Ann Rheum Dis* 2019;78(suppl 2):1391–1391.
- 12) Hansen RL, Jørgensen TS, Dreyer L, Gudbjornsson B, Askling J, Hetland ML, Glintborg B, DI Giuseppe D, Jacobsson LTH, Kvien TK, Nordström D, Aaltonen K, Provan SA, Kristianslund E, Wallman JK, Love TJ, and Kristensen LE. Secular changes in psoriatic arthritis patients starting first course of biologic therapies - Inflammatory hallmarks of lesser prominence: A Nordic populations-based cohort study. *Ann Rheum Dis* 2019;78(suppl 2):1263.2-1264.

- 13) Herly M, Stengaard-Pedersen K, Hørslev-Petersen K, Hetland ML, Østergaard M, Christensen R, Løgstrup B, Vestergaard P, Junker P, Ellingsen T. Are Vitamin D metabolite levels at time of diagnosis associated with long-term severe cardiovascular events in early diagnosed rheumatoid arthritis patients, aggressively treated during 10 year follow up? Post-hoc analyses of observational data from the CIMESTRA Cohort - ACR Meeting Abstracts. *Arthritis Rheumatol.* 2019; 71 (Suppl 10).
- 14) Herly M, Stengaard-Pedersen K, Vestergaard P, Christensen R, Østergaard M, Junker P, Hetland ML, Hørslev-Petersen K, and Ellingsen T. Low serum level of vitamin D at time of diagnosis is associated with higher one-year remission rate in patients with newly diagnosed RA, treated aggressively during follow-up: Post-hoc analyses of the CIMESTRA trial. *Annals of the Rheumatic Diseases* 2019; 78(Suppl 2):1112.1-1112
- 15) Huizinga T, Weinblatt M, Shadick N, Brahe C, Østergaard M, Hetland ML, Hambardzumyan K, Saevarsdottir S, Horton M, Mabey B, Flake D, Gutin A, Ben-Shachar R, Sasso E, Curtis J. Predicting Risk of Radiographic Progression for Patients with Rheumatoid Arthritis - ACR Meeting Abstracts. *Arthritis Rheumatol.* 2019; 71 (Suppl 10).
- 16) Linde L and Hetland ML. Predictors of death in 3693 patients with rheumatoid arthritis followed for up to 12 years in clinical practice. *Annals of the Rheumatic Diseases* 2019; 78(Suppl 2):1037.3-1038.
- 17) Lindström U, Glinthborg B, Giuseppe D DI, Askling J, Nordström D, Provan SA, Gudbjornsson B, Hetland ML, Aaltonen K, Krogh NS, Geirsson AJ, and Jacobsson LTH. Identical two-year treatment retention of originator and biosimilar Infliximab. Results of a Nordic collaboration including 1319 patients with spondyloarthritis. *Ann Rheum Dis* 2019;78(suppl 2):871–871.
- 18) Hetland ML, Haavardsholm EA, Rudin A, Nordström D, Nurmohamed M, Gudbjornsson B, Lampa J, Hørslev-Petersen K, Uhlig T, Grondal G, Østergaard M, Heiberg M, Twisk J, Lend K, Krabbe S, Lindqv J, van Vollenhoven R and The NORD-STAR Study Group. A Multicenter Randomized Study in Early Rheumatoid Arthritis to Compare Active Conventional Therapy versus Three Biological Treatments: 24 Week Efficacy and Safety Results of the NORD-STAR Trial - ACR Meeting Abstracts. *Arthritis Rheumatol.* 2019; 71 (Suppl 10).
- 19) Michelsen B, Brahe CH, Jacobsson LTH, Nissen M, Pombo-Suarez M, Mann H, Rotar Z, Sexton J, Santos MJ, Nordström D, Codreanu C, Gudbjornsson B, Yilmaz S, Iannone F, Lindström U, Loft AG, Moeller B, Sánchez-Piedra C, Pavelka K, Tomsic M, Kristianslund E, Santos H, Hokkanen AM, Ionescu R, Love TJ, Pehlivan Y, Sebastiani M, Jones GT, van der Horst-Bruinsma I, Hyldstrup L, Krogh NS, Hetland ML, and Østergaard M. Remission and drug retention rates of Secukinumab in 1549 patients with psoriatic arthritis treated in routine care - pooled data from the observational EuroSpA research collaboration network. *Ann Rheum Dis* 2019;78(suppl 2):1281–82.
- 20) Michelsen B, Brahe CH, Askling J, Codreanu C, Ciurea A, Loft AG, Mann H, Pombo-Suarez M, Onen F, Sexton J, Rotar Z, Santos MJ, Eklund K, Gudbjornsson B, Iannone F, DI Giuseppe D, Ionescu R, Nissen M, Pavelka K, Sánchez-Piedra C, Akar S, Kristianslund E, Tomsic M, Santos H, Trokovic N, Geirsson AJ, Favalli EG, van der Horst-Bruinsma I, Macfarlane G, Hyldstrup L, Krogh NS, Østergaard M, and Hetland ML. Pooled 6-month treatment outcomes and drug retention rates in 1556 patients with axial spondyloarthritis treated with Secukinumab in routine clinical practice in 12 European countries in the EuroSpA Research collaboration. *Ann Rheum Dis* 2019;78(suppl 2):888–89.
- 21) Michelsen B, Ørnbjerg L, Loft AG, Sexton J, Ciurea A, Mann H, Eklund K, Yazici A, Santos MJ, Askling J, Rotar Z, Gudbjornsson B, Pombo-Suarez M, Codreanu C, van der Horst-Bruinsma I, Kristianslund E, Nissen M, Pavelka K, Trokovic N, Inanc N, Vieira-Sousa E, DI Giuseppe D, Tomsic M, Geirsson AJ, Ionescu R, van de Sande M, Iannone F, Sánchez-Piedra C, Jones GT, Hyldstrup L, Krogh NS, Hetland ML, and Østergaard M. High baseline patients compared with evaluator's global assessment is associated with

lower retention and remission rates of first TNF inhibitor in AxSpA patients - Data from the EuroSpA collaboration. *Ann Rheum Dis* 2019;78(suppl 2):887.2-888.

- 22) Michelsen B, Ørnbjerg L, Mann H, Sexton J, Nissen M, Santos MJ, Nissen M, Santos MJ, Nordström D, Jacobsson LTH, Rotar Z, Gudbjornsson B, Koca SS, Codreanu C, Pombo-Suarez M, van der Horst-Bruinsma I, Loft AG, Pavelka K, Kristianslund E, Moeller B, Vieira-Sousa E, Hokkanen AM, Lindström U, Tomsic M, Love TJ, Goker B, Ionescu R, Sánchez-Piedra C, van de Sande M, Macfarlane G, Iannone F, Hyldstrup L, Krogh NS, Østergaard M, and Hetland ML. Does discordance between patient's and evaluators global assessment of disease activity impact retention and remission rates of TNF inhibitors in patients with psoriatic arthritis? Data from the EuroSpA research collaboration. *Ann Rheum Dis* 2019;78(suppl 2):919.1-919.
- 23) Michelsen B, DiGuseppe D, Loft AG, Pombo-Suarez M, Mann H, Rotar Z, Iannone F, Kvien T, Santos M, Eklund K, Gudbjornsson B, Codreanu C, Yilmaz S, Askling J, Sánchez-Piedra C, Pavelka K, Tomsic M, Conti F, Sexton J, Santos H, Trokovic N, Love T, IONESCU R, Pehlivan Y, Nissen MJ, Macfarlane G, van der Horst-Bruinsma I, Georgiadis S, Ørnbjerg L, Brahe CH, Hetland ML, and Østergaard M. Secukinumab Effectiveness in 1134 Patients with Psoriatic Arthritis Treated in Routine Clinical Practice in 11 European Countries in the EuroSpA Research Collaboration Network - ACR Meeting Abstracts. *Arthritis Rheumatol.* 2019; 71 (Suppl 10).
- 24) Ørnbjerg LM, Brahe C, Loft A, Askling J, Ciurea A, Mann H, Akar S, Kristianslund E, Nordström D, Santos M, Codreanu C, Pombo-Suarez M, Rotar Z, Gudbjornsson B, DiGuseppe D, Nissen M, Pavelka K, Senel S, Sexton J, Eklund K, Barcelos A, IONESCU R, Sánchez-Piedra C, Tomsic M, Geirsson AJ, van der Horst-Bruinsma I, Macfarlane G, Iannone F, Michelsen B, Hyldstrup L, Krogh NS, Hetland ML, and Østergaard M. Does Retention and Remission Rates to 2nd and 3rd TNF Inhibitors in Patients with Axial Spondyloarthritis Depend on the Reason from Withdrawal to the Previous Treatment? – Real World Data from 12 European Countries in the EuroSpA Research Collaboration - ACR Meeting Abstracts. *Arthritis Rheumatol.* 2019; 71 (Suppl 10).
- 25) Møller-Bisgaard S, Hørslev-Petersen K, Ejbjerg B, Hetland ML, Ørnbjerg L, Glinatsi D, Møller JM, Boesen M, Stengaard-Pedersen K, Madsen O, Jensen B, Villadsen J, Hauge EM, Bennett P, Hendricks O, Asmussen K, Kowalski M, Lindegaard HM, Bliddal H, Krogh NS, Ellingsen T, Nielsen A, Balding L, Jurik AG, Thomsen H, and Østergaard M. Magnetic resonance imaging tenosynovitis and osteitis are independent predictors of radiographic and MRI damage progression in rheumatoid arthritis patients in clinical remission. *Annals of the Rheumatic Diseases* 78(Suppl 2):248.2-249
- 26) Møller-Bisgaard S, Hørslev-Petersen K, Ejbjerg B, Hetland ML, Ørnbjerg LM, Glinatsi D, Møller J, Boesen M, Stengaard-Pedersen K, Madsen OR, Jensen B, Villadsen J, Hauge E, Bennett P, Hendricks O, Asmussen K, Kowalski M, Lindegaard H, Bliddal H, Krogh NS, Ellingsen T, Nielsen A, Balding L, Jurik AG, Thomsen H, and Østergaard M. Magnetic Resonance Imaging in Patients in Clinical Remission: Tenosynovitis and Osteitis Are Independent Predictors of Radiographic and MRI Damage Progression - ACR Meeting Abstracts. *Arthritis Rheumatol.* 2019; 71 (Suppl 10).
- 27) Pathi A, Smed M, Pachter L, Purdom E, Wright M, Jewell N, Nelson J, Olsen J, Hetland ML, Zoffmann V, Jawaheer D. The Pre-Pregnancy Rheumatoid Arthritis Gene Expression Signature Correlates with Improvement or Worsening of Disease Activity During Pregnancy: A Pilot Study - ACR Meeting Abstracts. *Arthritis Rheumatol.* 2019; 71 (Suppl 10).
- 28) Ramos-Bello D, Hammer HB, Axelsen MB, Østergaard M, Ng SN, Hetland ML, Pedersen SJ, and Terslev L. Is monitoring synovitis in the hands by ultrasound enough to assess treatment effect in patient with RA in clinical practice? *Annals of the Rheumatic Diseases* 78(Suppl 2):2048.1-2048.

- 29) Skej  C, Nielsen MA, Hvid M, Hansen AS, Stengaard-Pedersen K, Hetland ML, H rslev-Petersen K, Junker P,  stergaard M, Greisen SR, Deleuran M, and Deleuran B. T-CELL immunoglobulin and mucin domain 3 (TIM-3) is increased in active rheumatoid arthritis and associated with clinical disease activity and radiographic progression. *Annals of the Rheumatic Diseases* 78(Suppl 2):1067.2-1068
- 30) Wright M, Goin D, Smed M, Pachter L, Nelson J, Jewell N, Olsen J, Lund Hetland M, Zoffmann V, Jawaheer D. Investigating the Post-Partum Flare in Rheumatoid Arthritis Using Transcriptome Analysis - ACR Meeting Abstracts. *Arthritis Rheumatol.* 2019; 71 (Suppl 10).
- 31)  rnbjerg L, Brahe CH, Loft AG, Askling J, Ciurea A, Mann H, Brahe CH, Loft AG, Askling J, Ciurea A, Mann H, Onen F, Kristianslund E, Nordstr m D, Santos MJ, Codreanu C, Pombo-Suarez M, Rotar Z, Gudbjornsson B, DI Giuseppe D, Nissen M, Pavelka K, Birlik M, Sexton J, Eklund K, Barcelos A, Ionescu R, S nchez-Piedra C, Tomsic M, Geirsson AJ, van der Horst-Bruinsma I, Jones GT, Iannone F, Hyldstrup L, Krogh NS, Hetland ML, and  stergaard M. Treatment response and drug retention rates in 23,956 biologic-na ve patients with axial spondyloarthritis initiating TNFi treatment - Routine care data from 12 registries in the EuroSpA collaboration. *Ann Rheum Dis* 2019;78(suppl 2):1408–9.
- 32)  rnbjerg L, Brahe CH, Loft AG, Askling J, Ciurea A, Mann H, Akar S, Kristianslund E, Nordstr m D, Santos MJ, Codreanu C, Pombo-Suarez M, Rotar Z, Gudbjornsson B, DI Giuseppe D, Nissen M, Pavelka K, Senel S, Sexton J, Eklund K, Barcelos A, Ionescu R, S nchez-Piedra C, Tomsic M, Geirsson AJ, van der Horst-Bruinsma I, Macfarlane G, Iannone F, Michelsen B, Hyldstrup L, Krogh NS, Hetland ML, and  stergaard M. Does drug effectiveness of 2nd and 3rd TNF inhibitors in patients with axial spondyloarthritis depend on the reason from withdrawal from the previous treatment? - Results from the EuroSpA research collaboration. *Ann Rheum Dis* 2019;78(suppl 2):872–73.
- 33)  rnbjerg L, Georgiadis S, Jacobsson L, Loft A, Iannone F, Moeller B, Sexton J, Mann H, Santos M, Pombo-Suarez M, Eklund K, Tomsic M, Gudbjornsson B, Erten S, Codreanu C, van der Horst-Bruinsma I, Wallman J, Sebastiani M, Nissen M, Kristianslund E, Pavelka K, Vieira-Sousa E, S nchez-Piedra C, Trokovic N, Rotar Z, Love TJ, Yolbas S, IONESCU R, van de Sande M, Jones G, Michelsen B,  stergaard M, and Hetland ML. Predictors of DAPSA28 Remission at 6 Months in Bio-Naive Patients with Psoriatic Arthritis Starting a TNF Inhibitor in Clinical Practice– Results from the EuroSpA Collaboration - ACR Meeting Abstracts. *Arthritis Rheumatol.* 2019; 71 (Suppl 10).
- 34)  rnbjerg L, Georgiadis S, Lindstr m U, Loft A, Ciurea A, Mann H, Akko  N, Iannone F, Kristianslund E, Hokkanen A, Santos M, Codreanu C, S nchez-Piedra C, Tomsic M, Gudbjornsson B, van der Horst-Bruinsma I, Askling J, Nissen M, Pavelka K, Gunduz O, Atzeni F, Sexton J, Nordstr m D, Santos H, IONESCU R, Pombo-Suarez M, Rotar Z, Geirsson AJ, van de Sande M, Macfarlane G, Michelsen B, Hetland ML, and  stergaard M. Predicting ASDAS Inactive Disease After 6 Months of TNFi Treatment in Bio-Naive Axial Spondyloarthritis Patients Treated in Clinical Practice – Results from the EuroSpA Collaboration - ACR Meeting Abstracts. *Arthritis Rheumatol.* 2019; 71 (Suppl 10).
- 35)  rnbjerg L, Jacobsson L, Loft A, Iannone F, Nissen M, Kristianslund E, Mann H, Santos M, Pombo-Suarez M, Eklund K, Rotar Z, Gudbjornsson B,  zt rk M, Codreanu C, van de Sande M, Wallman J, Favalli E, Moeller B, Sexton J, Pavelka K, Vieira-Sousa E, S nchez-Piedra C, Trokovic N, Tomsic M, Love T, Cefle A, IONESCU R, van der Horst-Bruinsma I, Jones G, Brahe CH, Hetland ML, and  stergaard M. Patient Reported Outcomes over 2 Years in Psoriatic Arthritis Patients Initiating Treatment with 1st, 2nd or 3rd TNF Inhibitor in Routine Care – Was PRO Remission Achieved? Results from the EuroSpA Collaboration - ACR Meeting Abstracts. *Arthritis Rheumatol.* 2019; 71 (Suppl 10).
- 36)  rnbjerg L, Askling J, Loft AG, Nissen M, Mann H, Direskeneli H, Iannone F, Sexton J, Nordstr m D, Santos M, Codreanu C, Pombo-Suarez M, Rotar Z, Gudbjornsson B, van der Horst-Bruinsma I, Lindstr m U, Ciurea A, Pavelka K, Yilmaz N, Gremese E, Kristianslund, Hokkanen AM, Barcelos A, IONESCU R, S nchez-Piedra MT, Geirsson AJ, van de Sande M, Marfarlane G, Brahe CH, Hetland ML, and  stergaard

M. Patient Reported Outcomes over Time in 25,988 Axial Spondyloarthritis Patients Initiating Treatment with 1st, 2nd or 3rd TNF Inhibitor in Clinical Practice – Is PRO Remission Achieved? Results from the EuroSpA Collaboration - ACR Meeting Abstracts. *Arthritis Rheumatol.* 2019; 71 (Suppl 10).

- 37) Madsen OR. Fatigue, pain, and patient global assessment are poorly interconnected and poorly explained by other clinical outcome measures in individual patients with psoriatic arthritis. Abstr 37th Scand Congr Rheumatol Helsinki, Finland, Sept 5th-8th, 2018.
- 38) Primdahl J, Kjeldgaard A, Christensen RD, Søndergaard J, Hørslev-Petersen K. Nurse-led screening: changes in cardiovascular risk profile and association to socio-economic status in outpatients with inflammatory arthritis. In: FRIDAY, 15 JUNE 2018. BMJ Publishing Group Ltd and European League Against Rheumatism, 2018, p 1815.3-1816.
- 39) Inanc N, Ozen G, Yalcinkaya Y, Dalkilic E, Koca SS, Can G, Karatas A, Pehlivan Y, Yazici A, Cefle A, Tufan A, Akar S, Senel S, Oz B, Akkoc N, and Onen F. Is there any difference in ra patients for methotrexate use vs. leflunomide use as a concomitant treatment with biological and targeted synthetic dmards in turkbio registry? In: FRIDAY, 15 JUNE 2018. BMJ Publishing Group Ltd and European League Against Rheumatism, 2018, p 611.2-612.
- 40) Kristensen LE, Jørgensen TS, Coates LC, Frederiksen P, Gudbjornsson B, Wallman JK, McHugh N, Kapetanovic MC, Dreyer L, Tillet W. Haq in psoriatic arthritis is driven by gender, inflammation and ageing: observational data from cohort studies in uk, denmark, iceland and sweden. In: THURSDAY, 14 JUNE 2018: BMJ Publishing Group Ltd and European League Against Rheumatism, 2018, pp 360–361.
- 41) Højgaard P, Ballegaard C, Cordtz R, Zobbe K, Clausen M, Kristensen LE, Glinthorg B, Dreyer L. Gender differences in biologic treatment outcomes – a study of 1750 patients with psoriatic arthritis using danish health care registers. In: THURSDAY, 14 JUNE 2018: BMJ Publishing Group Ltd and European League Against Rheumatism, 2018, p 376.1-376.
- 42) Jørgensen TS, Skougaard M, Ballegaard C, Mease P, Strand V, Dreyer L, Kristensen L. Fatigue remains a dominant symptom despite tumour necrosis factor inhibitor therapy in psoriatic arthritis: a population-based cohort study. In: THURSDAY, 14 JUNE 2018: BMJ Publishing Group Ltd and European League Against Rheumatism, 2018, p 384.2-385.
- 43) Ørnberg LM, Østergaard M, Onen F, Can G, Rotar Z, Tomsic M, Gudbjornsson B, Geirsson A, Santos M, Barcelos A, Nordström D, Aaltonen K, Nissen M, Ciurea A, Kristianslund E, Kvien T, Codreanu C, Hauge E, Jacobsson L, Mann H, Jones G, Iannone F, Hernandez M, van der Horst-Bruinsma I, Hyldstrup L, Krogh NS, and Hetland ML. Creation of a european database of patients with axial spondyloarthritis treated in clinical practice– initial, preliminary findings from the EuroSpA research network collaboration. In: Saturday, 16 JUNE 2018. BMJ Publishing Group Ltd and European League Against Rheumatism, 2018, pp 1009–1009.
- 44) Canet LM, Sánchez-Maldonado JM, Rodríguez-Ramos A, Lupiáñez CB, Canhão H, Martínez-Bueno M, Escudero A, Segura-Catena J, Sørensen SB, Hetland ML, Soto-Pino MJ, Ferrer MA, Garcia, A, Glinthorg B, Filipescu I, Pérez-Pampin E, Gonzalez-Utrilla A, López-Nevot MA, Conesa-Zamora P, den Broeder AA, da Vita S, Hove Jacobsen SE, Collantes E, Quartuccio L, Fonseca JE, Coenen MJ, Andersen V, Cáliz-Cáliz R, and Sainz J. Polymorphisms in phase i-metabolising enzyme and hormone receptor genes influence the

response to anti-tnf therapy. In: THURSDAY, 14 JUNE 2018. BMJ Publishing Group Ltd and European League Against Rheumatism, 2018, p 234.2-235.

- 45) Pálsson O, Guðbjörnsson B, Jóhannsdóttir GA, Gunnarsdóttir A, Gunnarsson PS, Love TJ, Rúnarsdóttir E. Patients with psoriatic arthritis who are not eligible for randomised clinical trials for tnf inhibitors have similar treatment response and drug survival. results from the icebio registry. In: THURSDAY, 14 JUNE 2018: BMJ Publishing Group Ltd and European League Against Rheumatism, 2018, p 359.3-360.
- 46) Rintek Madsen O. Patient and physician global assessments reflect strongly diverging attitudes between patients with psoriatic arthritis and their rheumatologists to severity of disease and to the relative importance of different outcome measures. In: Psoriatic arthritis. BMJ Publishing Group Ltd and European League Against Rheumatism, 2018, p 1595.1-1595.
- 47) Glintborg B, Sørensen IJ, Omerovic E, Mehnert F, Manilo N, Danebod K, Jensen DV, Nordin H, Loft AG, Hendricks O, Chrysidis S, Andersen BL, Raun JL, Lindegaard H, Espesen J, Jakobsen SH, Hansen IMJ, Dalsgaard EB, Pedersen DD, Kristensen S, Linauskas A, Andersen LS, Grydehøj J, Krogh NS, and Hetland ML. One-year treatment retention after a nationwide non-medical switch from originator to biosimilar etanercept in 2,061 patients with inflammatory arthritis followed in the danbio registry. In: THURSDAY, 14 JUNE 2018. BMJ Publishing Group Ltd and European League Against Rheumatism, 2018, pp 313–314.
- 48) Glintborg B, Sørensen IJ, Omerovic E, Mehnert F, Manilo N, Danebod K, Jensen D, Nordin H, Loft A, Hendricks O, Chrysidis S, Andersen B, Raun J, Lindegaard H, Espesen J, Jakobsen S, Hansen I, Dalsgaard E, Pedersen D, Kristensen S, Linauskas A, Andersen L, Grydehøj J, Krogh NS, and Hetland ML. One-year follow-up of a nationwide cohort of patients with inflammatory arthritis, who switched from originator to biosimilar etanercept, focusing on patients who switched back to originator. an observational danbio study. In: FRIDAY, 15 JUNE 2018. BMJ Publishing Group Ltd and European League Against Rheumatism, 2018, p 595.2-596.
- 49) Ørnbjerg LM, Østergaard M, Onen F, Birlik M, Rotar Z, Tomsic M, Gudbjornsson BL, Nissen MJ, Ciurea A, Nordström DT, Santos MJ, Carcelos AK, Kvien T, Codreanu C, Hauge E-M, Askling J, Iannone F, Mann H, Hernandez MV, Macfarlane G, van de Sande M, Hyldestrup L, Krogh NS, and Hetland ML. Creating a european database of psoriatic arthritis patients treated in routine care – first, preliminary results from the EuroSpA research network collaboration. In: THURSDAY, 14 JUNE 2018: BMJ Publishing Group Ltd and European League Against Rheumatism, 2018, p 376.2-377.
- 50) Rintek Madsen O. Concordance between fatigue, pain and patient global assessment in individual patients with psoriatic arthritis. In: Psoriatic arthritis. BMJ Publishing Group Ltd and European League Against Rheumatism, 2018, p 1595.2-1595.
- 51) Michelsen B, Sexton J, Smolen J, Aletaha D, Krogh NS, van der Heijde D, Kvien TK, and Hetland ML. Can disease activity in patients with psoriatic arthritis be adequately assessed by a modified disease activity index for psoriatic arthritis (DAPSA) based on 28 joints? In: THURSDAY, 14 JUNE 2018. BMJ Publishing Group Ltd and European League Against Rheumatism, 2018, p 343.1-343.
- 52) Brahe CH, Ørnbjerg LM, Jacobsson L, Nissen MJ, Kristianslund EK, Jos e Santos M, Eklund K, Rotar Z, Gudbjornsson B, Onen F, Codreanu C, Lindström U, Gabay C, Kvien T, Ionescu ABR, Loft AG, Mann HF, Pavelka K, van de Sande M, van der Horst-Bruinsma I, Gomez-Reino JJ, Sanchez-Piedra C, Macfarlane

- GJ, Iannone F, Hyldstrup L, Krogh NS, Østergaard M and Hetland ML. Drug Retention and Response Rates of TNFi Treatment in 13,170 Patients with Psoriatic Arthritis Treated in Routine Care – Pooled Data from the EuroSpA Research Network Collaboration - ACR Meeting Abstracts. *Arthritis Rheumatol.* 2018; 70 (suppl 10).
- 53) Jørgensen TS, Skougaard M, Hansen RL, Ballegaard C, Mease PJ, Strand V, Dreyer L and Kristensen LE. The Agreement between TNFi Treatment Responses and Fatigue Responses Is Weak to Moderate Suggesting Heterogeneity between Experienced Fatigue and Joint Inflammation: A Danish Population-Based Cohort Study - ACR Meeting Abstracts. *Arthritis Rheumatol.* 2018; 70 (suppl 10).
- 54) Cordtz R, Bech-Illum L, Prieto-Alhambra D, Hoejgaard P, Zobbe K, Imbæk N and Dreyer L. Impact of Tobacco Smoking on 1-Year Mortality Following Total Hip and Total Knee Arthroplasty Among Rheumatoid Arthritis Patients – a Danish Cohort Study Using Nationwide Health Care Registers - ACR Meeting Abstracts. *Arthritis Rheumatol.* 2018; 70 (suppl 10).
- 55) Nielsen MA, Kragstrup TW, Stengaard-Pedersen K, Hørslev-Petersen K, Hetland ML, Østergaard M, Junker P, Hvid M, Nilsson U, Stegmayr J, Leffler H DB. Galectin-3 Is a Regulator of 4-1BB/CD137 Activity and Associates with Outcome in Rheumatoid Arthritis. - ACR Meeting Abstracts. *Arthritis Rheumatol.* 2018; 70 (suppl 10).
- 56) Møller-Bisgaard S, Hørslev-Petersen K, Ejbjerg BJ, Hetland ML, Glinatsi D, Ørnbjerg L, Møller JM, Boesen M, Christensen R, Stengaard-Pedersen K, Madsen OR, Jensen B, Villadsen JA, Hauge E-M, Bennett P, Hendricks O, Asmussen K, Kowalski MR, Lindegaard H, Nielsen SM, Bliddal H, Krogh NS, Ellingsen T, Nielsen A, Balding L, Jurik AG, Thomsen HS, and Østergaard M. The Value of Adding MRI to a Clinical Treat-to-Target Strategy in Rheumatoid Arthritis Patients in Clinical Remission: Clinical and Radiographic Outcomes from the Imagine-RA Randomized Controlled Trial - ACR Meeting Abstracts. *Arthritis Rheumatol.* 2018; 70 (suppl 10).
- 57) Michelsen B, Sexton J, Smolen JS, Aletaha D, Krogh NS, van der Heijde D, Kvien T HM. Can Disease Activity in Patients with Psoriatic Arthritis be Adequately Assessed by a Modified Disease Activity Index for Psoriatic Arthritis (DAPSA) Based on 28 Joints? - ACR Meeting Abstracts. *Arthritis Rheumatol.* 2018; 70 (suppl 10).
- 58) Sundin U, Østergaard M, Glinatsi D, Aga AB, Hørslev-Petersen K, Hetland ML, Junker P, Ejbjerg BJ, Bird P, Conaghan PG, Lillegraven S HE. Validity and Responsiveness of Inflammation and Joint Damage Scores Based on the Omeract Rheumatoid Arthritis MRI Scoring System - ACR Meeting Abstracts. *Arthritis Rheumatol.* 2018; 70 (suppl 10).
- 59) Grøn KL, Arkema EV, Glintborg B, Mehnert F, Østergaard M, Dreyer L, Nørgaard M, Krogh NS, Askling J, and Hetland ML. Rheumatoid Arthritis Patients Treated with Abatacept, Rituximab and Tocilizumab in Denmark and Sweden: Risk of Serious Infections - ACR Meeting Abstracts. *Arthritis Rheumatol.* 2018; 70 (suppl 10).
- 60) Glintborg B, Omerovic E, Danebod K, Jensen DV, Nordin H, Loft AG, Chrysidis S, Raun JL, Hendricks O, Lindegaard H, Espesen J, Jakobsen S, Hansen IMJ, Grydehøj J, Dalgaard E, Dalsgaard Pedersen D, Manilo N, Smedegaard Andersen L, Kristensen S, Linauskas A, Krogh NS, Lund Hetland M. One-Year Clinical Outcomes in 1623 Patients with Inflammatory Arthritis Who Switched from Originator to Biosimilar

Etanercept – an Observational Study from the Danish Danbio Registry [abstract]. *Arthritis Rheumatol.* 2017;69(suppl 10).

- 61) Goin DE, Smed M, Pachter L, Purdom E, Nelson JL, Kjaergaard H, Olsen J, Lund Hetland M, Ottesen B, Zoffmann V, Jawaheer D. Transcriptome Analysis in Women with Rheumatoid Arthritis Who Improve or Worsen during Pregnancy [abstract]. *Arthritis Rheumatol.* 2017; 69 (suppl 10).
- 62) Goin DE, Smed M, Jewell N, Pachter L, Nelson JL, Kjaergaard H, Olsen J, Lund Hetland M, Ottesen B, Zoffmann V, Jawaheer D. Longitudinal Changes in Gene Expression Associated with Disease Activity during Pregnancy and Post-Partum Among Women with Rheumatoid Arthritis [abstract]. *Arthritis Rheumatol.* 2017; 69 (suppl 10).
- 63) Rintek Madsen O. Inter-Connections between Fatigue, Pain and Patient Global Assessment in Patients with Active Spondyloarthritis Followed in the Daily Clinic [abstract]. *Arthritis Rheumatol.* 2017;69 (suppl 10).
- 64) Rintek Madsen O. Patient and Physician Global Assessment Are Poorly Inter-Connected and Poorly Explained By Other Clinical Markers of Disease Activity in Individual Patients with Psoriatic Arthritis [abstract]. *Arthritis Rheumatol.* 2017; 69 (suppl 10).
- 65) Grøn KL, Arkema EV, Glinborg B, Askling J, Hetland ML. Baseline Characteristics and Rates of Hospitalized Infections in Patients with Rheumatoid Arthritis Treated with Non-TNF Inhibitors in Denmark and Sweden. *Arthritis Rheumatol.* 2017; 69 (suppl 10).
- 66) Glinatsi D, Brahe CH, Hetland ML, Ørnbjerg L, Krabbe S, Baker J, Boesen M, Rastimadabadi Z, Morsel-Carlsen L, Rogind H, Jensen HS, Hansen A, Nørregaard J, Jacobsen S, Terslev L, Huynh T, Manilo N, Jensen DV, Møller JM, Krogh NS, Østergaard M. Are Magnetic Resonance Imaging Features of the Hand Associated with Patient Reported Physical Function, Global Assessment of Disease Activity, Pain and Health Related Quality of Life in Rheumatoid Arthritis in Clinical Remission? – Longitudinal Results from an Observational Cohort. *Arthritis Rheumatol.* 2017;69(suppl 10).
- 67) Glinborg B, Lindström U, Aaltonen K, Kristianslund EK, Gudbjornsson B, Chatzidionysiou K, Askling J, Nordström D, Hetland ML, Di Giuseppe D, Dreyer L, Jørgensen TS, Kristensen LE, Eklund K, Grondal G, Ernestam S, Joensuu J, Kvien TK, Lie E, Fagerli KM, Geirsson AJ, Jonsson H, Jacobsson LTH. First Line Biological Treatment in Ankylosing Spondylitis, Prescription Rates, Baseline Demographics and Disease Activity. A Collaboration between Biological Registers in the Five Nordic Countries. *Arthritis Rheumatol.* 2017;69(suppl 10).
- 68) Holmsted K, Jørgensen NR, Rintek Madsen O. Reliability of the Biochemical Bone Markers CTX and P1NP during a TNF-Inhibitor Treatment Cycle in Patients with Rheumatoid Arthritis [abstract]. *Arthritis Rheumatol.* 2017;69(suppl 10).
- 69) Curtis JR, Brahe CH, Østergaard M, Lund Hetland M, Hambardzumyan K, Saevarsdottir S, Wang X, Sasso EH, Huizinga TWJ. High Multi-Biomarker Disease Activity Score Is Associated with High Risk of Radiographic Progression in Six Cohorts [abstract]. *Arthritis Rheumatol.* 2017; 69 (suppl 10).
- 70) Curtis JR, Flake DD II, Weinblatt M, Shadick NA, Østergaard M, Lund Hetland M, Brahe CH, Hwang YG, Furst DE, Strand V, Etzel CJ, Pappas DA, Wang X, Hwang CC, Sasso EH, Gutin A, Hitraya E, Lanchbury JS. Development of an Adjusted Multi-Biomarker Disease Activity (MBDA) Score for Rheumatoid Arthritis (RA) That Accounts for Age, Sex and Adiposity, with Subsequent Evaluation of Ability to Predict Risk for Radiographic Damage [abstract]. *Arthritis Rheumatol.* 2017;69(suppl 10).

- 71) Glintborg B, Sørensen IJ, Loft AG, Esbesen J, Lindegaard H, Jensen DV, Danebod K, Dieperink S, Hendricks O, Hansen IMJ, Linauskas A, Kristensen S, Andersen LS, Hossein M, Nordin H, Andersen BL, Chrysidis S, Raun JL, Manilo N, Grydehøj J, Dalgaard EB, Pedersen DD, Krogh NS, Hetland ML. Clinical outcomes from a nationwide non-medical switch from originator to biosimilar etanercept in patients with inflammatory arthritis after 5 months follow-up. Results from the DANBIO registry. *Ann Rheum Dis* 2017;76(suppl 2): 553.
- 72) Hetland ML, Østergaard M, Askling J, Gabay C, Nordstrom D, FitzGerald O, Hernández Miguel M, Santos M, Rotar Z, Mann H, Iannone F, Nissen MJ, Hauge E, Gomez-Reino J, Díaz-González F, Tomsic M, Pavelka K, O'Shea F, Sullivan C, van de Sande M, van der Horst-Bruinsma IE, Macfarlane GJ, Jones GT, Gudbjörnsson B, Kvien TK, on behalf of EuroSpA Study Group. Commonalities and differences in data collection across European spondyloarthritis registries. *Ann Rheum Dis* 2017;76(suppl 2):656.
- 73) Madsen OR, Egsmose EL. Interplay between patient global assessment, pain and fatigue and influence of other clinical disease activity measures in patients with active spondyloarthritis. *Ann Rheum Dis* 2017;76(suppl 2):669.
- 74) Jørgensen TS, Dreyer L, Guðbjörnsson B, Hetland ML, Glinborg B, Askling J, Chatzidionysiou K, Di Giuseppe D, Jacobsson L, Wallman JK, Kristianslund EK, Olsen IC, Fagerli K, Lie E, Nordström D, Aaltonen K Joensuu J, Love TJ, Geirsson AJ, Kristensen LE. Prescription patterns of tumour necrosis factor inhibitor and ustekinumab in psoriatic arthritis: a Nordic population- based cohort study. *Ann Rheum Dis* 2017;76(suppl 2):686.
- 75) Emamifar A, Hviid Larsen R, Andreasen Asmussen R, Jensen Hansen IM. Presence of thyroid disease in rheumatoid arthritis patients is predictor of worse initial treatment response: An observational, cohort study. *Ann Rheum Dis* 2017;76(suppl 2):533.
- 76) Emamifar A, Stilgren L, Hviid Larsen R, Andreasen Asmussen R, Jensen Hansen IM. Prevalence of hyperparathyroidism is higher among rheumatoid arthritis patients compared to the general population: an observational, cohort study. *Ann Rheum Dis* 2017;76(suppl 2):533.
- 77) Hetland ML, Stengaard-Petersen K, Junker P, Lindegaard H, Ellingsen T, Pødenphant J, Skjødt H, Vestergaard A, Ejbjerg B, Jacobsen S, Krogh NS, Østergaard M, Hørslev-Petersen K. 11 years' follow-up of a Danish 2-year treat-to-target randomized controlled trial in patients with early rheumatoid arthritis: Baseline predictors of functional and radiographic outcomes. *Ann Rheum Dis* 2017; 76 (suppl 2): 784.
- 78) Secher AE, Glinborg B, Gudbergesen H, Krogh NS, Jensen DV, Sørensen IJ, Christensen R, Skougaard M, Hetland ML. Comparing electronic collection of patient reported outcomes at home versus touch-screens in the waiting area among patients with arthritis in clinical practice: A randomised agreement study with online recruitment using DANBIO. *Ann Rheum Dis* 2017;76 (suppl 2): 456.
- 79) Grøn KL, Glinborg B, Nørgaard M, Mehnert F, Østergaard M, Dreyer L, Krogh NS, Hetland ML. Mandatory choice of first bDMARD in Denmark – an opportunity to study real-life effectiveness? Results from the DANBIO registry. *Ann Rheum Dis* 2017; 76 (suppl 2): 451.
- 80) Glinborg B, Chatzidionysiou K, Askling J, Aaltonen K, Kristianslund E, Gudbjörnsson B, Nordström D, Hetland ML, Dreyer L, Kristensen LE, Jørgensen TS, Eklund K, Grondal G, Ernestam S, Joensuu J, Kvien T, Lie E, Fagerli K, Geirsson AJ, Jonsson H, Jacobsson L. Prescription patterns of biological disease modifying drugs and biosimilars in ankylosing spondylitis – a collaboration between biological registries in the five Nordic countries. *Ann Rheum Dis* 2017; 76 (suppl 2): 341.

- 81) Cordtz RL, Kristensen LE, Overgaard S, Odgaard A, Lindegaard H, Dreyer L. Risk of revision, prosthetic joint infection and death following total hip or knee arthroplasty in patients with rheumatoid arthritis – a nationwide study from Denmark. *Ann Rheum Dis* 2017; 76 (suppl 2): 226.
- 82) Glinborg B, Sørensen J, Hetland ML. Use of outpatient rheumatologic health care services before and after switch from originator to biosimilar infliximab . *Ann Rheum Dis* 2017;76(suppl 2):450.
- 83) Emamifar A, Hviid Larsen R, Andreasen Asmussen R, Jensen Hansen IM. What is the role of steroids in inducing diabetes mellitus in patients with rheumatoid arthritis? An observational cohort study. *Ann Rheum Dis* 2017;76(suppl 2):246.
- 84) Curtis JR, Brahe CH, Ostergaard M, Hetland ML, Hambardzumyan K, Saevarsdottir S, Wang X, Sasso EH, Huizinga TW. High multi-biomarker disease activity score is associated with high risk of radiographic progression in six studies. *Ann Rheum Dis* 2017;76(suppl 2):234.
- 85) Møller Døhn U, Brahe CH, Hetland ML, Fana V, Krabbe S, Ammitzbøll-Danielsen M, Østergaard M, Terslev L. Ultrasound shows signs of inflammation in most patients with rheumatoid arthritis in longstanding clinical remission, irrespective of conventional synthetic or biologic dmard therapy. *Ann Rheum Dis* 2017; 76 (suppl 2): 726.
- 86) Glinatsi D, Baker JF, Hetland ML, Hørslev-Petersen K, Ejbjerg BJ, Stengaard-Pedersen K, Junker P, Ellingsen T, Lindegaard HM, Hansen I, Lottenburger T, Møller JM, Ørnbjerg L, Vestergaard A, Jurik AG, Thomsen HS, Torfing T, Bisgaard SM, Axelsen MB, Østergaard M. Wrist inflammation as assessed by magnetic resonance imaging is associated with patient-reported physical impairment, global disease activity and pain in early rheumatoid arthritis: long-term results from two randomized controlled trials. *Ann Rheum Dis* 2017; 76 (suppl 2): 732.
- 87) Munk HL, Fakih D, Sørensen GL, Qihua T, Christiansen L, Christensen AF, Ejstrup L, Loft AG, Kyvik KO, Jounblat R, Holmskov U, Junker P. Molecular size profile of surfactant protein-D in spondyloarthritis. *Clin Exp Rheumatol* 2016;34:766.
- 88) Ørnbjerg LM, Østergaard M, Jensen TD, Hørslev-Petersen K, Stengaard-Pedersen K, Junker P, Ellingsen T, Ahlquist P, Lindegaard H, Linauskas A, Schlemmer A, Yde Dam M, Hansen I, Lottenburger T, Ammitzbøll CG, Jørgensen A, Krintel SB, Raun JL, Hetland ML. Hand Bone Loss in Early Rheumatoid Arthritis Is Independent of Adalimumab Treatment – Results from a Randomized Controlled Clinical Trial. *Arthritis Rheumatol* 2016;68(suppl 10).
- 89) Ørnbjerg LM, Christensen KB, Tennant A, Lund Hetland M. Validation of the Danish Version of the Stanford Health Assessment Questionnaire Disability Index and Determination of the Minimal Clinically Important Difference in a Cohort of Rheumatoid Arthritis Patients Using the Rasch Measurement Model. *Arthritis Rheumatol* 2016;68(suppl 10).
- 90) Brahe CH, Østergaard M, Johansen JS, Defranoux NA, Hwang CC, Wang X, Bolce RJ, Sasso EH, Hørslev-Petersen K, Stengaard-Pedersen K, Ørnbjerg LM, Junker P, Ellingsen T, Ahlquist P, Lindegaard H, Linauskas A, Schlemmer A, Yde Dam M, Tønder Hansen I, Lottenburger T, Ammitzbøll CG, Jørgensen A, Krintel SB, Raun JL, Hetland ML. Multi-Biomarker Disease Activity (MBDA) Score and Prediction of Radiographic Progression in a Randomized Study of Patients with Early RA Treated with Methotrexate Alone or with Adalimumab. *Arthritis Rheumatol* 2016;68(suppl 10).
- 91) Courvoisier D, Alpizar Rodriguez D, Gottenberg JE, Iannone F, Lie E, Santos MJ, Pavelka K, Lund Hetland M, Turesson C, Mariette X, Choquette D, Finckh A. Drug Retention of Biologics in Rheumatoid Arthritis Patients: The Role of Baseline Characteristics and Impact of Time-Varying Factors. *Arthritis Rheumatol* 2016;68(suppl 10).

- 92) Heftdal LD, Stengaard-Pedersen K, Hetland ML, Hørslev-Petersen K, Junker P, Østergaard M, Hvid M, Deleuran B, Møller HJ, Greisen S. Soluble CD206 Plasma Levels Decreases with Treatment and Reflects Anti-Tnfa Discontinuation in Rheumatoid Arthritis. *Arthritis Rheumatol* 2016;68(suppl 10).
- 93) Sode J, Vogel U, Bank S, Andersen PS, Hetland ML, Loch H, Heegaard NHH, Andersen V. Genetic Variants in TNF, TNFRSF1A, and IL23R Are Associated with Risk of Ankylosing Spondylitis. *Arthritis Rheumatol* 2016;68(suppl 10).
- 94) Thomsen T, Aadahl M, Beyer N, Hetland ML, Loeppenthin K, Midtgaard J, Christensen R, Østergaard M, Jennum P, Appel Esbensen B. The Efficacy of Motivational Counselling and SMS-Reminders on Daily Sitting Time in Patients with Rheumatoid Arthritis: A Randomised Controlled Trial. *Arthritis Rheumatol* 2016;68(suppl 10).
- 95) Kringelbach T, Glintborg B, Johansen J, Høgdall E, Hetland ML. The nationwide Danish rheumatologic biobank – paving the road to personalized treatment of patients with inflammatory rheumatic diseases. *Ann Rheum Dis* 2016;75(Suppl2):1262.
- 96) Brahe CH, Terslev L, Krabbe S, Østergaard M, Røgind H, Jensen HS, Hansen A, Nørregaard J, Jacobsen S, Ellegaard K, Fana V, Juul L, Huynh T, Jensen D, Manilo N, Asmussen K, Frandsen PB, Pedersen ST, Krogh NS, Hetland ML. Agreement between DAS28, ACR/EULAR, SDAI, CDAI and ultrasound remission in patients with rheumatoid arthritis receiving biological treatment in routine care. *Ann Rheum Dis* 2016;75(Suppl2):989.
- 97) Gottenberg J-E, Courvoisier D, Hetland ML, Turesson C, Canhão H, Hernandez MV, Iannone F, Lie E, Pavelka K, Choquette D, Mariette X, Finckh A. Glucocorticoid-sparing effects of abatacept in rheumatoid arthritis are associated with both abatacept effectiveness and seropositivity. *Ann Rheum Dis* 2016;75(Suppl2):967.
- 98) Kristensen A-M, Hetland ML, Hørslev-Petersen K, Junker P, Østergaard M, Stengaard-Pedersen K, Höllsberg P, Hvid M, Deleuran B. Soluble CD83 plasma levels are associated with disease activity and course of disease in early rheumatoid arthritis. *Ann Rheum Dis* 2016;75(Suppl2):909.
- 99) Hansen SM, Hetland ML, Pedersen J, Østergaard M, Rubak TS, Bjorner JB. The prospective risk for long term sickness absence, unemployment, and disability pension, and the probability for return to work in patients with rheumatoid arthritis. *Ann Rheum Dis* 2016;75(Suppl2):890.
- 100) Glintborg B, Juul Sørensen I, Østergaard M, Mahamoud AA, Krogh NS, Andersen LS, Raun JL, Hendricks O, Kowalski MR, Danielsen L, Christensen SR, al Chaer N, Pelck R, Nordin H, Pedersen JK, Kraus DGA, Jensen Hansen IM, Espesen J, Schlemmer A, Loft AG, Salomonsen L, Dreyer L, Hetland ML. HLA-B27 status is associated with TNF α inhibitor treatment outcomes in ankylosing spondylitis and non-radiographic axial spondyloarthritis – observational cohort study from the nationwide DANBIO registry. *Ann Rheum Dis* 2016;75(Suppl2):801.
- 101) Finckh A, Courvoisier D, Gottenberg J, Hernandez M, Iannone F, Lie E, Canhão H, Pavelka K, Hetland ML, Turesson C, Mariette X, Choquette D. Is information about the reason for previous biologics discontinuation useful to predict the effectiveness of a biologic with a different mode of action? *Ann Rheum Dis* 2016;75(Suppl2):682.
- 102) Munk HL, Fakh D, Sørensen GL, Qihua T, Christiansen L, Christensen AF, Ejstrup L, Loft AG, Kyvik KO, Jounblat R, Holmskov U, Junker P. Circulating surfactant protein-D (SP-D) molecular size profile differs between patients with untreated axial spondyloarthritis and healthy control subjects. *Ann Rheum Dis* 2016;75(Suppl2):674.
- 103) Ørnbjerg LM, Christensen K, Tennant A, Hetland ML. Validation of the Danish version of the Stanford Health Assessment Questionnaire Disability Index and determination of the minimal clinically

important difference in a cohort of rheumatoid arthritis patients using the Rasch Measurement Model. *Ann Rheum Dis* 2016;75(Suppl2):652.

- 104) Møller-Bisgaard S, Ejbjerg B, Eshed I, Hørslev-Petersen K, Hetland ML, Jurik AG, Thomsen H, Torfing T, Stengaard-Pedersen K, Junker P, Krogh NS, Lottenburger T, Ellingsen T, Andersen LS, Skjødt H, Svendsen A, Tarp U, Hansen I, Pødenphant J, Pedersen JK, Lindegaard H, Vestergaard A, Glinatsi D, Østergaard M. Magnetic resonance imaging joint space narrowing is an independent predictor of radiographic and MRI damage progression in patients with early rheumatoid arthritis. *Ann Rheum Dis* 2016;75(Suppl2):638.
- 105) Ørnbjerg LM, Østergaard M, Jensen T, Hørslev-Petersen K, Stengaard-Pedersen K, Junker P, Ellingsen T, Ahlquist P, Lindegaard H, Linauskas A, Schlemmer A, Dam MY, Hansen I, Lottenburger T, Ammitzbøll CG, Jørgensen A, Krintel S, Raun J, Hetland ML. Hand bone loss in early rheumatoid arthritis is independent of adalimumab treatment. A substudy of the optimized treatment algorithm in early RA (OPERA) trial. *Ann Rheum Dis* 2016;75(Suppl2):633.
- 106) Courvoisier DS, Gottenberg J-E, Hernandez MV, Iannone F, Lie E, Canhao H, Pavelka K, Hetland ML, Turesson C, Mariette X, Choquette D, Finckh A. Trajectories of disease activity in rheumatoid arthritis patients after abatacept initiation and their association with clinical characteristics. *Ann Rheum Dis* 2016;75(Suppl2):451.
- 107) Brahe CH, Østergaard M, Johansen J, Defranoux N, Hwang C-C, Bolce R, Sasso E, Hørslev-Petersen K, Steengaard-Pedersen K, Junker P, Ellingsen T, Ahlquist P, Lindegaard H, Linauskas A, Schlemmer A, Dam MY, Hansen I, Lottenburger T, Ammitzbøll C, Jørgensen A, Krintel S, Raun J, Hetland ML. Changes in multi-biomarker disease activity (MBDA) score correlate with changes in established disease activity measurements in patients with early RA from the Opery Study. *Ann Rheum Dis* 2016;75(Suppl2):450.
- 108) Højgaard P, Glinborg B, Kristensen LE, Love TJ, Gudbjornsson B, Dreyer L. Obesity impairs the response to tumour necrosis factor-alpha inhibitors in psoriatic arthritis: results from the DANBIO and ICEBIO registries. *Ann Rheum Dis* 2016;75(Suppl2):340.
- 109) Heegaard Brahe C, Terslev L, Krabbe S, Østergaard M, Rogind H, Jensen H, Hansen A, Nørregaard J, Jacobsen S, Ellegaard K, Fana V, Juul L, Huynh TK, Jensen DV, Manilo N, Asmussen KH, Brown-Frandsen P, Torp-Pedersen ST, Krogh NS, Hetland ML. Agreement Between DAS28, ACR/EULAR, SDAI, CDAI and Ultrasound Remission in Patients with Rheumatoid Arthritis Receiving Biological Treatment in Routine Care. *Arthritis Rheum* 2015;67(10):S157.
- 110) Kragstrup TW, Greisen S, Nielsen MA, Rhodes C, Stengaard-Pedersen K, Hetland ML, Hørslev-Petersen K, Junker P, Østergaard M, Hvid M, Vorup-Jensen T, Robinson WH, Sokolove J, Deleuran B. The IL-20 Receptor Axis in Early Rheumatoid Arthritis: Novel Inflammation-Independent Links Between Autoantibody Positivity and Radiographic Progression. *Arthritis Rheum* 2015;67(10):S543.
- 111) Finckh A, Gottenberg J, Hernández MV, Iannone F, Lie E, Canhao H, Pavelka K, Turesson C, Hetland ML, Mariette X. The Impact of Tobacco Smoking on the Effectiveness of Abatacept in Rheumatoid Arthritis: Data from a Pan-European Analysis of RA Registries. *Arthritis Rheum* 2015;67(10):S592.
- 112) Issa SF, Duer A, Østergaard M, Lindegaard H, Hørslev-Petersen K, Hetland ML, Møller JM, Christensen AF, Junker P. MRI Erosions in Undifferentiated Arthritis. Different Associations with the Collagen IIA N-Terminal Propeptide (PIIANP) and Galectin-3 in Pre-RA and Other Arthritides. *Arthritis Rheum* 2015;67(10):S1306.
- 113) Bisgaard SM, Ejbjerg BJ, Eshed I, Hørslev-Petersen K, Hetland ML, Jurik AG, Vallø J, Thomsen H, Torfing T, Stengaard-Pedersen K, Junker P, Krogh NS, Lottenburger T, Ellingsen T, Andersen LS, Hansen I, Skjødt H, Svendsen A, Tarp U, Pødenphant J, Pedersen JK, Lindegaard H, Østergaard M. Effect of a Non Biologic Treat-to-Target Strategy on MRI-Determined Inflammatory and Destructive Changes in Early

Rheumatoid Arthritis – Results from a 2-Year Investigator-Initiated Double-Blind Randomized Controlled Clinical Trial. *Arthritis Rheum* 2015;67(10):S1311.

- 114) Ørnbjerg LM, Østergaard M, Jensen TD, Mortensen PB, Hyldstrup L, Boyesen P, Thormann A, Tarp U, Bøhme W, Lindegaard H, Poulsen UE, Hansen A, Schlemmer A, Graudal N, Andersen AR, Espesen J, Kollerup G, Glinborg B, Madsen OR, Jensen DV, Hetland ML. Tumour Necrosis Factor Inhibitor Treatment Normalises Hand Bone Loss in a Minority of Rheumatoid Arthritis Patients Treated in Clinical Practice. Results from the Copenhagen Osteoarthritis Study and the Danbio Registry. *Arthritis Rheum* 2015;67(10):S1313.
- 115) Ammitzbøll CG, Steffensen R, Bøgsted M, Nielsen KR, Ellingsen T, Hetland ML, Junker P, Pødenphant J, Østergaard M, Johansen J, Hørslev-Petersen K, Stengaard-Pedersen K. Associations Between 49 Susceptibility SNPs and Disease Activity Including Radiographic Damage in Early Untreated Rheumatoid Arthritis. *Arthritis Rheum* 2015;67(10):S2589.
- 116) Gottenberg J, Mariette X, Hernandez MV, Iannone F, Lie E, Canhãõ H, Pavelka K, Turesson C, Hetland ML, Finckh A. Glucocorticoid-Sparing Effects of Abatacept in Real Life Practice: Data from a Paneuropean Analysis of RA Registries. *Arthritis Rheum* 2015;67(10):S2766.
- 117) Steenbergen van H, Aletaha D, Beaart-van de Voorde L, Brouwer E, Codreanu C, Combe B, Fonseca JE, Hetland ML, Humby F, Kvien TK, Landewe R, Niedermann K, Nuno L, Oliver S, Rantapaa-Dahlqvist S, Raza K, Schaardenburg van D, Schett G, Smet de S, Szűcs G, Vencovsky J, Wiland P, Helm-van Mil van der A. Development of draft criteria for arthralgia that is clinically suspect for progression to rheumatoid arthritis; results of phase 1. *Ann Rheum Dis* 2015;74(S2):240.
- 118) Glinborg B, Hojgaard P, Hetland ML, Chrysidis S, Espesen J, Holland-Fischer M, Johansen FJ, Jensen J, Hansen IMJ, Hansen TH, Kollerup G, Krogh NS, Loft AGR, Lorenzen T, Mosborg P, Nilsson C, Nordin H, Oeftiger SF, Pelck R, Rasmussen C, Unger B, Dreyer L. Association between tobacco smoking and response to tumor necrosis factor alpha inhibitor treatment in ankylosing spondylitis: Results from the Danish nationwide DANBIO registry. *Ann Rheum Dis* 2015;74(S2):284.
- 119) Christensen AW, Rifbjerg-Madsen S, Christensen R, Hetland M, Bliddal H, Kristensen LE, Danneskiold-Samsø B, Amris K. Fatigue is correlated to pain mechanism rather than to inflammatory load in patients with rheumatoid arthritis: A descriptive cross-sectional DANBIO registry survey. *Ann Rheum Dis* 2015;74(S2):306.
- 120) Rifbjerg-Madsen S, Christensen AW, Christensen R, Hetland ML, Bliddal H, Kristensen LE, Danneskiold-Samsøe B, Amris K. Pain mechanisms in patients with inflammatory arthritis: A nationwide cross-sectional DANBIO registry survey. *Ann Rheum Dis* 2015;74(S2):313.
- 121) Tuyl van LH, Sadlonova M, Hewlett S, Davis B, Flurey C, Goel N, Gossec L, Heegaard Brahe C, Hill C, Hoogland W, Kirwan J, Hetland ML, Schaardenburg van D, Smolen J, Singh J, Stamm T, Voshaar M, Wells GA, Boers M on behalf of the OMERACT Working. The patient perspective on absence of disease activity in rheumatoid arthritis: A survey to identify key domains of patient perceived remission. *Ann Rheum Dis* 2015;74(S2):435.
- 122) Cordtz RL, Mellemejkjar L, Glinborg B, Hetland ML, Madsen OR, Dreyer L. Risk of virus-associated malignancies in female arthritis patients treated with biological DMARDs. *Ann Rheum Dis* 2015;74(S2):470.
- 123) Chatzidionysiou K, Lie E, Nasonov E, Lukina G, Hetland ML, Hauge E, Pavelka K, Gabay C, Nordstrom D, Canhãõ H, Tomsic M, Riel van P, Gomez-Reino J, Ancuta I, Kvien T, Vollenhoven van R, Saevarsdottir S. Smoking and response to rituximab in anti-ccp positive and negative rheumatoid arthritis – results

from an international European collaboration. *Ann Rheum Dis* 2015;74(S2):484.

- 124) Walker UA, Jaeger VK, Chatzidionysiou K, Hetland ML, Hauge EM, Pavelka K, Nordstrom DC, Canhao H on behalf of Rheumatic Diseases Portugal Register, Tomšič M, Vollenhoven van R, Gabay C. Rituximab done! What's next in rheumatoid arthritis? A European observational longitudinal study assessing the effectiveness of biologics after rituximab treatment in rheumatoid arthritis. *Ann Rheum Dis* 2015;74(S2):492.
- 125) Moller-Bisgaard S, Ejbjerg BJ, Eshed I, Horslev-Petersen K, Jurik AG, Vallo J, Thomsen H, Torfing T, Stengaard-Pedersen K, Hetland ML, Junker P, Krogh NS, Lottenburger T, Ellingsen T, Andersen LS, Hansen I, Skjodt H, Svendsen AJ, Tarp U, Podenphant J, Pedersen JK, Lindegaard H, Ostergaard M. Effect of methotrexate and intra-articular betamethasone with or without additional cyclosporine on magnetic resonance imaging (MRI)-determined inflammatory and destructive changes in very early rheumatoid arthritis – results from a 24-months' randomized double blind placebo controlled trial. *Ann Rheum Dis* 2015;74(S2):648.
- 126) Kragstrup TW, Greisen SR, Nielsen MA, Rhodes C, Stengaard-Pedersen K, Hetland ML, Horslev-Petersen K, Junker P, Ostergaard M, Hvid M, Vorup-Jensen T, Robinson W, Sokolove J, Deleuran B. The IL-20 receptor axis in early rheumatoid arthritis: Novel inflammation-independent links between rheumatoid arthritis-associated autoantibodies and radiographic progression. *Ann Rheum Dis* 2015;74(S2):650.
- 127) Ornbjerg L, Ostergaard M, Jensen T, Hyldstrup L, Bach-Mortensen P, Boyesen P, Thormann A, Tarp U, Lindegaard H, Schlemmer A, Graudal N, Andersen A, Espesen J, Kollerup G, Glinborg, B, Madsen O, Jensen D, Hetland M. Tumour necrosis factor alpha inhibitor treatment normalises hand bone loss in a minority of rheumatoid arthritis patients treated in clinical practice. Results from the Copenhagen osteoarthritis study and the DANBIO registry. *Ann Rheum Dis* 2015;74(S2):677.
- 128) Andersen MD, Petersen SJ, Axelsen MB, Ostergaard M, Hetland M, Hansen MS, Poggenborg RP, Terslev L. Ultrasound abnormalities at the entheses are not an uncommon finding in patients with rheumatoid arthritis. *Ann Rheum Dis* 2015;74(S2):1260.
- 129) Sokka T, Khan N, Nikiphorou E, Verstappen S, Hetland M, Inanc N, Laurindo I, Stropuviene S, Combe B, Cutolo M, Jacobs J on behalf of QUEST-RA investigators. Joint operations as an indicator of disease severity and burden in the Quest-RA study. *Ann Rheum Dis* 2015;74(S2):1298.
- 130) Nielsen MA, Andersen T, Steengaard-Pedersen K, Hoerslev-Petersen K, Hetland ML, Junker P, Ostergaard M, Hvid M, Deleuran B. Soluble 4-1BB is a marker of joint involvement and disease activity in rheumatoid arthritis. *Arthritis Rheum* 2014;66(S10):S154.
- 131) Egsmose EL, Cordtz R, Madsen OR. Fatigue fluctuates substantially over time in rheumatoid arthritis patients despite stable disease activity during treatment with biological agents. *Arthritis Rheum* 2014;66(S10):S160.
- 132) Greissen S, Moller HJ, Steengaard-Petersen K, Hetland ML, Hoerslev-Petersen K, Junker P, Ostergaard M, Hvid M, Deleuran B. Soluble CD163 is a marker of disease activity in early rheumatoid arthritis and reflects TNF α levels. *Arthritis Rheum* 2014;66(S10):S174.
- 133) Finckh A, Neto D, Hernandez MV, Iannone F, Lie E, Canhao H, Pavelka K, Turesson C, Mariette X, Hetland ML, Gottenberg J. Abatacept after Rituximab in rheumatoid arthritis. A Pan-European collaboration of RA registries. *Arthritis Rheum* 2014;66(S10):S218.

- 134) Kalyoncu U, Torgutalp M, Babaoglu H, Kilickap S, Kiraz S, Akdogan A, Karadag O, Erden A, Bilgen SA, Ertenli I. Etanercept have better drug survival than monoclonal antibodies in rheumatoid arthritis: Results of single center Hur-BIO registry. *Arthritis Rheum* 2014;66(S10):S220.
- 135) Walker UA, Jaeger VK, Chatzidionysiou K, Hetland ML, Hauge EM, Pavelka K, Nordström DC, Canhao H, Tomsic M, van Vollenhoven R, Gabay C. Rituximab done! What's next in RA? *Arthritis Rheum* 2014;66(S10):S671.
- 136) Hetland ML, Jensen DV, Krogh NS. Monitoring patients with rheumatoid arthritis in routine care – experiences from a Treat-to-Target strategy using the DANBIO registry. *Arthritis Rheum* 2014;66(S10):S804.
- 137) Axelsen M, Laurberg TB, Christensen R, Fredberg U, Ellingsen T. Predicting failure of conventional disease modifying antirheumatic drugs in treatment naive early rheumatoid arthritis patients: A single centre inception prognostic factor cohort study . *Arthritis Rheum* 2014;66(S10):S891.
- 138) Kuettel D, Primdahl J, Ornbjerg LM, Horn HC, Christensen R, Horslev-Petersen K. The impact of patient-reported flares on radiographic progression in rheumatoid arthritis patients with low-disease activity: Secondary analyses from a randomized trial. *Arthritis Rheum* 2014;66(S10):S932.
- 139) Ammitzboll CG, Steffensen R, Thiel S, Jensenius JC, Horslev-Petersen K, Ellingsen T, Hetland ML, Junker P, Ostergaard M, Stengaard-Pedersen K. Polymorphisms in the FCN1 gene coding for M-ficolin are associated with disease activity, radiographic damage and are the strongest predictors of DAS28 remission in 180 DMARD naïve early rheumatoid arthritis patients. *Arthritis Rheum* 2014;66(S10):S947.
- 140) Sode J, Vogel U, Bank S, Andersen PS, Hetland ML, Loch H, Heegaard NHH, Andersen V. Genetic variation in the TLR5 locus is associated with anti-TNF response among rheumatoid arthritis patients. *Arthritis Rheum* 2014;66(S10):S1092.
- 141) Chatzidionysiou K, Lie E, Nasonov E, Lukina G, Hetland ML, Hauge E, Pavelka K, Gabay C, Nordström D, Canhao H, Tomsic M, van Riel P, Gomez-Reino JJ, Ancuta I, Kvien T, van Vollenhoven R, Saevarsdottir S. Smoking and response to Rituximab in Anti-CCP positive and negative rheumatoid arthritis – results from an international European collaboration. *Arthritis Rheum* 2014;66(S10):S1104.
- 142) Coenen MJH , Umicevic-Mirkov M, Krintel SB, Johansen J, Miceli-Richard C, Kallberg H, Scheffer H, Kievit W, van de Laar MA, van Riel PLCM, Mariette X, Saevarsdottir S, Hetland ML, Vermeulen S, Albers CA. Genome-wide association analysis of pain reduction in rheumatoid arthritis patients treated with TNF inhibitors. *Arthritis Rheum* 2014;66(S10):S1296.
- 143) Kynde I, Sorensen J, Hetland ML, Hjelmberg JVB. Delay in RA diagnosis of more than 12 months is associated with deteriorated functional status in patients in DMARD treatment – results from a prospective study. *Ann Rheum Dis* 2014;73(S2):273.
- 144) Lage-Hansen PR, Chrysidis S, Lage-Hansen M, Hougaard A. Concomitant fibromyalgia in rheumatoid arthritis is associated with increased use of biological therapy. *Ann Rheum Dis* 2014;73(S2):293.
- 145) Nissen CB, Hørslev-Petersen K, Primdahl J. Screening for cardiovascular risk according to EULAR 2010 recommendations in outpatients with psoriasis arthritis or ankylosing spondylitis. *Ann Rheum Dis* 2014;73(S2):333.
- 146) Coenen M, Mirkov Umicevic M, Krintel SB, Johansen JS, Miceli-Richard C, Kallberg H, Padyukov L, Scheffer H, Kievit W, van de Laar MA, van Riel PL, Mariette X, Saevarsdottir S, Hetland ML, Vermeulen SH, Albers CA. Genome-wide association analysis of pain reduction in rheumatoid arthritis patients

treated with TNF inhibitors. *Ann Rheum Dis* 2014;73(S2):348.

- 147) Egsmose EL, Madsen OR. Fatigue in patients with rheumatoid arthritis selected for biological treatment in the daily clinic: Associations with classical measures of disease activity. *Ann Rheum Dis* 2014;73(S2):412.
- 148) Logstrup BB, Deibjerg L, Hedemann-Kristensen A, Ellingsen T. Left ventricular function in treatment-naive early rheumatoid arthritis. *Ann Rheum Dis* 2014;73(S2):417.
- 149) Gottenberg JE, Neto D, Gomez-Reino J, Iannone F, Lie E, Canhao H, Pavelka K, Turesson C, Hetland M, Mariette X, Finckh A. Positivity for rheumatoid factor and anti-cyclic citrullinated peptide is associated with better drug retention of abatacept: Data from a Paneuropean analysis of RA registries. *Ann Rheum Dis* 2014;73(S2):S502.
- 150) Chatzidionysiou K, Lie E, Nasonov E, Lukina G, Hetland ML, Tarp U, Pavelka K, Gabay C, Nordstrom DC, Canhao H, Tomsic M, van Riel PL, Gomez-Reino J, Ancuta I, Kvien TK, van Vollenhoven RF. Fixed versus on-flare retreatment with rituximab in RA – Results from the CERERRA Collaboration. *Ann Rheum Dis* 2014;73(S2):505.
- 151) Gabay C, Riek M, Hetland M, Hauge EM, Pavelka K, Tomsic M, Canhao H, Chatzidionysiou K, van Vollenhoven R, Lukina G, Nordstrom D, Lie E, Ancuta I, Loza Santamaria E, van Riel P, Kvien T. Retention of tocilizumab therapy: a comparison between tocilizumab in monotherapy and in combination with DMARDs based on the TOCERRA Collaboration. *Ann Rheum Dis* 2014;73(S2):601.
- 152) Egsmose EL, Cordtz R, Madsen OR. Fatigue fluctuations in patients with stable rheumatoid arthritis treated with biological agents. *Ann Rheum Dis* 2014;73(S2):609.
- 153) Jorgensen T, Kristensen L, Christensen R, Bliddal H, Lorenzen T, Hansen M, Ostergaard M, Jensen J, Zanjani L, Laursen T, Butt S, Dam M, Lindegaard H, Espesen J, Hendricks O, Kumar P, Kincses A, Larsen L, Andersen M, Naser E, Jensen D, Grydehoj J, Unger B, Dufour N, Sorensen V, Vildhoj S, Hansen I, Raun J, Krogh N, Hetland M. Effectiveness and drug adherence of biologic monotherapy in Danish rheumatoid arthritis patients: A cohort study of clinical practice in the DANBIO registry. *Ann Rheum Dis* 2014;73(S2):613.
- 154) Chatzidionysiou K, Lie E, Nasonov E, Lukina G, Hetland ML, Tarp U, Pavelka K, Gabay C, Nordstrom DC, Canhao H, Tomsic M, van Riel PL, Gomez-Reino J, Ancuta I, Kvien TK, van Vollenhoven RF. Effectiveness of repeated courses of rituximab in RA – results from the CERERRA collaboration. *Ann Rheum Dis* 2014;73(S2):674.
- 155) Hojgaard P, Glintborg B, Hetland ML, Hansen TH, Nilsson C, Lage-Hansen PR, Petersen MH, Holland-Fischer M, Loft AG, Andersen BN, Adelsten T, Jensen J, Omerovic E, Christensen R, Tarp U, Ostgaard R, Dreyer L. Association between tobacco smoking and response to tumor necrosis factor alpha inhibitor treatment in psoriatic arthritis: Results from the DANBIO registry. *Ann Rheum Dis* 2014;73(S2):743.
- 156) Ammitzbøll CG, Steffensen R, Junker P, Østergaard M, Johansen J, Pødenphant J, Hetland ML, Lindegaard HM, Ellingsen T, Steengaard-Pedersen K. Genotypic and haplotypic effects of 7 single-nucleotide polymorphisms in the CRP gene on levels of C-reactive protein and DAS28 in a cohort of 180 untreated newly diagnosed rheumatoid arthritis patients (OPERA study). *Ann Rheum Dis* 2014;73(S2):804.
- 157) Axelsen MKM, Laurberg TB, Christensen R, Fredberg U, Ellingsen T. Predicting failure of conventional disease modifying antirheumatic drugs in treatment naive early rheumatoid arthritis

patients: a single centre inception prognostic factor cohort study. *Ann Rheum Dis* 2014;73(S12):S894.

- 158) Yurtsever A, Rasmussen C. Spontaneous ankle and knee fractures in rheumatoid arthritis: A case report study. *Ann Rheum Dis* 2014;73(S12):S906.
- 159) Primdahl J, Nissen CB, Hørslev-Petersen K. Gender differences in risk factors for cardiovascular disease in outpatients with rheumatoid arthritis. *Ann Rheum Dis* 2014;73(S12):S913.
- 160) Hetland ML, Sørensen J. Duration of symptoms before diagnosis in patients with rheumatoid arthritis, psoriatic arthritis and ankylosing spondylitis. *Arthritis Rheum* 2013;65(10):S42.
- 161) Ammitzbøll CG, Steffensen R, Junker P, Østergaard M, Johansen J, Pødenphant J, Hetland ML, Lindegaard HM, Ellingsen T, Steengaard-Pedersen K. Genotypic and haplotypic effects of 7 single-nucleotide polymorphisms in the CRP gene on levels of C-reactive protein and DAS28 in a cohort of 180 untreated newly diagnosed rheumatoid arthritis patients (OPERA study). *Arthritis Rheum* 2013;65(10):S64.
- 162) Egholm CL, Krogh NS, Dreyer L, Ellingsen T, Glintborg B, Kowalski M, Lorenzen T, Madsen OR, Nordin H, Rasmussen C, Hetland ML. Are physician gender, age and clinical experience associated with discrepancy in global disease score in rheumatoid arthritis, ankylosing spondylitis and psoriatic arthritis? Data from the nationwide DANBIO registry. *Arthritis Rheum* 2013;65(10):S74.
- 163) Glintborg B, Gudbjornsson B, Krogh NS, Omerovic E, Manilo N, Holland-Fischer M, Lindegaard HM, Loft AG, Nordin H, Johnsen L, Oeftiger SF, Hansen A, Rasmussen C, Grondal G, Geirsson A, Hetland ML. Impact of low infliximab dose regimen on treatment response and drug survival in 462 patients with psoriatic arthritis. Results from the nationwide registries DANBIO and ICEBIO. *Arthritis Rheum* 2013;65(10):S133.
- 164) Gabay C, Riek M, Hetland ML, Tarp U, Pavelka K, Tomsic M, Canhao H, Chatzidionysiou K, van Vollenhoven RF, Lukina G, Nasonov E, Nordstrom DC, Lie E, Ancuta I, Santamaria EL, van Riel P, Kvien TK. Effectiveness of tocilizumab in monotherapy and in combination with different synthetic DMARDs: A registry-based comparison study. *Arthritis Rheum* 2013;65(10):S195.
- 165) Finckh A, Iannone F, Gomez-Reino J, Neto D, Lie E, van Riel P, Hetland ML, Pavelka K, Turesson C, Mariette X, Gottenberg JE. The impact of inadequate response to prior biologic agents on abatacept drug retention in rheumatoid arthritis patients. A Pan-European analysis of RA registries. *Arthritis Rheum* 2013;65(10):S217.
- 166) Chatzidionysiou K, Lie E, Nasonov E, Lukina G, Hetland ML, Tarp U, Pavelka K, Gabay C, Nordstrom D, Canhao H, Tomsic M, van Riel P, Gomez-Reino J, Ancuta I, Kvien T, van Vollenhoven R. Effectiveness of repeated courses of rituximab in RA – results from the CERERRA collaboration. *Arthritis Rheum* 2013;65(10):S217.
- 167) Chatzidionysiou K, Lie E, Nasonov E, Lukina G, Hetland ML, Tarp U, Pavelka K, Gabay C, Nordstrom D, Canhao H, Tomsic M, van Riel P, Gomez-Reino J, Ancuta I, Kvien T, van Vollenhoven R. Fixed versus on-flare retreatment with rituximab in RA – results from the CERERRA collaboration. *Arthritis Rheum* 2013;65(10):S219.
- 168) Greisen S, Rasmussen T, Schelde K, Steengaard-Pedersen K, Hetland ML, Hørslev-Petersen K, Deleuran B, Hvid M. CXCL 13 is a marker of joint involvement in early rheumatoid arthritis. *Arthritis Rheum* 2013;65(10):S403.

- 169) Dreyer L, Mellekmjær L, Jensen Hansen IM, Hetland ML. Impact of biological treatment on overall mortality and on incidence of second cancers in arthritis patients – a follow-up study from the Danish DANBIO registry. *Arthritis Rheum* 2013;65(10):S442.
- 170) Hørslev-Petersen K, Ørnbjerg LM, Hetland ML, Junker P, Pødenphant J, Ellingsen T, Ahlqvist P, Lindegaard HM, Linauskas A, Schlemmer A, Dam MY, Hansen I, Lottenburger T, Jørgensen A, Krintel SB, Raun J, Ammitzbøll CG, Johansen J, Østergaard M, Steengaard-Pedersen K. Induction therapy with adalimumab on top of an aggressive treat-to-target strategy with methotrexate and intraarticular corticosteroid reduces radiographic erosive progression in early rheumatoid arthritis, even after withdrawal of adalimumab. Results of a 2-year trial (OPERA). *Arthritis Rheum* 2013;65(10):S600.
- 171) Krabbe S, Bolce RJ, Brahe CH, Døhn UM, Cruickshank S, Ejbjerg BJ, Hetland ML, Sasso EH, Chernoff D, Hansen MS, Knudsen LS, Hansen A, Madsen OR, Hasselquist M, Møller JM, Østergaard M. Early changes in a multi-biomarker disease activity score after starting adalimumab treatment predict change in MRI inflammation at 6 months. *Arthritis Rheum* 2013;65(10):S608.
- 172) Leffers HCB, Østergaard M, Glinborg B, Krogh NS, Tarp U, Lorenzen T, Hansen A, Dreyer L, Hetland ML. Three-year drug survival and effectiveness of abatacept and tocilizumab in patients with rheumatoid arthritis treated in routine care. Results from the nationwide Danish DANBIO registry. *Arthritis Rheum* 2013;65(10):S612.
- 173) Jørgensen TS, Kristensen LE, Lorenzen T, Jensen J, Zanjani L, Laursen T, Butt S, Dam MY, Lindegaard HM, Espesen J, Hendricks O, Kumar P, Kincses A, Larsen LH, Andersen M, Næser EK, Jensen DV, Grydehøj J, Unger B, Dufour N, Sørensen VN, Vildhøj S, Hansen IMJ, Raun J, Hetland ML. The prevalence of biological monotherapy among rheumatoid arthritis patients in Denmark: Results from the Danish nationwide DANBIO registry. *Arthritis Rheum* 2013;65(10):S628.
- 174) Sode J, Heegaard NHH, Loch H, Vogel U, Bank S, Hetland ML, Andersen V. Functional single nucleotide polymorphisms in the interferon- γ and the NLRP3 (cryopyrin) genes associated with anti-TNF response in Danish rheumatoid arthritis patients. *Arthritis Rheum* 2013;65(10):S1002.
- 175) Axelsen MB, Eshed I, Hørslev-Petersen K, Steengaard-Pedersen K, Hetland ML, Møller JM, Junker P, Pødenphant J, Ellingsen T, Ahlqvist P, Lindegaard HM, Linauskas A, Schlemmer A, Dam MY, Hansen I, Horn HC, Ammitzbøll CG, Jørgensen A, Krintel SB, Raun J, Johansen J, Krogh NS, Østergaard M. A treat-to-target strategy with methotrexate and intra-articular triamcinolone with or without added adalimumab reduces synovitis, osteitis and tenosynovitis and halts structural damage progression in early rheumatoid arthritis: The OPERA magnetic resonance imaging sub-study. *Arthritis Rheum* 2013;65(10):S1199.
- 176) Jørgensen TS, Kristensen LE, Lorenzen T, Jensen J, Zanjani L, Laursen T, Butt S, Dam MY, Lindegaard HM, Espesen J, Hendricks O, Kumar P, Kincses A, Larsen LH, Andersen M, Næser EK, Jensen DV, Grydehøj J, Unger B, Dufour N, Sørensen VN, Vildhøj S, Hansen IMJ, Raun J, Heltand ML. The prevalence of biological monotherapy among rheumatoid arthritis patients in Denmark: Results from the Danish Nationwide DANBIO registry. *Arthritis Rheum* 2013;65(10):S628.
- 177) Tarp S, Tarp U, Andersen LS, Lorenzen T, Lindegaard H, Stoltenberg M, Jensen HS, Brock B, Mikkelsen CM, Jensen DV, Asmussen K, Herlin T, Christensen R. Serious adverse events associated with using biological agents to treat rheumatic diseases: Network meta-analysis from a National guideline panel. *Arthritis Rheum* 2013;65(10):S997.
- 178) Hørslev-Petersen K, Hetland ML, Junker P, Pødenphant J, Ellingsen TJ, Ahlqvist P, Lindegaard HM, Linauskas A, Schlemmer A, Dam MY, Hansen I, Lottenburger T, Jørgensen A, Krintel SB, Raun J, Ammitzbøll CG, Johansen JS, Østergaard M, Steengaard-Pedersen K. Improved remission rates acquired

by adding adalimumab to methotrexate and intraarticular glucocorticoid can not be maintained after withdrawal of adalimumab. A 2-year investigator initiated, randomised, controlled study on early rheumatoid arthritis. *Ann Rheum Dis* 2013;72(S3):S236.

- 179) Egholm CL, Pincus T, Dreyer L, Ellingsen T, Glintborg B, Kowalski M, Lorenzen T, Madsen OR, Rasmussen C, Nordin H, Hetland ML. Patient and physician global estimates in the Danish nationwide DANBIO registry: Male and female physicians are more likely to underestimate severity in female than male patients. *Ann Rheum Dis* 2013;72(S3):338.
- 180) Laustsen JK, Kruse Rasmussen T, Steengaard-Pedersen K, Hetland ML, Hørslev-Petersen K, Hvid M, Deleuran BW. OX40 and OX40L are highly associated with autoantibody formation in early rheumatoid arthritis, and predict flare after anti-tnf discontinuation. *Ann Rheum Dis* 2013;72(S3):S374.
- 181) Grøn KL, Ørnbjerg LM, Hetland ML, Sokka-Isler T, QUEST-RA investigators. How is fatigue associated with comorbidity burden, disease activity, and disability in patients with rheumatoid arthritis? Results from 34 countries in the QUEST-RA program. *Ann Rheum Dis* 2013;72(S3):389.
- 182) Krintel SB, Dehlendorff C, Hetland ML, Hørslev-Petersen K, Andersen KK, Junker P, Pødenphant J, Ellingsen T, Ahlqvist P, Lindegaard HM, Linauskas A, Schlemmer A, Dam MY, Hansen I, Horn HC, Jørgensen A, Raun J, Ammitzbøll CG, Østergaard M, Steengaard-Pedersen K, Johansen JS. MicroRNA expression profiles as biomarkers for prediction of treatment response to adalimumab in patients with early rheumatoid arthritis. *Ann Rheum Dis* 2013;72(S3):S584.
- 183) Thomsen T, Aadahl M, Hetland ML, Beyer N, Loeppenthin KB, Esbensen BA. Sedentary behaviour in patients with rheumatoid arthritis. A qualitative study. *Ann Rheum Dis* 2013;72(S3):S780.
- 184) Greisen SR, Steengaard-Pedersen K, Hetland ML, Hørslev-Petersen K, Deleuran BW. Soluble PD-1 and SPD-L2 unaffected by adalimumab treatment in early RA and associated with presence of anti-CCP and IGM-RF. *Ann Rheum Dis* 2013;72(S3):803.
- 185) Egholm CL, Pincus T, Dreyer L, Ellingsen T, Glintborg B, Kowalski M, Lorenzen T, Madsen OR, Nordin H, Rasmussen C, Hetland ML. Physician's global assessment is affected by physician's age and gender, but not by patient age and gender in rheumatoid arthritis patients treated in routine care. Data from the Danish nationwide DANBIO registry. *Arthritis Rheum* 2012;64(10):S35.
- 186) Hetland ML, Myklebust G, Haugeberg G, Diamantopoulos AP. The diagnostic value of color doppler ultrasonography in giant cell arteritis. *Arthritis Rheum* 2012;64(10):S53.
- 187) Ørnbjerg LM, Østergaard M, Boyesen P, Jensen TD, Thormann A, Tarp U, Bohme W, Dencker D, Lindegaard HM, Poulsen UE, Hansen A, Ringsdal VS, Schlemmer A, Graudal N, Andersen AR, Espesen J, Kollerup G, Christensen TG, Pelck R, Glintborg B, Madsen OR, Jensen DV, Majgaard O, Hetland ML. Impact of tumour necrosis factor inhibitor treatment on hand bone loss in rheumatoid arthritis patients treated in clinical practice. Results from the nationwide Danish DANBIO registry. *Arthritis Rheum* 2012;64(10):S156.
- 188) Ørnbjerg LM, Østergaard M, Boyesen P, Jensen TD, Thormann A, Tarp U, Bohme W, Dencker D, Lindegaard HM, Poulsen UE, Hansen A, Ringsdal VS, Schlemmer A, Graudal N, Andersen AR, Espesen J, Kollerup G, Christensen TG, Pelck R, Glintborg B, Madsen OR, Jensen DV, Majgaard O, Hetland ML. Risk factors for radiographic progression during TNFinhibitor treatment in 932 rheumatoid arthritis patients treated in clinical practice: Results from the nationwide Danish DANBIO registry. *Arthritis Rheum* 2012;64(10):S157.

- 189) Ellingsen T, Petersen KH, Hetland ML, Junker P, Pødenphant J, Østergaard M, Pedersen KS. Dyslipidaemia in early rheumatoid arthritis patients is common and not influenced by two years of effective DMARD therapy. The Opera study. *Arthritis Rheum* 2012;64(10):S181.
- 190) Coenen MJH, Mirkov MU, Scheffer H, Krintel SB, Vermeulen SH, Johansen JS, Kievit W, van de Laar MAFJ, van Riel PLCM, Franke B, Hetland ML. Genome wide association analysis of pain reduction in rheumatoid arthritis patients treated with anti-TNF medication. Results of the DREAM and DANBIO registries. *Arthritis Rheum* 2012;64(10):S188.
- 191) Axelsen MB, Hetland ML, Petersen KH, Pedersen KS, Junker P, Pødenphant J, Møller JM, Bliddal H, Kubassova O, Boesen M, Østergaard M. Dynamic contrast-enhanced magnetic resonance imaging of the wrist in rheumatoid arthritis patients treated with methotrexate, intra-articular glucocorticoid and adalimumab/placebo. *Arthritis Rheum* 2012;64(10):S452.
- 192) Leffers HC, Østergaard M, Glintborg B, Krogh NS, Tarp U, Lorenzen T, Hansen A, Hansen MS, Dreyer L, Jakobsen MS, Hetland ML: Two-year drug survival and treatment effect of abatacept and tocilizumab in the treatment of rheumatoid arthritis in routine care. Results from the nationwide Danish DANBIO registry. *Arthritis Rheum* 2012;64(10):S543.
- 193) Ammitzbøll CG, Jensenius JC, Ellingsen T, Thiel S, Petersen KH, Hetland ML, Junker P, Johansen J, Østergaard M, Pødenphant J, Petersen KS. M-ficolin, an activator of the complement system, is the strongest predictor of both DAS28 remission and low disease activity in a cohort of 180 early DMARD naïve rheumatoid arthritis patients followed in the Opera-study. *Arthritis Rheum* 2012;64(10):S1065.
- 194) Chatzidionysiou K, Lie E, Nasonov E, Lukina G, Hetland M, Tarp U, Ancuta I, Pavelka K, Nordström D, Gabay C, Canhao H, Tomsic M, van Riel P, Gomez-Reino J, Kvien T, van Vollenhoven R. Seropositivity and response to RTX: Data from the Cererra collaboration. *Ann Rheum Dis* 2012;71(3):S182.
- 195) Hørslev-Petersen K, Hetland ML, Junker P, Pødenphant J, Ellingsen T, Ahlquist P, Lindegaard H, Linauskas A, Schlemmer A, Ammitzbøll CG, Johansen JS, Østergaard M, Steengaard-Pedersen K. Remission rates increase substantially by adding adalimumab to methotrexate and intra-articular glucocorticoid in patients with early rheumatoid arthritis – 1- year results of investigator-initiated, double-blinded randomized clinical trial (Opera). *Ann Rheum Dis* 2012;71(3):S360.
- 196) Duer Jensen A, Hørslev-Petersen K, Bak L, Johansen JS, Hansen MS, Hetland ML, Ejbjerg BJ, Lindegaard HM, Vinterberg H, Møller J, Østergaard M. Using MRI synovitis to count involved joints in the ACR/EULAR 2010 RA criteria increases their sensitivity and specificity. *Ann Rheum Dis* 2012;71(3):S601.
- 197) Axelsen MB, Ejbjerg BJ, Hetland ML, Hørslev-Petersen K, Lauridsen UB, Majgaard O, Boesen M, Kubassova O, Bliddal H, Østergaard M. Does dynamic contrast-enhanced MRI provide better separation of active early rheumatoid arthritis patients and healthy controls than conventional MRI? *Ann Rheum Dis* 2012;71(3):S604.
- 198) Linde L, Sørensen J, Østergaard M, Hetland ML. Predictors of gain in quality adjusted life years in RA patients treated with biologics for one year. *Ann Rheum Dis* 2012;71(3):S655.
- 199) Herly M, Steengaard-Pedersen K, Vestergaard P, Pødenphant J, Østergaard M, Junker P, Hetland ML, Hørslev-Petersen K, Ellingsen T. Patient's global assessment of general health by VAS at baseline predicts ACR/EULAR remission after 3, 6 and 12 month's of efficient treatment in DMARD- and steroid naïve early rheumatoid arthritis patients. The Danish Cimestra-study. *Ann Rheum Dis* 2012;71(3):S655.
- 200) Ørnbjerg LM, Østergaard M, Bøyesen P, Thormann A, Tarp U, Poulsen UE, Graudal N, Hansen A, Espesen J, Ringsdal VS, Schlemmer A, Andersen AR, Kollerup G, Glintborg B, Pelck R, Christensen TG,

Jensen DV et al. Predictors of radiographic progression in 940 rheumatoid arthritis patients during TNF-inhibitor treatment in clinical practice. *Scand J Rheum* 2012;41(suppl 126):33.

- 201) Dreyer L, Mellekjær L, Andersen AR, Bennett P, Poulsen UE, Juulsgaard T, Jensen DV, Linde L, Lindegaard HM, Loft AG, Nordin H, Omerovic E, Rasmussen C, Schlemmer A, Tarp U, Hetland ML. Incidence of cancer in TNF-inhibitor treated patients with rheumatoid arthritis and other types of arthritides – a follow-up study from the DANBIO registry. *Scand J Rheum* 2012;41(suppl 126).
- 202) Glintborg B, Østergaard M, Krogh NS, Tarp U, Manilo N, Loft AG, Hansen A, Schlemmer A, Fana V, Lindegaard HM, Nordin H, Rasmussen C, Ejstrup L, Jensen DV, Petersen PM, Hetland ML. Clinical response, drug survival and predictors thereof in 432 patients with ankylosing spondylitis switching anti necrosis factor–therapy: results from the Danish nationwide DANBIO registry. *Scand J Rheum* 2012;41(suppl 126):111.
- 203) Hørslev-Petersen K, Hetland ML, Junker P, Pødenphant J, Ellingsen T, Ahlqvist P, Lindegaard HM, Linauskas A, Schlemmer A, Dam MY, Hansen I, Horn HC, Jørgensen A, Krintel SB, Raun J, Ammitzbøll CG, Johansen J, Østergaard M, Stengaard-Pedersen K. Adalimumab added to methotrexate and intra-articular glucocorticoid increases remission rates at one year in early, DMARD-naïve patients with rheumatoid arthritis – an investigator-initiated randomized, controlled, double-blinded study. *Arthritis Rheum* 2011;63(10):S147.
- 204) Krintel SB, Palermo G, Wool A, Johansen JS, Essioux L, Schreiber E, Zekharya T, Akiva P, Østergaard M, Hetland ML. Genetic variations within the CD6 and syntaxin binding protein 6 genes associated with response to tumor necrosis factor alpha inhibitors in Danish patients with rheumatoid arthritis treated in routine care. *Arthritis Rheum* 2011;63(10):S149.
- 205) Lie E, Chatzidionysiou K, Nasonov EL, Lukina G, Pavelka K, Nordström DC, Tomsic M, Gabay C, Ancuta I, van Riel PLC, Gomez-Reino JJ, Fonseca JE, Hetland ML, Tarp U, van Vollenhoven RF, Kvien TK. Early versus delayed treatment with rituximab (RTX) in relation to long term clinical response – data from the CERERRA collaboration. *Arthritis Rheum* 2011;63(10):S169.
- 206) Lie E, Chatzidionysiou K, Nasonov EL, Lukina G, Pavelka K, Nordström DC, Tomsic M, Gabay C, Ancuta I, van Riel PLC, Gomez-Reino JJ, Fonseca JE, Hetland ML, Tarp U, Kvien TK, van Vollenhoven RF. Characterization of long-term responders to first treatment course of rituximab (RTX) – results from the CERERRA collaboration. *Arthritis Rheum* 2011;63(10):S877.
- 207) Dreyer L, Mellekjær L, Hetland ML. No increased cancer risk in patients with rheumatoid arthritis, psoriatic arthritis or other arthritides treated with anti-tumor necrosis factor agents – a long-term follow-up study from the nationwide Danish DANBIO registry. *Ann Rheum Dis* 2011;70(S3):410.
- 208) Jawaheer D, Olsen J, Hetland ML. Influence of gender on responses to anti-TNF therapy in early vs. established rheumatoid arthritis – results from the longitudinal Danish DANBIO registry. *Ann Rheum Dis* 2011;70(S3):445.
- 209) Leffers HC, Østergaard M, Glintborg B, Krogh NS, Foged H, Tarp U, Lorenzen T, Hansen A, Hansen MS, Jacobsen MS, Dreyer L, Hetland ML. Rheumatoid arthritis patients treated in routine care – efficacy of abatacept and tocilizumab based on data from the nationwide Danish DANBIO registry. *Ann Rheum Dis* 2011;70(S3):463.
- 210) Linde L, Hetland ML, Østergaard M, Sørensen J. Predictors of differences in quality adjusted life years in patients with rheumatoid arthritis treated with biologics for one year. *Ann Rheum Dis* 2011;70(S3):642.

- 211) Lie E, Chatzidionysiou K, Nasonov E, Lukina G, Hetland ML, Tarp U, Gebau C, van Riel P, Nordström D, Gomez-Reino JJ, Pavelka K, Tomsic M, van Vollenhoven R, Kvien TK. Sustained effectiveness over 3 years in patients with rheumatoid arthritis treated with rituximab in clinical practice: Results from the CERERRA collaboration. *Ann Rheum Dis* 2011;70(S3):721.
- 212) Hetland ML. DANBIO – powerful research tool and electronic patient record. *Scand J Rheumatol* 2010;S124:15.
- 213) Lie E, Chatzidionysiou K, Nasonov E, Lukina G, Gabay C, Pavelka K, Nordström DC, Tomsic M, Hetland ML, Tarp U, van Riel PLCM, Gomez-Reino J, Kvien TK, van Vollenhoven RF. Changes in EQ-5D and SF-6D during rituximab treatment – Results from the CERERRA collaboration. *Arthritis Rheum* 2010;62(S10):S21.
- 214) Pedersen SJ, Sørensen IJ, Hermann KG, Johansen JS, Madsen OR, Hansen A, Hansen MS, Thamsborg G, Andersen LS, Majgaard O, Loft AG, Erlendsson J, Asmussen K, Jurik AG, Møller J, Hasselquist M, Mikkelsen D, Skjødt T, Østergaard M. MRI inflammation in the sacroiliac joints is associated with CTX-II and changes in systemic inflammation during TNF- α -inhibitor therapy. *Arthritis Rheum* 2010;62(S10):S56.
- 215) Krintel SB, Grunert VP, Johansen JS, Hetland ML, Rothfuss M, Klause U. Early development of antibodies against infliximab predicts withdrawal due to adverse drug reactions in patients with rheumatoid arthritis. *Arthritis Rheum* 2010;62(S10):S159.
- 216) Gabay C, Chatzidionysiou K, Nasonov E, Lukina G, Hetland ML, Tarp U, van Riel PLCM, Nordström DC, Gomez-Reino J, Pavelka K, Tomsic M, Lie E, Kvien TK, van Vollenhoven RF. Effectiveness of different DMARD co-therapies in rituximab-treated rheumatoid arthritis (RA) patients – Results of a one-year follow up study from the CERERRA collaboration. *Arthritis Rheum* 2010;62(S10):S751.
- 217) Chatzidionysiou K, Lie E, Lukina G, Hetland ML, Tarp U, Gabay C, van Riel PLCM, Nordström DC, Gomez-Reino J, Pavelka K, Tomsic M, Nasonov E, Kvien TK, van Vollenhoven RF. Efficacy and safety of rituximab treatment in clinical practice: Data from the CERERRA collaboration. *Arthritis Rheum* 2010;62(S10):S753.
- 218) Leffers HC, Østergaard M, Glinthorg B, Krogh NS, Foged H, Tarp U, Lorenzen T, Hansen A, Hansen MS, Jacobsen MS, Hetland ML. Efficacy of abatacept and tocilizumab in rheumatoid arthritis patients treated in clinical practice. Results from the nationwide Danish DANBIO registry. *Arthritis Rheum* 2010;62(S10):S754.
- 219) Ørnbjerg LM, Østergaard M, Bøyesen P, Thormann A, Tarp U, Bøhme W, Dencker D, Lindegaard H, Poulsen U, Hansen A, Ringsdal V, Schlemmer A, Graudal N, Andersen AR, Espesen J, Kollerup G, Christensen T, Pelck R, Glinthorg B, Madsen OR, Jensen DV, Majgaard O, Hetland ML. Treatment with TNF-inhibitors reduces radiographic joint destruction in rheumatoid arthritis patients treated in clinical practice. Results from the nationwide Danish DANBIO registry. *Arthritis Rheum* 2010;62(S10):S770.
- 220) Pedersen SJ, Sørensen IJ, Lambert R, Hermann KG, Johansen JS, Madsen OR, Hansen A, Hansen MS, Thamsborg G, Andersen LS, Majgaard O, Loft AG, Erlendsson J, Asmussen K, Jurik AG, Møller J, Hasselquist M, Mikkelsen D, Skjødt T, Østergaard M. Radiographic Progression is Associated with Resolution of Systemic Inflammation in Patients with Axial Spondyloarthritis treated with TNF-inhibitors. *Arthritis Rheum* 2010;62(S10):S817.
- 221) Pedersen SJ, Sørensen IJ, Johansen JS, Madsen OR, Tvede N, Hansen MS, Thamsborg G, Andersen LS, Majgaard O, Loft AG, Erlendsson J, Asmussen K, Jurik AG, Møller J, Hasselquist M, Mikkelsen D, Skjødt T,

- Hansen A, Østergaard M. High sensitive CRP increases sensitivity and responsiveness of ASDAS. *Clin Exp Rheumatol* 2010;28(4):627.
- 222) Hetland ML. Efficacy of anti-TNFs in RA: Identical or different? *Ann Rheum Dis* 2010;69(S3):12.
- 223) Hetland ML. Progression of research studies to electronic patient records. *Ann Rheum Dis* 2010;69(S3):26.
- 224) Krintel SB, Palermo G, Johansen JS, Germer S, Essioux L, Benayed R, Hetland ML. Identification of polymorphisms associated with treatment response to anti-TNF in Danish RA patients by genome-wide association scan. *Ann Rheum Dis* 2010;69(S3):207.
- 225) Linde L, Sørensen J, Østergaard M, Hetland ML. Health-related quality of life in rheumatoid arthritis: Do women and men respond differently to biological therapy? *Ann Rheum Dis* 2010;69(S3):360.
- 226) Lundberg IE, Chinoy H, Vencovsky J, Danko K, Ponyi A, Hetland ML, Ohtamaa M, Krogh NS. Euromyositis - a novel electronic register to facilitate research and clinical evaluation of myositis patients. *Ann Rheum Dis* 2010;69(S3):412.
- 227) Døhn UM, Terslev L, Szkudlarek M, Hetland ML, Hansen MS, Hansen A, Madsen OR, Hasselquist M, Møller JM, Østergaard M. Detection rates of bone erosions and estimation of erosion volume by ultrasonography in rheumatoid arthritis – a comparison with computed tomography. *Ann Rheum Dis* 2010;69(S3):456.
- 228) Døhn UM, Szkudlarek M, Hansen MS, Hetland ML, Hansen A, Madsen OR, Hasselquist M, Østergaard M. Decreased signs of inflammation and no erosive progression on ultrasonography at 6 and 12 months in patients with rheumatoid arthritis in adalimumab and methotrexate combination therapy. *Ann Rheum Dis* 2010;69(S3):457.
- 229) Ørnbjerg L, Østergaard M, Bøyesen P, Thormann A, Tarp U, Böhme W, Dencker D, Lindegaard H, Poulsen U, Hansen A, Ringsdal V, Schlemmer A, Graudal N, Andersen A, Espesen J, Kollerup G, Christensen T, Pelck R, Glinthorg B, Madsen O, Jensen D, Majgaard O, Hetland ML. Impact of drug discontinuation on radiographic progression 2 years after initiation of TNF-inhibitor treatment in clinical practice. *Ann Rheum Dis* 2010;69(S3):459.
- 230) Primdahl J, Wagner L, Hørslev-Petersen K.: Being an outpatient with rheumatoid arthritis and self-efficacy. A focus group study on patients' experiences from a short course and one of three different outpatient settings. *Ann Rheum Dis* 2010;69:732.
- 231) Jawaheer D, Olsen J, Hetland ML. Women with Rheumatoid Arthritis Have Better Responses to Anti-TNF Therapy in the First Year, but Men Respond Significantly Better in the Long-Term Results From the Danish DANBIO Registry. *Arthritis Rheum* 2009;60(Suppl 10):1601.
- 232) van Vollenhoven RF, Chatzidionysiou K, Nasonov E, Lukina G, Hetland ML, Tarp U et al. Six-Month Results From the Collaborative European Registries for Rituximab in Rheumatoid Arthritis (CERERRA). Efficacy of Rituximab Is Highest in RF-Positive Patients and in Those Who Failed at Most One Prior Anti-TNF. *Arthritis Rheum* 2009;60(Suppl 10):1671.
- 233) Linde L, Sorensen J, Østergaard M, Hetland ML. Quality Adjusted Life Expectancies in Patients with Rheumatoid Arthritis. A Comparison of the EQ-5D, SF-6D and 15D. *Arthritis Rheum* 2009;60(Suppl 10):1381.

- 234) Plant D, Cornelis F, Rantapaa-Dahlqvist S, Goulielmos G, Hetland ML, Klareskog L et al. Investigation of Potential Non-HLA RA Susceptibility Loci in a European Cohort Increases the Evidence for 10 Markers. *Arthritis Rheum* 2009;60(Suppl 10):744.
- 235) Hetland ML, Christensen IJ, Tarp U, Dreyer L, Hansen A, Hansen IT et al. Direct Comparison of 4 Years Drug Survival of Adalimumab, Etanercept and Infliximab in Rheumatoid Arthritis Patients. An Observational Study From the DANBIO Registry. *Arthritis Rheum* 2009;60(Suppl 10):997.
- 236) Ørnberg LM, Østergaard M, Boyesen P, Thormann A, Tarp U, Rogind H et al. Predictors of Radiographic Joint Destruction in Rheumatoid Arthritis Patients During TNF-Inhibitor Treatment in Clinical Practice. *Arthritis Rheum* 2009;60(Suppl 10):1000.
- 237) Pedersen SJ, Sørensen IJ, Madsen OR, Tvede N, Hansen MS, Thamsborg G et al. How Is the New Ankylosing Spondylitis Disease Activity Score (ASDAS) Related to Different Aspects of Health-Related Quality of Life? A Comparison with SF-36 in a Longitudinal Study of Spondyloarthritis Patients Treated with TNF- Inhibitors. *Arthritis Rheum* 2009;60(Suppl 10):1774.
- 238) Linde L, Sørensen J, Østergaard M, Hørslev-Petersen K, Hetland ML. Does remission lead to normalization of health status (EQ-5D) in RA? *Ann Rheum Dis* 2009;68(Suppl 3):404.
- 239) Hetland ML, Christensen I, Tarp U, Andersen LS, Linde L, Ringsdal VS, Østergaard M. 4 years' drug survival of TNF- α -inhibitors in rheumatoid arthritis patients. An observational study from the DANBIO registry. *Ann Rheum Dis* 2009;68(Suppl 3):739.
- 240) van Vollenhoven RF, Chatzidionysiou K, Gabay C, Hetland ML, Tarp U, Gomez-Reino JJ, van Riel PLCM, Pavelka K, Nordström DC, Tomsic M, Lie E, Kvien TK. Rheumatoid factor predicts response to rituximab in a European registrybased cohort: 6-month results from the collaborative European registries for rituximab in rheumatoid arthritis (CERERRA). *Ann Rheum Dis* 2009;68(Suppl 3):579.
- 241) Hostenkamp G, Sørensen J, Hansen A, Hetland ML. Real-life dosages and costs of TNF-inhibitor therapy for RA patients in Denmark. *Ann Rheum Dis* 2009;68(Suppl 3):239.
- 242) Hetland ML, Christensen IJ, Tarp U, Linde L, Ringsdal VS, Østergaard M. Efficacy of adalimumab, etanercept and infliximab in the treatment of rheumatoid arthritis. Results from the nationwide Danish DANBIO registry. *Ann Rheum Dis* 2009;68(Suppl 3):428.
- 243) Pedersen SJ, Hermann KG, Sørensen IJ, Madsen OR, Tvede N, Hansen MS, Thamsborg G, Andersen LS, Loft AG, Erlendsson J, Asmussen K, Majgaard O, Hansen A, Møller J, Jurik AG, Hasselquist M, Skjødt T, Mikkelsen D, Østergaard M. MRI Assessment of Sacroiliac Joint Inflammation and Destruction and Spine Inflammation During Anti-TNF-Alpha Therapy - An Investigator Initiated 1-year Follow-up Study of Patients with Axial Spondyloarthritis. *Arthritis Rheum* 2008;58(9 Suppl):S583.
- 244) Linde L, Sørensen J, Østergaard M, Hørslev-Petersen K, Jensen DV, Rasmussen C, Hetland ML. Does The SF-12 Identify Important Aspects Of The Health Status In RA Patients? A Comparison With The HAQ. *Arthritis Rheum* 2008;58(9 Suppl):S205.
- 245) Van Vollenhoven RF, Gabay C, Hetland ML, Gomez-Reino JJ, van Riel P, Pavelka K, Nordström DC, Tomsic M, Smolen JS, Kvien TK. Seven-Hundred and Fifty Patients Treated with Rituximab for RA in European Registries: Baseline Data Analysis from the Collaborative European Registries for Rituximab in RA (CERERRA). *Arthritis Rheum* 2008;58(9 Suppl):S301.
- 246) Pedersen SJ, Sørensen IJ, Garnero P, Johansen JS, Madsen OR, Tvede N, Hansen MS, Thamsborg G, Andersen LS, Majgaard O, Loft AG, Erlendsson J, Asmussen K, Hansen A, Østergaard M. Changes in

biomarkers of cartilage and bone turnover in patients with spondyloarthritis treated with TNFA inhibitors – results from the Danish investigator initiated multicentre study BIOSPA. *Ann Rheum Dis* 2008;64(Suppl II):513.

- 247) Pedersen SJ, Hermann KG, Sørensen IJ, Madsen OR, Tvede OR, Hansen MS, Thamsborg G, Andersen LS, Loft AR, Erlendsson J, Asmussen K, Majgaard O, Hansen A, Møller J, Jurik AG, Hasselquist M, Skjødt T, Mikkelsen D, Østergaard M. MRI-Assessment of sacroiliac joint inflammation and destruction during anti-TNF-alpha therapy – results from the Danish investigator initiated cohort study BIOSPA. *Ann Rheum Dis* 2008;64(Suppl SII):566.
- 248) Linde L, Sørensen J, Østergaard M, Hørslev-Petersen K, Rasmussen C, Hetland ML. Rheumatoid Arthritis: Demographic, Disease- and Treatment Related Factors Associated With HAQ in Clinical Practice. *Ann Rheum Dis* 2008;64(Suppl II):S476.
- 249) Hetland ML, Andersen LS, Linde L, Ringsdal VS, Tarp U. The odds for achieving a good/moderate EULAR response after one year of anti TNF treatment in clinical practice increases with concomitant methotrexate, and decreases with high HAQ score. Results from the nationwide DANBIO Registry. *Ann Rheum Dis* 2008;64(Suppl II):S302.
- 250) Pedersen SJ, Sørensen IJ, Madsen OR, Tvede N, Hansen MS, Thamsborg G, Andersen LS, Majgaard O, Loft AG, Erlendsson J, Asmussen K, Hansen A, Østergaard M. Early and significant increases in health related quality of life in spondyloarthritis patients treated with TNF- α -inhibitors. *Clin Exp Rheumatol* 2008;26(4):749.
- 251) Pedersen SJ. Circulating Levels of Plasma IL-6, VEGF, YKL-40, and COMP in Spondyloarthritis Patients During anti-TNF- α -Treatment. *Scand J Rheum* 2008;S123:38.
- 252) Pedersen SJ. Recommendations regarding physical exercise therapy for ankylosing spondylitis patients within the 3e project. *Scand J Rheum* 2008;S123:33.
- 253) Pedersen SJ, Sørensen IJ, Johansen SJ, Madsen OR, Tvede N, Hansen MS, Thamsborg G, Andersen LS, Majgaard O, Loft AG, Erlendsson J, Asmussen K, Hansen A, Østergaard M. Changes in plasma IL-6, VEGF, YKL-40 and COMP in Spondyloarthritis Patients During Treatment with TNF- α -Inhibitors. *Arthritis Rheum* 2007;56(9 Suppl).
- 254) Hetland ML, Tarp U, Pødenphant J, Ringsdal V, Hansen A, Unkerskov J. Prescription Practice Of Biologics In Rheumatoid Arthritis Is Changing Over Time. Does That Affect The EULAR Treatment Response? Results From The Nationwide DANBIO Registry. *Arthritis Rheum* 2007;56(9 Suppl):S180.
- 255) Hetland ML, Hansen A, Lindegaard H, Tarp U. Is treatment response to biologics in rheumatoid arthritis affected by changes in prescription practice? Results from the nationwide DANBIO Database. *Ann Rheum Dis* 2007;64(Suppl II):S172.
- 256) Pedersen SJ, Hetland ML, Østergaard M, Jensen T, Knudsen LS, Krogh NS, Nielsen HJ, Linde L, Johansen JS. Changes in Interleukin-6, Vascular Endothelial Growth Factor and YKL-40 in ankylosing spondylitis and psoriatic arthritis patients during treatment with TNF- α -inhibitors. The 5th International Congress on Spondyloarthropathies, Belgium 2006.
- 257) Pedersen SJ, Hetland ML, Østergaard M, Jensen T, Knudsen LS, Krogh NS, Nielsen HJ, Linde L, Johansen JS. New Biomarkers in Monitoring Disease Activity in AS and PsA Patients Treated With TNF- α -Inhibitors. *Arthritis Rheum* 2006;54(9 Suppl).

- 258) Linde L, Hetland ML, Krogh NS, Asmussen L, Hansen A, Peen E, Tarp U, Østergaard M. Efficacy, Safety And Drug Survival Of TNF-alpha Inhibitors In Ankylosing Spondylitis And Psoriatic Arthritis: Data From The Nationwide Danish "DANBIO" Database. *Arthritis Rheum* 2005;52(9 Suppl):S484.
- 259) Østergaard M, Unkerskov J, Krogh NS, Friis M, Ravn T, Petri A, Andersen LS, Tarp U, Hansen A, Hetland ML. Poor remission rates but long drug survival in rheumatoid arthritis patients treated with infliximab or etanercept – results from the nationwide Danish "DANBIO" database. *Ann Rheum Dis* 2005;64(Suppl III):59.
- 260) Hjørdem E, Østergaard M, Hetland ML. Do patients benefit from switching to a second biologic drug when the first is withdrawn due to lack of efficacy or adverse events? *Arthritis Rheum* 2004;50(9 Suppl):S392.
- 261) Unkerskov J, Ravn AT, Friis M, Tarp U, Andersen LS, Petri A, Almstrup D, Østergaard M, Hetland ML. Adverse events in patients treated with infliximab or etanercept – results from the Danish Database for Biological Therapies in Rheumatology. The 8th World Congress on Clinical Pharmacology and Therapeutics, august 2004.
- 262) Hetland ML, Unkerskov J, Friis M, Tarp U, Andersen LS, Petri A, Janjua H, Almstrup D, Østergaard. A Routine Database Registration Procedure Increases the Number of Adverse Events Reported in Patients Treated with TNF inhibitors. The Danish Experience. *Arthritis Rheum* 2003;48(9 suppl): S329.
- 263) Hetland ML, Unkerskov J, Friis M, Tarp U, Andersen LS, Petri A, Janjua H, Almstrup D, Østergaard M. Adverse events in patients treated with infliximab or etanercept - results from the Danish Database for Biological Therapies in Rheumatology. *Ann Rheum Dis* 2003;62(S1):189.
- 264) Østergaard M, Unkerskov J, Friis M, Petri A, Andersen LS, Tarp U, Janjua H, Hetland ML. Infliximab and etanercept reduce rheumatoid disease activity significantly, but clinical remission is only present in 20% of visits - results from the Danish Database for Biological Therapies in Rheumatology. *Ann Rheum Dis* 2003;62(S1):160.

Øvrige foredrag

- 1) Oplæg på workshopen Succes med PRO, Danske Regioner, København den 31. oktober 2019. Hetland ML.
- 2) Danske bidrag til ny viden om behandling af inflammatoriske gigtsygdomme – fra randomiserede forsøg til observationelle studier. Temadag om fremtidens behandling og rehabilitering af reumatologiske patienter, Dansk Gigthospital, Sønderborg den 6. juni 2019. Hetland ML.
- 3) DANBIO – status og nyheder. Dansk Reumatologisk Selskabs Årsmøde, Kolding den 13. april 2019. Jensen DV.
- 4) The Danish experience on switching from originator to biosimilars for non-medical reasons including subsequent back-switching. Inviteret præsentation ved TNF BIO specialistseminar, Oslo, Norge den 7. januar 2019. Hetland ML.
- 5) Switching from originator to biosimilars for non-medical reasons – the real life DANBIO experience. Rheumatology & Biosimilars Exchange meeting den 22. November 2018. Diakonhjemmet, Oslo, Norge. Hetland ML.
- 6) Nanna Svartz forelæsning, den 21. september ved Reumadagene i Uppsala, Sverige. Hetland ML.

- 7) Hvilke erfaringer har patienter med inflammatorisk gigtsygdom med at besvare PRO data i forbindelse med ambulante besøg? Erfaringer fra DANBIO databasen. RKKP Databasedagen, København den 11. april 2018. Esbensen BA.
- 8) Introduktion til DANBIO. Besøg fra Reumatologisk afdeling i Göteborg. Glostrup den 23. november 2017. Meincke RH.
- 9) Monitorering af inflammatoriske reumatologiske patienter. Netværksmøde for stomi-sygeplejersker, Bispebjerg den 23. november 2017. Meincke RH.
- 10) Monitorering af inflammatoriske reumatologiske patienter i biologisk behandling. TEVA lungesymposium, København den 22. september 2018. Meincke RH.
- 11) Monitorering af inflammatoriske reumatologiske patienter i DANBIO. Tværfagligt møde i skleroseklinikken, Rigshospitalet Glostrup, den 4. maj 2017. Meincke RH.
- 12) Monitoring of rheumatological patients in biologic treatment. Nordic Severe Asthma Network møde, København den 30. november 2016. Meincke RH.
- 13) Monitorering af inflammatoriske reumatologiske patienter i medicinsk behandling. Styregruppemøde for PRO i psykiatrien, Glostrup den 18. november 2016. Meincke RH.
- 14) DANBIO – national reumatologisk kvalitetsdatabase. Database Research Forum, Århus den 21. juni 2016. Jensen DV.
- 15) DANBIO – på vej mod de 15 år. Dansk Reumatologisk Selskabs forårsmøde den 24. april 2016. Jensen DV.
- 16) DANBIO som klinisk kvalitetsdatabase, der anvendes i dagligdagen. Muligheder og Udfordringer. Dansk Børnereumatologisk Selskab den 15. marts 2016. Lindegaard HM.
- 17) The nationwide Danish DANBIO registry of RA patients – what can be learned? The COP 2015, Learning Modern Management and Assessment of Rheumatoid Arthritis and Spondyloarthritis – An Interactive Approach, København den 5. oktober 2015. Hetland ML.
- 18) Biosimilære lægemidler inklusiv NOR-SWITCH studiet. I "Highlights in Rheumatology" organiseret af Dansk Reumatologisk Selskab, Svendborg den 25. september 2015. Hetland ML.
- 19) Hvordan bruges DANBIO i reumatologisk forskning – aktuelle og mulige projekter. I "Highlights in Rheumatology" organiseret af Dansk Reumatologisk Selskab, Svendborg den 25. september 2015. Hetland ML.
- 20) DANBIO – status. Dansk Reumatologisk Selskabs forårsmøde den 18. april 2015. Jensen DV.
- 21) Hvad vi ved om patienternes oplevelse af smerter, og hvordan bruger vi det i behandlingen? Symposium, Gigtforeningen, Gentofte, den 10. februar 2015. Hetland ML.
- 22) DANBIO – en national klinisk kvalitetsdatabase. Dansk Oftalmologisk Selskab, Glostrup Hospital, 16. januar 2015. Jensen DV.
- 23) Introduction to the DANBIO registry at the Danish Imaging Summit 2015 in Copenhagen. Hetland ML.

- 24) The Danish rheumatologist' experience with biologic agents. The DANBIO register. Danish Society of Nephrology, 9th of January 2014. Dreyer L.
- 25) DANBIO. Danish Society for Pharmacology, 6th meeting af 15th of January 2014. Lindegaard HM.
- 26) How to implement imaging results in clinical registries in Scandinavia. How could it be done in Denmark? At the 4th Nordic Imaging Summit – Advances in imaging in rheumatology, Helsinki, Finland, 4th of February 2014. Hetland ML.
- 27) Screening for cardiovascular risk in rheumatic disease. Dansk Selskab for Intern Medicins årsmøde ved uddeling af Hagedorn prisen. København, den 21. marts 2014. Hetland ML.
- 28) Effekten af TNF-hæmmere på lednært knogletab i hånden hos patienter med reumatoid artrit behandlet i klinisk praksis. Resultater fra DANBIO databasen. Dansk Reumatologisk Selskabs Årsmøde i Svendborg, april 2014. Ørnbjerg LM.
- 29) Sammenhæng mellem rygning og effekt af TNF-hæmmere hos patienter med psoriasis artrit: resultater fra DANBIO databasen. Dansk Reumatologisk Selskabs Årsmøde i Svendborg, april 2014. Højgaard P.E
- 30) r plasma micro-RNA associerede med behandlingseffekt af anti-TNF hos reumatoid artrit patienter? Åben forskerdag, Region Syddanmark, april 2014. Sode J.
- 31) Udfordringer og barrierer når en forskningsdatabase implementeres som dagligt redskab – med udgangspunkt I den kliniske kvalitetsdatabase for reumatologi DANBIO. Sundhedsstyrelsens konference om Nationale Kliniske Retningslinjer afholdt I DGI-byen, 28. oktober 2013. Schiøttz-Christensen B.
- 32) Clinical Registries - how to overcome. Status for DANBIO. Tyrkisk Reumatologisk Selskab, Izmir, Tyrkiet, september 2013, Izmir. Jensen DV.
- 33) Polymorphisms in TNF-alpha/NFkB pathway and anti-tumor-necrosis-factor response in reumatoid arthritis. Åben forskerdag, Region Syddanmark, april 2013. Sode J.
- 34) Kan genetiske markører bruges til at optimere behandling med TNF-alfa hæmmere hos reumatoid artrit patienter? Åben Forskerdag, Region Syddanmark, april 2013. Sode J.
- 35) Temadage for fysioterapeuter: Fokus på inflammatoriske gigtsygdomme – DANBIO, en klinisk kvalitetsdatabase. Professionshøjskolen Metropol, København, januar 2013. Jensen DV.
- 36) DANBIO – en klinisk national kvalitetsdatabase, hvordan fungerer brugen i en travl dagligdag? Fællesmøde: De Danske Selskaber for Infektionsmedicin, Reumatologi, Dermatologi samt Gastroenterologi & Hepatologi, 27. november 2012, Rigshospitalet, København. Jensen DV.
- 37) What has DANBIO taught us regarding treatment of early rheumatoid arthritis. Symposium on early rheumatoid arthritis in Tampere, Finland, Arr: Pfizer. June 2012. Hetland ML.
- 38) Can we predict outcome i.e. clinical remission and structural progression in RA? In: Predictors in rheumatoid arthritis. Symposium at the Scandinavian Congress of Rheumatology, Arr: MSD. September 2012. Hetland ML.

- 39) Kontrol eller udvikling? Elektronisk kvalitetsredskab, forskningsdatabase og patientjournal. Udfordringer og muligheder. Erfaringer fra DANBIO – Dansk Reumatologisk Database. På mødet: Kvalitetsudvikling – hvordan kan det give mening? Foreningen af speciallæger, Munkebjerg Hotel, Vejle, Danmark. Oktober 2012. Hetland ML.
- 40) The value and feasibility of establishing and maintaining registries in rheumatology; The DANBIO Experience. Arr. Tyrkisk Reumatologisk Selskab, April 2012, Izmir, Tyrkiet. Dreyer L.
- 41) Klinisk og radiologisk status på ambulante patienter med reumatoid artrit fulgt hos læge, i shared care eller hos sygeplejerske – et to-årigt randomiseret studie. Åben Forskerdag, Fredericia april 2012. Primdahl, J, Horn HC, Hørslev-Petersen K.
- 42) DANBIO – et eksempel på registrering af patienter med kronisk sygdom, som bruges både i den daglige klinik og til forskning. Arr. Danmarks Bløderforening, temadag, November 2011. Jensen DV.
- 43) How far has DANBIO come in 10 years? Foredrag ved DANBIOs 10 års jubilæumsseminar, København. September 2011. Hetland ML.
- 44) The nationwide Danish DANBIO registry of RA patients – what can be learned? Experiencia, Arr: BMS. September 2011. Hetland ML.
- 45) Bechtereforeningens landsmøde: Bechterewprisen gik for nyligt til DANBIO databasens ledelse. Hvilken forskel kan DANBIO gøre for patientbehandlingen fremover? Maj 2011. Hetland ML.
- 46) Aftenkursus for Yngre Reumatolger: Hvilke vigtige resultater har DANBIO givet os? Gentofte Hospital. Marts 2011. Hetland ML.
- 47) Region Hovedstaden: Sikkerhed og effektivitet – Seminardag om klinisk kvalitet og patientsikkerhed. Foredrag: DANBIO databasen - hvor effektive er biologiske præparater i behandling af leddegigt? Januar 2011. Hetland ML.
- 48) EULAR task-force on biologics registers for safety: Implementation workshop. Zürich, Schweiz. Foredrag: Hardware/software platforms for data collection and statistical analyses. Januar 2011. Hetland ML.
- 49) EULAR task-force on biologics registers for safety: Implementation workshop. Zürich, Schweiz. Panel: What can be learned from our mistakes and successes? How do we maintain registration over time? Januar 2011. Hetland ML.
- 50) Har forskellige typer ambulant opfølgning betydning for, hvordan self-efficacy udvikler sig hos patienter med leddegigt? Åben forskerdag, Fredericia, Danmark, April 2011. Primdahl J, Wagner L, Hørslev-Petersen K.
- 51) Dokumenterede forskelle i effekt for RA, PsA og AS? Norsk Revmatologisk Forenings Høstmøde samt Diakonhjemmets 30 års jubilæum. November 2010. Hetland ML.

- 52) Use of empirical data in understanding effectiveness and safety of biological treatment within rheumatologic disease. An Abbott exchange Network seminar. Foredrag: DANBIO – effectiveness data within rheumatoid arthritis, psoriatic arthritis and ankylosing spondylitis. November 2010. Hetland ML.
- 53) Registrering af kardiovaskulære risikofaktorer i DANBIO. Hvad skal vi registrere og hvor hyppigt? "Highlights in Rheumatology", arrangeret af Dansk Reumatologisk selskab, Svendborg, september 2010. Hetland ML og Hansen A.
- 54) Effekt og præparatoverlevelse på baggrund af DANBIO data. September 2010. "Highlights in Rheumatology", arrangeret af Dansk Reumatologisk selskab, Svendborg, september 2010. Hetland ML.
- 55) Formål, baggrund, udvikling og organisering. Pligter, rettigheder og resultater. Schering Plough Symposium, København. September 2010. Hansen A.
- 56) The importance of real-world data in informing clinical decisionmaking in RA. Effectiveness of biologics. Pfizer Symposium, EULAR, Rome, June 2010. Hetland, ML.
- 57) Hvordan kan data fra helseregistre bedre patientbehandlingen og sikre rationel brug af mediciner i et samfundsperspektiv? På mødet "Forskning ved hjælp af helseregistre" arrangeret af LMI, Lægemedelindustrien, Oslo, Norge. Maj 2010. Hetland ML.
- 58) DANBIOs fortræffeligheder. Schering Plough Symposium, København. April 2010. Hansen A.
- 59) Kvalitetsdatabasen DANBIO. Hvordan bruges den i reumatologisk kvalitetsarbejde? Møde i kvalitetsrådet, Glostrup Universitetshospital, marts 2010. Hetland ML.
- 60) Er der forskel på effekten af forskellige TNF alfa hæmmere? Om et forskningsprojekt, der ikke kunne lade sig gøre. Staff-meeting, Glostrup Universitetshospital, marts 2010. Hetland ML.
- 61) DANBIO – Er kriterierne for opstart af biologisk behandling ændret fra 1999 til 2009? Schering Plough symposium, København, november 2009. Hansen A.
- 62) DANBIO – Dansk Reumatologisk Database. Bechterew Foreningen, marts 2009. Hansen A.
- 63) Self-efficacy og reumatoid artrit: Oversættelse og test af validitet, reliabilitet og sensitivitet af den danske version af Rheumatoid Arthritis Self-Efficacy Questionnaire (RASE). Åben Forskerdag, Fredericia, Danmark, April 2009. Primdahl J, Wagner L, Hørslev-Petersen K.
- 64) Responsiveness of the ankylosing spondylitis disease activity score (ASDAS) and clinical and magnetic resonance imaging measures of disease activity in a 1 year prospective study of patients with spondyloarthritis treated with TNF- α -inhibitors. Dansk Reumatologisk Selskabs årsmøde 2009. Pedersen SJ.
- 65) MRI-Assessment of sacroiliac joint inflammation and destruction during anti-TNF-alpha therapy – results from the Danish investigator initiated cohort study, BIOSPA. Dansk Reumatologisk Selskabs årsmøde 2008. Pedersen SJ.
- 66) Changes in biomarkers of cartilage and bone turnover in patients with spondyloarthritis treated with TNF-alpha inhibitors - results from the Danish investigator initiated cohort study BIOSPA. Dansk Reumatologisk Selskabs årsmøde 2008. Pedersen SJ.

- 67) Nordic database meeting in Stockholm. "Presentation of DANBIO", April 2008. Hetland ML.
- 68) DANBIO. The Danish Experience: Establishing a nationwide registry based on open source software. 5th European Registries Meeting, Manchester, England, September 2007. Hetland ML.
- 69) DANBIO-databasen. Resultater, struktur og finansiering. 7. nationale DCCD (Dansk Crohn og Colit Database)-møde, Radisson SAS, København, september 2007. Hetland ML.
- 70) Status from the Danish registry DANBIO. Roche Symposium on MabThera, Copenhagen, March 2007. Hetland ML.
- 71) Ankylosing spondylitis in Denmark – what can we learn from the DANBIO database? Gigtforeningens Forskningsseminar, Herlev Hospital, marts 2007. Hetland ML.
- 72) Biomarkers of inflammation in spondyloarthritis. Gigtforeningens Forskningsseminar om Morbus Bechterew, Herlev Hospital, marts 2007. Pedersen SJ.
- 73) Biomarkers of inflammation in spondyloarthritis. Staff-meeting Herlev Hospital, marts 2007. Pedersen SJ.
- 74) Erfaringer med 1. valg af TNF-hæmmere i Danmark. Foredrag ved LIS (legemiddelinnkjøpsamarbejd) seminar om TNF-hæmmere, Asker, Norge. Januar 2007. Hetland ML.
- 75) Regionale forskelle i brugen af biologiske lægemidler. Wyeth temadag om behandling af kronisk leddegigt. Landstingsalen, Christiansborg, januar 2007. Hetland ML.
- 76) DANBIO – the Danish Database for Biological Therapies in Rheumatology. European Biologics Registries Meeting, Uppsala, Sverige. Foredrag:. October 2005. Hetland ML.
- 77) DANBIO. Aktuel status, resultater og planer for fremtiden. Dansk Reumatologisk Selskabs efterårsmøde November 2005. Hetland ML.
- 78) Karolinska-dagen, Stockholm, Sverige. Foredrag: "Surveillance of RA from a Danish perspective", October 2005. Hetland ML.
- 79) Forskningsdag 2005 på Hvidovre Hospital. Foredrag: "DANBIO – en landsdækkende, reumatologisk database", september 2005. Hetland ML.
- 80) Øresunds-symposium om rheumatoid artrit: Anti TNF-behandling nu og i fremtiden. Foredrag: "DANBIO databasen: Eksponentielt stigende antal patienter i behandling med biologiske præparater. Mulige implikationer heraf for indikationer, klinisk effekt og bivirkninger." Arrangør: Wyeth, marts 2005. Hetland ML.
- 81) Spondylarthritis. Nye aspekter, diagnostik og behandling. Wyeth symposium, København. Foredrag: "Dansk Biologisk Database (DANBIO): Hvad viser DANBIO om indikationer, effekt og bivirkninger ved behandling af SpA med biologiske lægemidler i Danmark?" Februar 2005. Hetland ML.
- 82) "Remicade in Rheumatology, Dermatology and Gastroenterology", symposium sponsoreret af Schering-Plough, København. Foredrag: "Danish Databases in Rheumatology", January 2005. Hetland ML.

- 83) Danish Society of Rheumatology, Autumn Meeting 2004: "More than 10,000 visits registered in the DANBIO (Danish Database for Biological Therapies in Rheumatology). Present status, results and plans for the future", November 2004. Hetland ML.
- 84) Symposium om "Research in Rheumatoid Arthritis", Gigthospitalet Skælskør, Arrangør: Gigtforeningen: "Epidemiology and databases. Danish databases – data on biological therapies." Marts 2004. Hetland ML.
- 85) Temadag, H:S Hvidovre Hospital: Biologisk behandling og den biologiske database. Januar 2004. Hetland ML.
- 86) Efterårsmøde i Dansk Reumatologisk Selskab: Den danske database for biologiske behandlinger i reumatologi. Hvad viser de første års registreringer os? November 2003. Hetland ML.
- 87) Humira lancerings Symposium. The Danish Database for Biological Therapies – What do we need it for? November 2003. Hetland ML.